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Abstract
Amantadine and rimantadine are anti-influenza A drugs that target the M2 protein, 
located within the viral envelope. Over the last century, the circulating human 
Influenza A viruses in the UK have included H1N1, H2N2 and H3N2 antigenic 
subtypes. The main aim of this study was to analyse the national archive of 
influenza A viruses for amantadine susceptibility as there is limited data on natural 
resistance over the entire period of circulation of influenza A viruses. Over 2300 
influenza A viruses were screened from a period representing all influenza 
seasons and antigenic variants over the last 40 years in the UK. Phenotypic and 
genotypic analyses determined the frequency of amantadine-resistance. Enzyme- 
linked immunoassay and plaque reduction assay determined resistance to be 
2.4% and 2.1% for H3N2 and MINI viruses, respectively. No evidence of 
amantadine-resistance was found in the limited number of H2N2 viruses screened. 
Amino acid mutations within the M2 protein transmembrane domain were found in 
22/48 of resistant viruses. Serine to asparagine substitutions at amino acid 
position 31 were most frequent, conferring resistance in 9/22 viruses. A large 
group of phenotypically resistant viruses did not contain any M2 transmembrane 
mutations; no other mutations within the matrix genes could be attributed to the 
resistance. The occurrence of resistance over time was sporadic and often 
occurred in clusters. Some of the clusters were traced to outbreaks of influenza 
where amantadine had been used to limit the spread of disease. The emergence 
of natural resistance within the population was low and did not persist through 
influenza seasons. Analysis of the M gene sequence indicated that the two matrix 
gene products. Ml and M2, evolved independently of each other. M2 evolved at a 
faster rate of nucleotide and amino acid change than M l.
Twelve influenza A H3N2 viruses were isolated from a persistent infection of an 
immunocompromised host. An amantadine-resistant virus population emerged 
following a short course of amantadine treatment and was maintained for eighteen 
months in the absence of drug pressure. Virus isolates were mixtures of 
amantadine-sensitive and -resistant variants, which varied over time. Mutations 
within the haemagglutinin (HA) molecule suggested that the viral population had 
undergone antigenic drift over the study period. There was no detectable immune 
response within the host, therefore the drift, or evolution of these viruses had 
occurred without the selection pressure of a competent immune system. Fixed
mutations within antigenically important regions of the HA molecule were found to 
affect receptor-binding properties of the viruses. The HA molecule had an 
increased rate of evolution compared to field virus strains that circulated over the 
same period as the persistent infection. The emergence and progression of 
amantadine-resistance and viral evolution within the normal and 
immunocompromised host will be discussed.
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Chapter 1 -  General Introduction
Chapter 1
General Introduction
Chapter 1 -  General Introduction
1.1 The History of Influenza Episodes
The identification of influenza epidemics and pandemics from historical records 
and anecdotal evidence is fraught with difficulty. Over the past 250 years, at least 
ten, and perhaps as many as twenty pandemics have swept the globe 
interspersed with a much larger number of milder, more localised epidemics. 
Influenza appears to have afflicted human beings since ancient times, perhaps the 
earliest recorded epidemic was in 412 BC when symptoms and traits of a disease 
that could have been influenza was recorded by Hippocrates (285). Numerous 
episodes of influenza were described during the Middle Ages, but it wasn't until the 
early 15th century in Italy that the term influenza was introduced, describing an 
epidemic that was attributed to the influence of the stars (177).
The first pandemic with well-defined records occurred in 1580 and was believed to 
have originated in Asia from where it spread to Africa and Europe. The whole of 
Europe was affected from North to South in a six-month period, and infection 
subsequently spread to North America. From 1700 data concerning infiuenza 
pandemics is more informative and there are several documented episodes 
occurring throughout that century. The first truly global pandemic to be described 
was that of 1889. That pandemic was better documented than any other previous 
episode, since communications and travel were still relatively slow, the spread of 
infection was monitored without too much confusion (285).
Of all pandemics, none proved to be more of a threat to human survival than the 
one of 1918-19. Estimates of mortality run from a minimum of 20 million deaths 
globally, to as many as twice that number (266, 299). Influenza killed more people 
in a few months than all the armies of the 1914-18 war in five years. The US 
armed forces were particularly badly hit, about 80 percent (43,000) of the total 
number of American deaths were accounted for by influenza in 1918 (62). Why 
this pandemic was so lethal is still not clear, but an important factor was probably 
a marked increase in the virulence of the virus during the first phases of the 
pandemic. Certainly, in the pre-antibiotics age, secondary bacterial infections 
causing pneumonia and other complications accounted for many, if not most, of 
the deaths. The pandemic has been extensively chronicled and large selections of 
literature review the events in countries, towns and military camps, and personal 
experiences (62, 121, 365). Recent work has been undertaken to establish the
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genetic sequence of the 1918 virus, in particular to attempt to identify the causes 
behind its obvious virulence. Sequencing of the major surface glycoproteins has 
been accomplished but this has not revealed the underlying markers for virulence 
'(297, 298, 354). Current efforts have now been focused on sequencing the major 
internal genes of the virus (21).
Man has speculated on the cause of influenza for centuries. By the end of the 19th 
century, when the microbiological concept of infectious disease had taken root, a 
bacillus was discovered in the throats of many influenza patients that remained a 
leading suspect as the causative agent of influenza for many years. It was not until 
the late 1920s that the true viral cause of influenza was established when it was 
shown that swine influenza could be transmitted with filtered clinical samples 
(327). Initial studies on swine influenza characterised the disease produced in the 
animals and established the presence of different strains of the same virus (326). 
During an epidemic of influenza sweeping London in 1933, Smith et al. (1933) 
isolated influenza virus from the throat washings of patients (335). Washings were 
filtered and inoculated into a range of test animals with little success until some 
ferrets used in canine distemper studies were inoculated. The animals developed 
classic signs of the disease and it was found that the virus could be transmitted to 
healthy ferrets either by inoculation of infected tissue or by simple contact (335). 
Smith next performed an experiment using ferrets infected with a swine influenza 
virus from Shope’s earlier studies and found that the animals developed disease 
that was indistinguishable from that produced by virus of human origin. Shope 
(1934) confirmed Smiths findings and performed neutralisation studies using both 
swine and ferret sera (325). Influenza was first grown in cell culture during 
attempts to cultivate the virus on the chorio-allantoic membrane of developing 
hens' eggs when virus was grown in minced chick embryo suspended in Tyrode's 
solution medium (334).
'Since the original isolation of human influenza in 1933, pandemics have been 
accurately identified as a direct result of the isolation and identification of the 
viruses responsible. It has been agreed that since 1933 there have been three 
definite pandemic events (1957-58, 1968-70 and 1977-78) (52, 81, 197) and one 
episode that was not considered a pandemic only because it was not truly global 
(1946-48) (186). As influenza has the potential to be economically and socially
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devastating, it is important to analyse records from the past to gather vital 
information that might help predict or prevent pandemics of the future.
1.2 The Virus
1.2.1 Taxonomy
Three types of influenza virus (A, B and 0) and thogotoviruses comprise the family 
Orthomyxoviridae. The influenza viruses are differentiated into the three types. A, 
B and 0, on the basis of differences in the major internal proteins, the 
nucleoprotein (NP) and matrix (Ml) protein (309). Influenza A viruses have an 
animal reservoir whereas types B and 0 are found only in man. Influenza A 
viruses are further divided into subtypes based on differences in the 
haemagglutinin (HA) and neuraminidase (NA) genes. There are fifteen subtypes of 
HA of which only three, HI, H2 and H3 are frequently associated with human 
infection, and nine subtypes of NA of which two, N1 and N2 have been associated 
with human infection (382) (Table 1.1). The natural reservoir of influenza A is 
considered to be aquatic fowl as all influenza subtypes are found in wild birds 
whereas there is only limited distribution of subtypes in certain mammal species 
(383).
1.2.2 Particle Structure
Influenza viruses are small (80-120 nm in diameter) pleomorphic particles that are 
generally spherical but can also be isolated in a filamentous state (302) (Figure
1.1). The surface of the virus is covered with a layer of radial glycoprotein 
projections; there are two different types of glycoprotein spike, HA and NA (Figure
1.2). A third membrane protein, M2 is present embedded in the virus lipid 
membrane; the function of this protein is to form an ion channel (282).
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TABLE 1.1 HA and NA subtypes of influenza A viruses isolated from humans, lower animals, and 
birds
Virus Found in Species of Origin'
Subtype Humans Swine Horses Birds
HA
HI PR/8/34 Sw/la/15/30 b Dk/Alb/35/76‘=
H2 Sing/1/57 - - Dk/Ger/1215/73
H3 HK/1/68 Sw/Taiwan/70 Eq/Miami/1/63 Dk/Ukr/1/63
H4 - - - Dk/Cz/56
H5 - - - Tern/S.A./61
H6 - - - Ty/Mass/3740/65
H7 - - Eq/Prague/1/56 FPV/Dutch/27
H8 - - - Ty/Ont/6118/68
H9 - - - Ty/Wis/1/66
H10 - - - Ck/Ger/N/49
H11 - - - Dk/Eng/56
H12 - - - Dk/Alb/60/76
H13 - - - Gull/IVId/704/77
H14 - - - Dk/Gurjev/263/82
H15 - - - Dk/Aust/341/83
NA
N1 PR/8/34 Sw/la/15/30 - Ck/Scot/59
N2 Sing/1/57 Sw/Taiwan/70 - Ty/Mass/3740/65
N3 - - - Tern/S.A./61
N4 - - - Ty/Ont/6118/68
N5 - - - Sh/Austral/1/72
N6 - - - Dk/Cz/56
N7 - - Eq/Prague/1/56 FPV/Dutch/27
N8 - - Eq/Miami/1/63 Dk/Ykr/1/63
N9 - - - Dk/Mem/546/74
^ - The reference strains of influenza viruses, or the first isolates from that species are 
presented. - Not found in this species.  ^ - Subtypes are based upon the host of origin, 
geographic origin, strain number and year of isolation; the subtype is given in parenthesis, 
e.g. A/Equine/Prague/1/56 (H7N7). The host of the human influenza A strains is excluded 
from this nomenclature e.g. A/Singapore/1/57 (H2N2). Adapted from (383) and (305).
Chapter 1 - General Introducti^
FIGURE 1.1 Electron micrograph showing a cluster of influenza A virions
2'::  ^ :
FIGURE 1.2 A schematic view of the influenza A virion structure
Nucleoprotein 
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Haemagglutinin (HA)
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1.2.3 The Genome
Influenza viruses are single-stranded RNA viruses in the negative sense with a 
segmented genome. Influenza A and B virus genomes consist of eight segments 
of RNA and influenza C virus consists of seven. Each segment of the genome is 
independently encapsidated by the viral nucleoprotein (NP) and associated with a 
polymerase complex (309). The ribonucleoprotein (RNP) particle consists of viral 
RNA (vRNA), NP, and the polymerase complex. The polymerase complex is made 
up of three proteins, PB1, PB2, and PA (383). The RNP particles lie within a shell 
consisting of Ml protein, which lines the viral lipid membrane. The viral lipid 
membrane of influenza virus is acquired from the modified plasma membrane of a 
host cell during the process of budding after infection. Table 1.2 summarises the 
genome segments of influenza A and their gene products.
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1.2.4 Replication cycle
Studies on the replication cycle of influenza viruses have determined the 
approximate time for an infectious single cycle and each different stage. Following 
initial infection, detection of viral antigens at the cell surface is possible after 
approximately 4-5 hours, and budding of progeny virions from cell membranes 
after 5-6 hours (343). Compared to other viruses this is a relatively short cycle e.g. 
herpes simplex has a replication cycle of approximately 18 hours (390). The cycle 
can be categorised into 5 basic stages: 1) attachment and internalisation, 2) 
uncoating, 3) replication of genetic material, 4) assembly and 5) budding.
HA attaches to sialic acid containing glycoprotein and glycolipid receptors on 
target cells (84). The virus enters the cell by host cell-mediated endocytosis (235). 
The acidic environment within the endosome promotes the uncoating and release 
of the RNP core. This triggers a conformational change of the HA, which promotes 
fusion of viral and endosomal membranes releasing the contents of the endosome 
into the cytoplasm (106). Prior to this event, the lowered endosomal pH activates 
the M2 ion channel that opens, allowing H  ^ions to flow into the virion. This causes 
an acid-induced dissociation of the matrix protein from the RNP that allows the 
migration of the RNP through the cytoplasm into the nucleus (39).
In the early stages of virus replication the viral RNP is used as a template by the 
viral RNA polymerase complex to synthesise two different species of RNA (141). 
These are an mRNA species with a 5’-cap and poly(A) tail, and a complementary 
RNA (cRNA) that represents a full length copy of the viral RNA (vRNA) (174). PB2 
of the viral polymerase complex recognises and binds to the methylated caps at 
the 5’ termini of host cell mRNA. Endonuclease activity cleaves this short 
sequence that then acts as a primer for viral mRNA synthesis. The mRNAs initially 
synthesised are incomplete transcripts with additional short length sequences 
attached at both 5' and 3’ ends. In order for there to be production of genomic 
RNA, exact complementary template cRNAs are synthesised with no additional 
.sequences (141).
In the influenza replication cycle, there are two expression stages, early and late. 
The early stage follows primary transcription and predominantly involves the 
synthesis of the NP and NS genes (322). The synthesis of these proteins reflects
9
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their importance in the regulation of transcription and replication. It is believed that 
synthesis of the NP and NS triggers a switch from mRNA synthesis to cRNA and 
vRNA synthesis. During late stages of gene expression, the structural proteins are 
synthesised and splicing of M and NS genes occurs (139). PB1, PB2, PA and NP 
contain signals necessary for migration into the nucleus where they assemble into 
functional complexes and nucleocapsids (199). Nucleocapsids are then exported 
into the cytoplasm where a complement of genome RNP segments are assembled 
by a mechanism that is still poorly understood (139).
The structural proteins, HA, NA and M2 are synthesised in the endoplasmic 
reticulum and inserted into its membrane. During the transport of the structural 
proteins through the trans Golgi network (TGN) to the plasma membrane, the 
proteins mature and modify into their multimeric states (139). The proteins are 
incorporated into the cell plasma membrane and Ml associates with the 
membrane. It is thought that Ml forms the basis for interactions whereby vRNP 
associate with M l, assemble and bud out of the infected cell. The basis of these 
interactions is poorly understood.
' 1.2.5 Polymerase Complex (PB1, PB2, PA)
The influenza virus polymerase molecule exists as a complex formed by the PB1, 
PB2 and PA proteins (73). During viral replication, the complex is responsible for 
the synthesis of three classes of RNA molecules; 1) mRNA species that are 
capped and polyadenylated, 2) vRNA and 3) cRNA that serves as a template for 
vRNA synthesis (195). Each subunit of the polymerase complex has a unique 
function. The role of the PB1 subunit in the viral replication cycle is to aid 
elongation of the mRNA chain. Located within the PB1 protein is a series of motifs 
that are typical of an RNA-dependent RNA polymerase (284). The PB2 subunit 
binds to cap structures and is thought to be responsible for the initiation of 
transcription (28, 35). Studies have shown that replication of vRNA requires the 
PB2 subunit of the polymerase complex indicating the importance of this protein 
(279). The function of the PA subunit is not fully understood but it is thought to be 
involved in the synthesis of vRNA during the virus replication cycle.
10
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1.2.6 Non-Structural (NS1, NS2)
Segment eight of the influenza A virus genome encodes two overlapping 
polypeptides, NS1 and NS2 (201). NS1 is an RNA-binding protein and the only 
true non-structural influenza protein, only found in infected host cells. NS1 has 
been shown to have several important functions including; 1) the inhibition of host 
mRNA polyadenylation, which may contribute to virus-induced shutoff of host 
protein synthesis (257), 2) the inhibition of nuclear export of mRNA (289) and 3) 
preventing the host interferon-mediated antiviral responses (104).
Current studies have investigated the role of NS1 in controlling viral virulence; 
transfectant viruses lacking the NS1 gene (delNSI) have reduced growth in tissue 
culture and eggs when compared to wild-type viruses (104). The inhibition of virus 
growth is linked with the interferon responses in these systems. When delNSI 
virus is inoculated into interferon-lacking systems, the virus demonstrates wild- 
type growth, but in interferon-competent systems the delNSI viruses have altered 
growth properties (104). Therefore, it appears that NS1 plays an important role in 
inhibiting the interferon-mediated antiviral responses of the host. This work has 
created a novel approach to vaccine production. Viruses with altered NS1 proteins 
have been shown to be highly attenuated in mice, but provide good protection 
when the host is challenged with wild-type virus (353).
The NS2 protein is synthesised after splicing of NS1 mRNA (201). Although 
originally considered a non-structural protein, NS2 has been shown to be 
associated with purified influenza particles (403). The NS2 protein is thought to 
contain the specific nuclear export signal required to mediate vRNA export from 
the infected host cell nucleus and thus, is also referred to as the nuclear export 
protein (265). It is thought that the Ml protein plays an important role in nuclear 
export of vRNA, studies have shown a specific molecular association between 
NS2 and Ml (403).
. 1.2.7 Nucleoprotein (NP)
The influenza A virus genome is composed of ribonucleoprotein complexes 
consisting of the three polymerase molecules, and the nucleoprotein (NP). The NP
11
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is a major structural protein and has been implicated as a major factor in 
determining host specificity of influenza A H3N2 viruses (318). NP has multiple 
functions in the replication cycle of influenza viruses. NP encapsidates the naked 
RNA, it has been estimated that approximately one protein molecule interacts with 
20 RNA nucleotides (47). It is thought that multiple regions of the NP are involved 
in RNA binding, several sequences within the C-terminal two-thirds of the protein 
are in direct contact with the RNA (89).
NP is also a critical factor in the influenza replication cycle, it has been implicated 
in switching viral RNA synthesis from transcription to replication. The processes 
involved in mRNA transcription and vRNA replication are different, therefore the 
switch is essential for vRNA replication to occur. Although the exact role of NP in 
this process is not clear, there is evidence to suggest that the NP interacts with the 
influenza virus polymerase complex (27). It is suggested that NP binding to the 
PB2 unit might affect either the 5’-cap recognition or cap cleavage function of PB2 
resulting in cap-independent initiation of RNA synthesis (27).
1.2.8 Haemagglutinin (HA)
The HA molecule of influenza is an integral membrane glycoprotein and is 
encoded by RNA segment 4 (339, 383) (Table 1.2). HA is synthesised as a 
precursor, HAO; the mature HA consists of a 220 kDa trimer of identical subunits, 
each of which consists of two disulphide-linked glycopeptides, HA1 and HA2 
(192). HA1 primarily forms a membrane-distal globular head, and HA2 a central 
helix-rich stem structure (396).
Maturation and post-translational processing of HA occurs, consisting of three 
main events. There is cleavage of the amino terminal hydrophobic signal 
sequence of 14-18 amino acids, addition of N-linked carbohydrate side chains, 
and covalent attachment of palmitic acid to cysteine residues near the HA carboxy 
terminus (339, 383). Cleavage of HAO is considered to be the final processing 
step. It is cleaved into HA1 and HA2, linked by a single disulphide bond between 
residues 141 and 1372. This proteolytic processing of HAO activates the 
membrane fusion potential of HA1 and therefore it is essential for virus inf activity 
(192, 396).
12
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Influenza HA mediates the binding of the virus to target cell surfaces during the 
infection cycle. It is known that cell surface glycoproteins and glycolipids contain 
sialic acids that are receptors for influenza virus (236). Initial X-ray structure 
analysis of the HA molecule revealed that the receptor binding sites for sialic acid 
are located at the distal tip of each subunit of the HA trimer (396). Binding sites 
consisted of pockets of conserved residues whilst other residues surrounding the 
conserved pocket varied, especially when undergoing antigenic drift (396). Binding 
to sialic acids can differ between different strains of influenza virus. For example, 
human influenza A strains bind preferentially to terminal sialic acids attached with 
a-(2,6) linkages while avian strains favour binding to a-(2,3) linked sialic acid, it is 
thought that there are differences in the way that receptors with these linkages 
bind to HA (57).
Following attachment to host cells and internalisation of virus particles by host cell- 
mediated endocytosis, viral nucleic acid is released into the infected cell by a 
process involving the fusion of host and viral membranes (406, 44). Cellular proton 
pumps progressively acidify the endosomal compartments, as conditions within 
the endosome approach pH5, the HA undergoes an irreversible conformational 
change (366). One consequence of this change is that the amino terminal of HA2, 
normally buried in the interior of the native HA trimer, becomes exposed. This 
hydrophobic domain of HA2 is commonly referred to as the ‘fusion peptide’ 
because it is thought to have an important role in fusion possibly through 
interactions with target membranes (339). The HA stalk becomes inverted which 
brings the viral and target membranes closer together, and with the fusion peptide 
relocated in its correct position, membrane fusion occurs (235).
An important feature of HA is that it functions as a primary target for neutralising 
antibodies within the host. However, the RNA polymerase of influenza is extremely 
error-prone which produces a very high mutation frequency (338). Consequently, 
the HA is subject to a very high rate of mutation, estimated to be about 5.3 x 10'  ^
nucleotide substitutions per site per year (96). Influenza viruses are able to evade 
the immune system through selecting viruses with mutations in the HA molecule 
which result in either failed or reduced antibody binding. Mutations occur in the 
globular domain of HA1 around the conserved receptor-binding sites (339, 393).
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1.2.9 Neuraminidase (NA)
The NA molecule of influenza is a tetrameric membrane glycoprotein (247). It has 
a molecular mass of 240 kDa and electron microscopy studies of negatively 
stained material reveal that the protein has a mushroom-shaped morphology 
(400). The protein is membrane-anchored by a hydrophobic stalk peptide, and it 
has been shown that this anchor is located near the N-terminus of the NA 
molecule (53). Attached to the NA stalk is a globular head that contains the active 
enzyme site and the antigenic sites of the molecule (54).
Sequence comparisons of the catalytic site of the NA molecule have revealed that 
the structure is highly conserved (54). It has been shown that within the globular 
head regions, any two NA subtypes are of the order of 45 percent identical and 
sequence variation within subtypes is very low (53). The discovery that the 
catalytic site of the NA molecule shared sequence homology between all influenza 
viruses led to the realisation that inhibitors directed against this enzyme may have 
provided an effective target antiviral target influenza (374). Several NA inhibitors, 
e.g. RWJ-270201 are currently undergoing clinical trials while others e.g. 
zanamivir and oseltamivir have been licensed for clinical use (154, 228, 330).
The NA enzyme catalyses the cleavage of both a-(2,3) and a-(2,6) linkages 
between sialic acid residues and glycoconjugates (398). Sialic acid is an integral 
part of the influenza virus receptor and therefore the virus, through the activity of 
NA, destroys its own receptor (158). By destroying these HA receptors NA allows 
progeny virus particles to bud from infected cell surfaces and subsequently be 
released (222). When a virus is cultured in the presence of a neuraminidase 
enzyme inhibitor e.g. FANA, the result is that the virus is restricted to a single 
replication cycle (271). This is due to the fact that progeny virus are immobilised at 
the cell surface, evidence of which can be observed by electron microscopy when 
virions can be seen in clusters and chains at the surface of infected cells (271).
Another function of NA is that it facilitates the passage of virus through protective 
mucin covering target cells of the respiratory tract by desialyation of the sialic acid 
rich mucin (191). It is also thought that NA prevents aggregation by HA of freshly 
synthesised viral glycoproteins via sialyated carbohydrates (368).
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1.2.10 Matrix Protein (M l, M2)
The matrix gene of influenza A is coded by gene segment seven and represents a 
highly conserved bicistronic gene (203). It codes for two proteins; one open 
reading frame codes for the matrix (Ml) protein and the other for the M2 protein in 
a +1 reading frame (204). The Ml protein represents the most abundant protein 
found in the influenza A virion, forming a matrix the lies between the lipid 
membrane and the ribonucleoprotein (RNP) core (402). Ml protein plays a role in 
regulating the switch from RNA replication to virus maturation (402, 404). Studies 
have demonstrated this by providing evidence that Ml protein inhibits the 
transcription activity of the RNP-associated RNA polymerase (133).
The potential for a second coded matrix polypeptide was discovered when a 
second open reading frame was found within the matrix gene (4, 200). The 
influenza M2 protein is abundantly expressed at the infected cell surface (161), 
although M2 is greatly underrepresented in virions with as few as 23-60 molecules 
incorporated into virus particles (411). M2 is a 97 amino acid integral membrane 
protein consisting of a disulphide-linked homotetramer (348). It comprises three 
domains, a 24 amino acid N-terminal extracellular domain, a transmembrane 
domain of 19 amino acids and a cytoplasmic tail consisting of 54 amino acids 
(Figure 1.3) (136).
The M2 protein of influenza forms an ion channel within the lipid envelope of the 
virus (Figure 1.3) (282). The discovery of the ion channel activity of M2 was a 
consequence of investigations with the anti-influenza drug, amantadine (346). M2 
predominantly forms proton channels promoting the transfer of ions (281). 
Electrophysical measurement studies carried out using M2 expressed in Xenopus 
laevis (282), expressing M2 in mammalian cells (46), and by incorporating M2 into 
planar lipid membranes (360) have demonstrated the ion channel activity of M2. It 
has been shown that M2 ion channel has high selectivity for ions and low 
permeability for other cations and anions e.g. and Cl' (46).
15
Chapter 1 General Introduction
FIGURE 1.3 The influenza A M2 protein
External
Cytoplasmic
The structure of the protein is illustrated as (A) the 97 amino acid monomer, (B) the tetramer 
structure that forms a channel in the virus membrane and (0 ) the hydrophobic 
transmembrane domain of the protein spanning the virus membrane. Adapted from (202) 
and (348).
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M2 has been shown to play a functional role in two stages of the replication cycle 
of influenza (136). Each stage has been shown to be related to the functionality of 
haemagglutinin (139). After attachment and internalisation of the influenza virion, 
proton pumps cause a gradual reduction in endosomal pH. When internal 
conditions reach between pH 5 and 6, they trigger a conformational change in the 
haemagglutinin which promotes fusion of viral and endosomal membranes (106). 
As a result of lowered endosomal pH, the M2 ion channel opens allowing H  ^ ions 
to penetrate the virion, thus lowering the pH. This causes a dissociation of the Ml 
protein structure, liberating the RNP for transport to the nucleus.
In certain pathogenic avian strains of influenza, e.g. fowl plague virus, M2 has a 
second role in modifying the pH of the TGN (346). Within the lumen of cisternae 
and vesicles of the TGN, acidic conditions are maintained by cellular proton 
pumps which transport H  ^ ions into the lumen. The fusion activity of these avian 
HAS is proteolytically activated by proteases such as furin (341). This occurs in the 
TGN and renders them vulnerable to structural changes on exposure to low pH 
(157). Electron microscopy studies with amantadine have shown that the direct 
consequence of avian HA being exposed to pH lower than pH 5 is not preventing 
the formation of budding particles, but blocking their release (346).
The function of the M2 ion channel is discussed in greater detail later in Chapter 4, 
section 4.1.4.
1.3 Infection and disease
Influenza is generally a self-limiting disease of the upper respiratory tract in 
humans. The most common route of transmission person to person is through 
respiratory secretions. Infectious virus particles are spread through droplets of 
several microns in diameter expelled from coughing and sneezing or by the 
production of finer particle aerosols (3). There is also evidence that influenza can 
be transmitted by indirect contact via contaminated surfaces (351).
Infection is initiated in the upper regions of the respiratory tract, primarily the 
tracheobronchial epithelium, and then gradually spreads to the rest of the 
respiratory tract. The replication cycle of the virus lasts approximately four hours,
17
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whereby progeny virions are released from infected cells and capable of infecting 
surrounding cells, and so the cycle continues. The incubation period of the virus 
can range from 1-7 days but on average lasts approximately 2-3 days (260). Titres 
of virus found in respiratory secretions can be high and this, coupled with the short 
incubation period and relatively long periods of virus shedding, has resulted in a 
highly infectious virus. Influenza can rapidly spread through a population with 
devastating effects as demonstrated in frequent epidemics and less frequent but 
more severe pandemics that have occurred over history (62).
The onset of illness for influenza A gives rise to symptoms including malaise, 
feverishness, chills and headache. The onset of disease is usually accompanied 
by a non-productive cough and such symptoms may last for 3-4 days but cough 
and malaise might persist for 1-2 weeks (260).
Complications associated with typical influenza infections are rare but individuals 
within at risk groups e.g. the elderly and those suffering from respiratory or other 
chronic medical conditions, are at greatest risk for developing complications (259). 
These may include acute bronchitis (56), otitis media (108) and pneumonia (219). 
Influenza viruses have been associated with croup (laryngotracheobronchitis), 
especially influenza A which appears to cause more severe disease than influenza 
B or 0 (344). Neurological complications have been associated with influenza 
infections, the most common ailment in children is Reye’s syndrome. This 
presents as an acute encephalopathy that has been linked with children taking 
aspirin during, or after, an influenza infection (60, 241). This complication has 
been associated mainly with young children infected with influenza B, which is the 
primary viral cause of the syndrome (58).
1.4 Immunity
1.4.1 Humoral Immunity
The immune response initiated by the body following the invasion of influenza 
virus particles takes on two forms, neutralising antibodies and a cell-mediated 
response. The neutralising antibody response represents the first line of specific 
defence against the virus. Evidence for this immune response was first discovered
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by studying the disease in ferrets where infected ferret serum neutralised virus in 
test animals (335). The primary neutralising antibody response against influenza 
infection is directed against the main surface antigen HA (372) although anti­
neuraminidase (188) and anti-M2 (362) antibodies have also been implicated in 
the antibody response against infection. The immunity provided by serum IgG 
antibody is short lived due to pressure exerted on the antigenic regions of the HA 
molecule, specifically the HA1 domain which drives it to mutate and therefore 
escape the neutralising effect of the antibody. This ensures that infection with one 
type or subtype of influenza does not provide protective immunity against others.
1.4.2 Cellular Immunity
A second form of immunity provided is cell mediated. Cytotoxic T cells can provide 
protection against influenza but unlike neutralising antibody they can provide 
cross-reactivity between different influenza A strains (419). The cross-reactive 
antigens recognised by the cytotoxic T cell repertoire appear to be the conserved 
internal proteins of influenza A viruses, e.g. the nucleoprotein (176). T-helper cells 
recognise peptide fragments of the virus in association with major 
histocompatibility complex class II molecules on the surface of antigen presenting 
cells.
Other parts of the immune system complete the overall response to an influenza 
infection; these include complement, natural killer cells and macrophages. Without 
neutralising antibody and cell mediated response these aspects of the immune 
system can not cope but together all form a good immune response.
1.5 Seasonality
Influenza virus circulates within a given population within defined seasons every 
year. This circulation occurs in the winter months in the Northern Hemisphere and 
in the wet season of Southern Hemisphere countries. The factors limiting influenza 
to these defined periods are still not well understood although social behaviour 
and climate are thought to play a part. Epidemics of influenza activity occur 
annually or every few years due to gradual genetic changes within the virus
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although pandemic activity is much more severe in nature but less frequent and 
unpredictable.
1.6 Genetic Diversity
1.6.1 Antigenic Drift
Influenza is a negative-stranded RNA virus that requires the presence of an RNA- 
dependent RNA polymerase to produce mRNA from a negative-sense template. 
The RNA polymerase molecule is highly error prone because it lacks 3’ to 5’ 
exonuclease activity, the proof-reading function of viral replication (338). The high 
mutation rate of the RNA polymerase, from 1 x 10'  ^ to 1 x 10'^ misincorporations 
per base site per round of copying (78), causes a build up of mutations within an 
influenza population. If any mutation confers a selective advantage then there may 
be a rapid build up of a variant population. This accumulation of mutations results 
in a gradual genetic change, or drift. If changes have occurred in the antigenic 
surface glycoproteins (HA or NA) then the virus may acquire a subtly different 
immunogenic profile, sufficient to evade the humoral antibody response and to 
reinfect. This phenomenon is described as “antigenic drift” and is responsible 
mainly for interpandemic periods of influenza activity causing large epidemics and 
localised outbreaks.
1.6.2 Antigenic Shift
The multipartite genome allows reassortment of two influenza viruses to occur. 
This genetic reassortment of dual-infecting viruses within a host cell has the 
potential to produce progeny virions with novel constellations of surface and 
internal proteins (317). This process is termed “antigenic shift”. This causes the 
sudden appearance of new viruses into the human population for whom the 
majority have no immunological memory to the novel antigenic subtype. This 
produces the infrequent severe influenza activity termed a “pandemic”.
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1.6.3 RNA Virus Populations as Quasispecies
It has been proposed that RNA viruses exist in complex populations that can 
evolve rapidly (160). Eigen etal. (1981) introduced the term “quasispecies” to refer 
to diverse RNA populations that had been studied and were observed to be 
undergoing constant change (83). Since the introduction of the term quasispecies, 
there has been some confusion to its exact definition and the word has been used 
in a variety of different ways. The widely accepted definition is that a quasispecies 
is a population of viruses containing diverse variants which are all phenotypically 
related but carry distinct genomic sequences as a result of mutation, drift and the 
impact of selection (333). However, several studies have confused the issue by 
using quasispecies to refer to each of the distinct virus sequences that together 
make up the quasispecies (92). In this study, quasispecies will be used to describe 
a population of phylogenetically related variants within an individual, i.e. a single 
strain of virus containing a heterogeneous population of variants.
The existence of quasispecies can be attributed to the genetic make-up of the 
viruses concerned. Mutant genomes are continuously generated in RNA viruses 
as a direct consequence of high mutation rates during viral replication (77). The 
RNA polymerase molecule found in influenza and other RNA viruses lacks 3’ to 5’ 
exonuclease proofreading activity, the result of which is a high rate of mutation of 
different genes (338). Mutation rates of RNA viruses during replication can be in 
the range of 1 x 10'^ to 1 x 10'  ^ misincorporations per base site per round of 
copying (78) compared to the low mutation rate in DNA replication that can be as 
low as 1 X 10'®to 1 X 10'^^  (159).
Within a quasispecies there appears to be a process of continual selection which 
has been compared to the concepts of Darwinian evolution (75). Selection 
pressures create a quasispecies that is stable until mutation happens to produce a 
new sequence that allows the variant to dominate over other existing sequences 
within the quasispecies e.g. through increased growth rate. When this happens, 
the new “fittest” sequence succeeds until it dominates and the old quasispecies 
disappears (83). The potential to generate new variants is a key feature of viral 
quasispecies and allows the virus to evolve at a fast rate. This is especially 
significant for influenza viruses where even in the absence of immune pressure, 
normally the driving force behind antigenic drift, the virus can undergo antigenic
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variation due to mutational pressure (75). This antigenic variation in the absence 
of immune pressure has been termed the “random change” model. It is proposed 
that antigenic sites located on the surface of envelope proteins will be subjected to 
less stringent structural requirements than domains involved in interactions with 
other structural proteins (76). Therefore, substitutions at these sites will tend to be 
represented more in the spectrum of mutants within the quasispecies (75).
The fitness of a virus or a particular genotype within a quasispecies is the measure 
of the individual’s ability to survive and reproduce. The success of an individual in 
evolving to gain fitness is determined not by absolute fitness, but relative fitness 
compared to other genotypes within the quasispecies (217). In order to increase 
fitness, mutations arising in the genotype must confer some sort of advantage to 
the carrier. The majority of new mutations arising in a quasispecies reduce the 
fitness of the carrier and are eventually removed from the population, this is 
classed as negative selection. A mutation arising may confer a genotype with 
fitness equal to the dominant mutation in the population, and this mutation is 
classed neutral. Occasionally, a mutation may arise that confers a selective 
advantage to its carrier enabling the individual to gain fitness with respect to the 
other genotypes present in the population; this is positive selection.
Therefore, it can be concluded that by way of a polymerase molecule that is error 
prone, RNA viruses are subject to high mutation rates and as a result exist as 
dynamic changing populations termed quasispecies. Through random change or 
when a selective pressure is exerted on the quasispecies, the distribution of 
genotypes within the population can be altered with dominant genotypes 
succeeding and displacing other variants to become the fittest genotype. An 
important source of data concerning the evolution of quasispecies can be obtained 
from individuals suffering with persistent infections. Several studies have 
discovered that in immunocomprimised patients, where persistence is as a result 
of lowered immunity, the viruses isolated can be genetically different due to 
random changes rather than immune pressure (90, 193, 304). These studies 
provided good models for investigating the dynamics of quasispecies. The fitness 
of different genotypes within quasispecies can be quantified using growth and 
competition assays, both of which will be discussed in greater detail later.
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1.7 Surveillance of influenza
Influenza activity in the UK varies considerably from year to year, a trend that is 
observed world-wide. During major epidemics a substantial proportion of the 
population can be affected and illness may be clinically severe in many. This may 
have important social and economic impacts on the infrastructure of the country 
and therefore surveillance of influenza activity during seasonal periods is 
essential. The World Health Organisation (WHO) global influenza surveillance 
monitors influenza activity on a world-wide basis. Data are collated from a network 
comprising four international centres in London, Atlanta, Melbourne and Tokyo 
and 110 national laboratories in 83 countries (391). Epidemiological data, 
antigenic and genetic composition of recently isolated strains and data on the 
ability of the current vaccine to evoke antibody responses are all assessed to aid 
the prevention and control of influenza.
Within the UK, several indicators are used to quantify the level of influenza activity 
within the population which, when considered together, describe the features of 
influenza activity each year. Data for influenza and influenza-like-illness (ILI) are 
collected in the sentinel general practice network of the Royal College of General 
Practitioners (ROGP) in England and Wales. Each week, new episodes of illness 
are calculated and the incidence rates calculated per 100,000 population (87); this 
weekly measure of activity is referred to as the ROGP index. The index provides a 
Tool to compare the influenza activity of different years and to identify epidemic 
activity (66-68, 70, 169, 170, 389). To aid the interpretation of influenza activity, 
defined thresholds have been implemented that identify baseline (<50 cases of I LI 
per 100,000 population), normal (50-200 per 100,000 population), high (200-400 
per 100,000 population) and epidemic (>400 per 100,000 population) influenza 
activity (69). Although limited in the amount of virological data that can be 
extrapolated from them, they represent a simple and logical representation of 
influenza activity.
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1.8 Prevention and treatment of influenza
1.8.1 Vaccination
The earliest vaccinations were performed by simple injection of live virus into 
human subjects who developed immunity to subsequent challenges (102). The 
first inactivated vaccine was produced in 1937 (336) but it was not until 1943 that 
the first vaccine trials were performed in the US showing that the newly developed 
influenza vaccine was approximately 70% effective at protecting subjects from 
infection. Larger trials were performed on US army recruits which provided more 
evidence that the vaccination afforded personnel with consistent protection (101). 
This eventually led to the licensing of the first influenza vaccine in the USA in 1947 
(399).
Since these early vaccine trials there have been several developments that have 
improved the overall efficacy and tolerance of influenza vaccines. Currently, 
influenza vaccines are manufactured as trivalent vaccines containing two type A 
viruses and one influenza B strain (60). The vaccines are inactivated and highly 
purified, cultured in pathogen-free embryonated hens’ eggs. There are four types 
of vaccine of which two are currently available, the split or disrupted particle and 
sub-unit or surface antigen vaccines (72). Vaccines are administered as an 
injection by the intramuscular route with generally one dose for adults and two for 
children less than twelve years of age. The overall efficacy of vaccines in healthy 
adults is approximately 70-90% but is often lower in certain groups such as the 
elderly and young children (60).
Current research, which is shaping the future of vaccine production, has recently 
had many encouraging breakthroughs. Cold-adapted vaccines have been used 
successfully in the former USSR and Russia for the past 30 years (185). They 
utilise a donor strain passaged in tissue culture at 25°C which becomes attenuated 
in humans. The vaccine strain is created by producing a reassortant cold-adapted 
virus presenting the surface antigens of the desired vaccine strain. The resulting 
virus induces longer lasting immunity than killed virus vaccines. Clinical trials in the 
USA have established the safety, immunogenicity and efficacy of cold-adapted live 
attenuated vaccines using A/Ann Abor/6/60 and B/Ann Arbor/1/66 as donor strains 
in children, young adults and the elderly (24, 254, 258).
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To improve the delivery of influenza vaccines, and therefore increase the 
immunological response, research has been carried out into liposomes which act 
as adjuvants for the vaccine antigen. Haemagglutinin and neuraminidase 
preparations have been incorporated into liposomal structures (virosomes) and 
tested in preclinical investigations. In the animal model these virosomes stimulated 
increased primary and secondary antibody responses when compared to original 
antigen preparations (120). Clinical trials of these vaccines in human subjects 
have demonstrated that immunogenicity in the host was significantly better than 
existing vaccines (55,109).
The other main area of research into novel vaccines involves DNA vaccination. 
The principle is to insert the DNA coding sequence of antigen of choice into a 
bacterial plasmid that is then delivered into the body, usually muscle, where the 
antigen is expressed from the plasmid and induces an immune response (381). 
Early investigations using animal models showed potential with DNA plasmids 
expressing HA eliciting protection to mice against lethal challenges with influenza 
virus (303). A similar investigation using a plasmid encoding influenza A 
nucleoprotein also provided mice with protection against influenza infection (363). 
Human trials with DNA vaccines have not yet started because there are still 
certain safety concerns. Anti-DNA antibodies, host immune status and 
transformation of cells into tumours must all be considered and investigated before 
any DNA vaccine can be injected into human subjects (380). The delivery of DNA 
vaccines with the help of adjuvants has been investigated. It has been found that 
adjuvants enhance the efficiency of influenza DNA vaccines; trials in mice using a 
cytokine gene as an adjuvant significantly improved the protection conferred by 
the vaccine (213).
1.8.2 Antiviral drugs
The potential threat of future influenza pandemics and the continuing generation of 
drug-resistant viruses to current compounds leave no doubt that the development 
of new antiviral drugs against influenza is required. Antiviral drugs have been, or 
are in the process of being designed to act against virtually every stage of the 
influenza infectious cycle. An obvious target is during attachment of influenza virus 
particles to the target cell. There are two possible mechanisms to achieve this, 1)
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by forming complexes with sialic acid receptors on target cells rendering them 
unavailable to haemagglutinin, or 2) by blocking the binding domains of the 
haemagglutinin molecule with a compound that complexes with sialic acid on the 
cell surface binding site. Research into sialic acid derivatives has produced 
compounds with varying potencies. The most potent compounds to date have 
been polyacrylamide derivatives incorporating sialic acid that bind to and block the 
receptor-binding sites on the haemagglutinin (214, 231). Published data 
concerning these, and other inhibitors of viral attachment, have involved in vitro 
testing and as yet no data on in vivo studies have been published (214, 231).
The stage of virus entry presents a major problem in the development of inhibitors. 
Influenza viruses enter the target cell after attachment by a process of host cell- 
mediated endocytosis. A compound targeting this would be very difficult to develop 
because this represents an important function of the host cell (207). During the 
process of virus uncoating, there are two stages that can be targeted. Firstly, 
during membrane fusion between viral and endosomal membranes, and secondly, 
the release of RNP by Ml allowing its migration to the nucleus (379).
A series of compounds, sulfonic acid polymers, were shown to be inhibiting 
towards influenza A in tissue culture. These compounds proved to be potent and 
selective when administered to immunocompetent mice and the mode of antiviral 
activity was determined to be inhibition of virus-cell fusion (171).
In order for virus replication to occur, release of the ribonucleoprotein (RNP) from 
Ml is essential. The antiviral drugs amantadine and rimantadine both affect the 
M2 ion channel, blocking the flow of ions and therefore inhibiting the release of 
the RNP (137). The majority of influenza antiviral research over the past two 
decades has focused on amantadine and rimantadine; these two compounds are 
discussed in section 1.8.3.
The preparation of anti-sense oligonucleotides has provided the means to block 
the copying of influenza virus. These short sequences of nucleotides can bind to 
the RNA polymerase and specifically inhibit cap-dependent mRNA synthesis 
(207).
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Ribavirin, a synthetic nucleoside analogue has been shown to have antiviral 
activity for several viruses including HIV, herpes simplex viruses and influenza A 
and B. It is thought to act by suppressing the synthesis of viral nucleic acid by 
reducing available guanosine triphosphate. Ribavirin has also been shown to have 
a direct effect on the viral polymerase (267). A number of clinical trials have 
demonstrated the effectiveness of ribavirin at reducing the severity of influenza 
virus infections in patients given the drug prophylactically, however, it had no 
effect on the manifestation of mild illness (229). The use of ribavirin is limited due 
to its administration, requiring lengthy therapy and hospitalisation.
For the remaining stages of the infectious cycle, i.e. secondary transcription, 
replication of vRNA, translation of mRNA, post-translational modification of viral 
proteins, and assembly and release of progeny virions, there are surprisingly few 
viral inhibitors that have been developed (207).
1.8.3 Amantadine and rimantadine
The antiviral activity of amantadine was first reported by Davies et al. (1964) in a 
series of experiments that demonstrated the inhibition of influenza infections in 
tissue culture, chick embryos and mice by amantadine (65). This work was 
followed by numerous other studies investigating the properties of amantadine. In 
1966 the drug was licensed for clinical use but only against influenza A subtype 
H2N2 (249). The following years saw the disappearance of H2N2 and the 
emergence of H3N2 subtypes which caused severe pandemics (52). Amantadine 
could not be legally used against these new influenza A viruses until 1976 when 
the drug was relicensed for all influenza A type viruses (249). Early studies 
concluded that amantadine prevented the adsorption of influenza to target cells 
(65) but it was not until approximately two decades later that the target protein of 
amantadine in influenza A was discovered (142).
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1.8.3.1 Structure
Amantadine is a symmetrical, thermally stable amine with a cage-like structure 
(Figure 1.4) (8). After the initial synthesis of amantadine in 1963 studies were 
carried out to discover more potent agents with a broader spectrum of action. 
Amino groups and other sites were substituted on the amantadine molecule and 
structural variations of the drug were developed and tested. It resulted that very 
few of these congeners had any useful antiviral activity against influenza. 
However, a small group of derivatives, where substitutions on a specific site had 
been performed, demonstrated increased potency against influenza, and one of 
these drugs was rimantadine (2). The structures of these two compounds are 
illustrated in Figure 1.4.
FIGURE 1.4 Influenza A anti-M2 protein drugs
NH2*HCI
H -G -C H 3
The structures of (A) 1-amino adamantane hydrochloride (amantadine) and (B) a-methyi-t 
adamantane methyiamine hydrochloride (rimantadine) are iiiustrated. Taken from (136).
Amantadine and rimantadine inhibit two stages of the infectious cycle of influenza 
A virus (136). Early studies revealed that the drugs had no direct inactivating effect 
on virus infectivity or adsorption to target cells but uncoating of virus was markedly 
inhibited by amantadine (179). It is now known that amantadine prevents initiation 
of primary transcription as a direct result of inhibiting the dissociation of Ml and
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RNP (137). The drugs act as allosteric blockers (8), which appear to bind to the 
M2 protein causing a conformational change within the pore-forming region. This 
inhibits the flow of protons through the ion channel and stops acidification of the 
virus interior (283). The consequence of this is that the RNP is not transported to 
the nucleus and hence transcription, translation, and assembly of progeny virions 
cannot occur.
Amantadine is also known to affect certain pathogenic avian strains of influenza A 
virus as an indirect consequence of inhibition of M2 function (136). Where 
intracellular proteolytic cleavage of HAO to HA1/HA2 occurs, it renders the virus 
sensitive to the late action of the drugs (136). Amantadine blocks the M2 channels 
which causes an increase in acidity within the TGN and triggers the irreversible 
conformational change in HA. As a result, release of virus is prevented and virus 
replication inhibited due to the expression of the low pH form of HA on the surface 
of the virus (310). The antiviral activity of amantadine and rimantadine is 
discussed in greater depth in Chapter 4, section 4.1.5.
1.8.3.2 Clinical Efficacy of Amantadine and Rimantadine
The effectiveness of amantadine and rimantadine for both the prophylaxis and 
treatment of influenza infections has been established through many studies over 
the past 30 years (37, 74, 149, 165). The benefits of prophylactic treatment have 
been proven using experimental challenges of healthy individuals with influenza A 
(300). Vital dose-response studies have helped determine the optimum dose for 
protection; the drugs have a low toxic-to-therapeutic ratio that makes dosing vitally 
important (8). In naturally occurring influenza infections in adults and children, 
amantadine and rimantadine have been shown to have an efficacy of up to 90% in 
preventing influenza illness (37, 61). Within closed populations, e.g. boarding 
schools, nursing homes, prisons etc, the drugs have also been shown to be 
effective in preventing illness, and in some cases reducing mortality (14, 275).
Amantadine and rimantadine have proven equally effective in treating acute 
influenza infections in healthy adults, children and the elderly (26, 130, 152). The 
drugs have an equal efficacy compared to the annual vaccine and are able to
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prevent illness or reduce influenza-like symptoms. However, it is thought that 
administration of amantadine and rimantadine must be initiated within 48 hours of 
the onset of symptoms if they are to be effective.
1.8.3.3 Disadvantages of Amantadine and Rimantadine
Until 2000, amantadine and rimantadine were the only antiviral drugs licensed for 
the treatment of influenza. They have been proven to be potent inhibitors of 
influenza and reduce disease but their use in the UK has been limited. The main 
limitation in their use is that they target the M2 ion channel and therefore are 
inhibitory only to influenza A viruses which possess the protein. Infections caused 
by influenza B or 0  virus cannot be treated with these drugs. Gene segment six of 
influenza B and 0 codes for the NB and CM2 proteins respectively (164, 323). 
These proteins have been shown to be analogous to the influenza A M2 protein in 
respect to size and post-translational modifications (218, 394), and the NB protein 
has been shown to form ion channels (349). However, the replication of influenza 
B and C viruses is not selectively inhibited in vitro or in vivo by amantadine or 
rimantadine (138).
Another major drawback that has limited the use of the drugs is the emergence of 
resistance. Influenza viruses resistant to amantadine and rimantadine can be 
readily isolated in vitro by growing the virus in the presence of drug (10). Data from 
animal models have suggested that virulence, pathogenesis and transmissibility of 
amantadine- and rimantadine-resistant viruses are unaltered compared with wild- 
type sensitive virus (22, 350). Studies with avian models demonstrate that 
resistant viruses can be readily detected in birds and that the virus is both virulent 
and transmissible to other birds (22). In the ferret model, inoculation of resistant 
viruses demonstrated their unaltered virulence and growth characteristics (350). It 
has been shown that viruses display cross-resistance to both amantadine and 
rimantadine (23).
It is well established that the principle determinant of amantadine-resistance and 
the target of the drug is the M2 protein (137). Comparisons of sequences of the M 
genes of resistant and sensitive viruses show that nucleotide changes within the M
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gene result in an amino acid change in the M2 protein (25). The position of these 
mutations are downstream of the termination site for translation of M1 and 
therefore it is only the sequence encoding M2 translated from the spliced mRNA 
that is altered (137). The genetic basis for resistance is single amino acid changes 
at one of five positions within M2 (118, 142). Resistance to amantadine and 
rimantadine will be discussed in greater detail in Chapters 3 and 4.
The emergence of resistant epidemic strains is, in theory, a possibility. If an M 
gene coding for resistance was introduced into a location where an epidemic strain 
was emerging, then it is possible that the resistant virus could disseminate widely 
(144). However, it is unknown whether the resistant strain would be stable enough 
to survive without selective drug pressure and whether it would be able to compete 
with the circulating wild-type virus. The relatively limited use of amantadine (25) 
may not be sufficient to exert enough selective pressure on the virus to cause 
substantial transmission of resistant virus during an epidemic.
When amantadine and rimantadine were first licensed, there were initial fears 
concerning side effects experienced by patients undergoing treatment. It has been 
reported that these occur in approximately 6% of patients, more often in the elderly 
and include neurological reactions, light-headedness and an inability to 
concentrate (25, 136). Due to the lower incidence of neurological side effects 
associated with rimantadine treatment, it is now perceived to be the drug of choice 
in some countries, although it can still cause gastro-intestinal complaints and 
nausea and vomiting in some cases (8). In general, there seems to be a lack of 
awareness of the potential of these drugs for preventing or limiting influenza A 
infections.
1.8.4 Neuraminidase Inhibitor Drugs
Early attempts to utilise the neuraminidase surface glycoprotein as a target for 
antiviral therapy were made by trying to synthesise analogues of sialic acid 
(Neu5Ac) as an antiviral agent (82). These experiments had little success in 
demonstrating any antiviral activity but gradually more potent molecules were 
developed. It was not until the mid-1970s that the actual mode of action of sialic 
acid as a neuraminidase inhibitor (Nl) was discovered. It was demonstrated by
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electron microscopy that by adding analogues of sialic acid to virus cultures, newly 
synthesised progeny virions were not released from the surface of the host cell 
(271). Particles would accumulate at the cell surface and released virions formed 
large aggregates mainly through virus-virus and virus-cell interactions (271). The 
next major breakthrough in the development of the drugs came with nucleotide 
sequencing and X-ray crystallography studies of the neuraminidase molecule (54, 
369). This allowed a greater understanding of the structure of the enzyme and its 
active binding site and further encouraged the development of new sialic acid 
derivatives with greater antiviral properties. One such group of compounds was 
reported by von Itzstein et al. (1993) and included 4-guanidino-Neu5Ac2en, 
zanamivir (374). Experimental evidence showed that the OH group found at 
carbon atom 4 in the structure of this compound was positioned close to the active 
site on the NA molecule (Figure 1.5). Substituting the OH group with a guanidino 
group resulted in an increase in antiviral potency (374). Zanamivir has been 
developed by Glaxo Wellcome under licence from the Australian company. Biota 
Holdings.
FIGURE 1.5 Diagrammatic representation of neuraminidase inhibitor compounds blocking the 
active site of the NA molecule
SIALIC ACID ZANAMIVIR OSELTAMIVIR
Hydrophobic
CarboxylateCarboxylate
Glycerol Glycerol
Guanidine
Hydrophobic 
pocketHydroxyl
Active site of 
neuraminidase
Green lines represent bonds formed between different groups on the drugs and amino acids 
within the site. Zanamivir and oseitamivir bind to the site more readily than sialic acid 
through a guanidine and hydrophobic group respectiveiy, increasing their antivirai potency. 
Adapted from (210).
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During all studies and trials involving zanamivir attempts have been made to 
monitor levels of resistance. In vitro, the levels of resistance are low compared to 
similar studies with anti-M2 protein drugs. Resistant viruses emerge after one or 
two passages in the presence of amantadine and rimantadine (268). Resistant 
viruses have been isolated by passaging in the presence of zanamivir but 
resistance is significantly slower to develop compared with the anti-M2 protein 
drugs (278). Mutations that reduce the sensitivity of influenza A and B viruses to 
neuraminidase inhibitors have been mapped to the active site of the 
neuraminidase (128, 243). These mutations interfere with the action of sialic acid 
analogues inhibiting the release of progeny virions from the infected cell. 
Mutations conferring resistance have also been mapped to the haemagglutinin 
molecule (124, 242). Mutations within the haemagglutinin are thought to affect the 
affinity or specificity of haemagglutinin binding reducing the dependence on the 
neuraminidase for progeny release (242). To date the generation of resistance in 
humans has not been readily documented. One of the few cases observed 
involved the isolation of a resistant influenza B virus from an immunosuppressed 
patient (127). The virus isolated had mutations within both the haemagglutinin and 
neuraminidase that reduced the sensitivity of the virus to zanamivir by 1000-fold. 
'Compared to amantadine and rimantadine where resistance has affected 
administration of the drugs, the resistance frequency of zanamivir is very low and it 
is thought that this will not affect the clinical usefulness of the drug (125).
Phase I and II clinical trials have proven the potency and safety of zanamivir and 
phase III trials have proven its efficacy in human subjects. The trials have 
consisted of randomised, double-blind placebo controlled studies of large groups 
of subjects in different locations. Results from trials in both the Northern 
Hemisphere (150, 153, 230, 250, 252) and the Southern Hemisphere (228) 
provided the evidence required to demonstrate the clinical usefulness of the drug. 
The main conclusions from these studies were that in subjects treated with 
zanamivir, symptoms of headache, sore throat, fever, cough, weakness and 
muscle ache were alleviated faster than placebo groups. This was 1 to 2.5 days 
between treated and placebo groups but for the drug to be clinically effective it had 
to be administered less than 30-40 hours after the onset of symptoms. The 
incidence of complications and use of antibiotics was also reported to be lower in 
treated groups. Side effects were described in approximately 3% of subjects, the 
most common being sinusitis, diarrhoea and nausea, but this was comparable to
I
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placebo groups. Zanamivir is applied topically to the respiratory tract, patients 
orally inhale the drug using a Diskhaler (252) but it has been reported that this can 
cause bronchospasm and/or a decline in lung function in some patients with 
underlying respiratory disease (395).
Another promising Nl drug, oseitamivir (Tamiflu) was first described in 1997 (190) 
and was licensed in the US in late 1999. The main advantage oseitamivir has 
over zanamivir is that the bioavailability of the drug is much greater and it can be 
taken orally. The efficacy and safety of oseitamivir has been proven and the 
results suggest that the drug is effective at reducing the duration and severity of 
illness (146, 154, 245, 261, 361). Oseitamivir significantly reduced the duration of 
illness in infected patients by 25% and if treatment was initiated within 24 hours of 
the onset of symptoms the reduction in duration of illness was further reduced to 
37%. It was reported that the overall health of treated patients was improved in 
respect of symptoms, activity and sleep quality with secondary complications 
including sinusitis, bronchitis and pneumonia also reduced. The overall 
conclusions from the above studies are that oseitamivir is well tolerated and 
treatment reduces the severity and duration of acute influenza infection.
Current research is continually developing new Nl drugs. One such compound, 
RWJ-270201 is produced by BioCryst Pharmaceuticals and is currently 
undergoing in vitro and in vivo trials (16, 330, 332). Preliminary results from these 
early studies suggest that human volunteers infected with influenza show 
significant reductions in virus titres after treatment with the drug. Further trials will 
be required to determine the full clinical effectiveness of the drug before it appears 
on the market.
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1.9 Objectives
The main objective of this thesis is to investigate the relationship of the evolution 
of influenza A matrix genes to their functional properties. The main function of one 
matrix gene spliced product, the M2 protein, is to regulate ion exchange across the 
influenza A virus envelope. This function has been shown to inhibited by the anti­
influenza drug amantadine.
The first set of objectives is to study the M2 protein of a large collection of 
influenza A viruses that circulated the UK general population from 1958-1999. The 
scale of the study has not previously been performed in respect to the number of 
viruses and years of circulation. It is made especially unique because the viruses 
in this study have circulated a geographically isolated population. It is important to 
assess the impact of antiviral drugs on a population and to identify causes of drug- 
resistance. There are several aims to this part of the work:
• Instigate methods and protocols to assess the susceptibility of influenza A
viruses to amantadine by phenotypic and genotypic methods
• Estimate the frequency of amantadine-resistance in influenza viruses of H3N2, 
H2N2 and HI Nl subtypes that circulated the UK from 1958-1999
• Sequence the M2 protein of resistant viruses to determine the underlying 
molecular changes responsible for reducing the sensitivity of virus to drug
• Assess the frequency of amantadine-resistance mutations occurring within the 
population
• Sequence a representative number of amantadine-sensitive viruses over an 
equivalent time period to analyse the drug genotype of these viruses
• Estimate the rate of evolution of the matrix gene and its’ spliced products (Ml
and M2) and relate findings to functional properties of the genes
The second set of objectives is to involve the study of a set of viruses obtained 
from a persistent infection of an immunocompromised patient. Twelve viruses 
were isolated over a period of eighteen months and represent a unique opportunity 
To study the progress of viral population dynamics and evolution over the period of 
infection. The main objectives in this research are:
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• Characterise each isolate phenotypically in respect to matrix gene function
• Sequence the matrix gene products of each virus to evaluate changes in 
genotype over the persistent infection
• Assess changes in the antigenic profile of each virus to evaluate selective 
pressures presented in the host
• Estimate the rate of evolution of the matrix and haemagglutinin genes from the 
persistent infection and compare to representative field strains
Therefore, it is proposed that the work is unique in two ways. Firstly, it represents 
the largest study of amantadine susceptibility in influenza A viruses to date, and is 
the first major assessment of resistance in the UK. With the predicted increase in 
use of influenza antiviral drugs, this kind of data is essential in understanding the 
mechanisms of emerging resistance. Secondly, the study of a persistent infection, 
to our knowledge the longest period of influenza persistence recorded to date, will 
enable a unique opportunity to study viral evolution within a single host. The two 
sets of data will complete a detailed analysis of matrix genes and relationships to 
functional properties in both a large population and a single host.
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2.1 Virus Stocks
The majority of viruses used in the study were originally isolated from clinical 
respiratory specimens in mammalian tissue culture (>75%) while viruses isolated 
prior to 1985 were isolated in the allantoic cavity of fertile hens’ eggs. Viruses were 
stored at -70°C or freeze-dried at time of isolation. Freeze-dried material was 
reconstituted in 1 ml phosphate buffered saline (PBS) and inoculated into Madin- 
Darby canine kidney cells (MDCK), which were obtained from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK).
2.2 Cells
Confluent MDCK monolayers were washed twice with PBS and then rinsed with 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; Life Technologies Ltd, 
Paisley, UK). Excess trypsin was removed and the monolayer incubated at 37°C 
for 15 min. Cells were resuspended in minimal essential medium (MEM) with 
Earle’s salts and 25 mM N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulphonic acid] 
(HEPES; Life Technologies Ltd) with 10% fetal bovine serum (FBS; Life 
Technologies Ltd) supplemented with gentamycin sulphate (50mg/ml; 
Biowhittaker, Walkersville, Maryland, US). Cells were incubated at 37°C until 
confluent and maintained at 33°C in MEM until required. MDCK cells were 
,subcultured with a split ratio of 1:4. Primary rhesus monkey kidney cells (RMK; 
ECACC) were passaged using the above method and subcultured at à splitting 
ratio of 1:2 to 1:4.
2.3 Culture of influenza Virus in Mammalian Tissue Culture
MDCK and RMK monolayers were subcultured into glass tissue culture tubes and 
incubated at 37°C until confluent. Cells were washed twice with PBS and 100 pi 
virus inoculum added to the tube. Two tubes, one MDCK and RMK were 
inoculated for each virus. An adsorption period of 1 hour was allowed during which 
the tubes were occasionally rocked to ensure the cell monolayers were covered by 
the virus inoculum. After the adsorption period, virus inoculum was removed from 
The tubes and 1 ml post-inoculation medium was added. Post-inoculation medium
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was pre-prepared containing MEM supplemented with penicillin/streptomycin 
solution (final concentration 1%; PAA Laboratories, Austria) and 1 Tosylamide-2- 
phenylethyl chloromethyl ketone-treated (TPCK) trypsin (final concentration 1.25 
mg/ml; Worthington Bioproducts Ltd., Lakewood, NJ, US). Tubes were incubated 
at 33°C on a roller for seven days during which each inoculated tissue culture was 
examined microscopically for the appearance of cytopathic effect (CPE). 
Haemagglutination assays (section 2.8) were performed on all cultures on day 7 to 
detect viral growth. Positive cultures were aliquoted and stored at -70°C, negative 
cultures were passaged into fresh tissue cultures and incubated for a further seven 
days. If no viral titre was detected after this further seven day incubation, the 
relevant tubes were discarded.
2.4 Culture of Influenza Virus in Fertile Hens’ Eggs
Isolates that failed to demonstrate any growth in tissue culture, or viruses to be 
prepared for antigen controls were cultured in fertile hens' eggs (122). Sterile eggs 
were incubated in a humid atmosphere at 35°C for ten days. Prior to inoculation, 
each egg was individually candled to ensure that the chick embryo was alive and 
to locate the exact position of the air sac within the egg. The shell above the air 
sac of a fertile egg was removed using sterile forceps and to aid the visualisation 
of the internal components of the egg the membrane was swabbed with liquid 
paraffin. Stock viruses were diluted in saline broth (100 ml saline, 10 ml brain heart 
Infusion broth, 100 pi gentamycin sulphate) and 200 pi inoculated into the allantoic 
cavity of the egg using a 0.6 x 25 mm gauge needle (Terumo, Belgium) taking 
care to avoid damaging any blood vessels or the embryo. The egg was sealed 
with tape and incubated in a humidified atmosphere at 37°C for 72 hours. 
Following incubation eggs were placed at -20°C for 1 hour to kill the embryo and 
the allantoic fluid harvested using a plastic pastette. A haemagglutination test was 
performed on all harvested fluids and the titre recorded. Viruses were either used 
immediately or aliquoted and stored at -70°C for future use.
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2.5 Virus Titration
Viruses grown in tissue culture or fertile eggs were titrated using a plaque assay. 
MDCK cells were plated out into 12-well flat bottom microplates (Life 
Technologies) at a seeding density of 5 x 10"^  cells per well in MEM with Earle’s 
salts and 25 mM HEPES (Life Technologies) containing 10% FBS (Life 
Technologies) and incubated for 3 days at 37°C with 5% CO2 until monolayers 
were confluent. Virus dilutions were prepared by adding 100 pi of virus to 900 pi of 
virus transport medium (VTM) and then transferring 100 pi of this dilution to 900 pi 
of VTM. The serial dilution was continued until 1 x 10® and the last 100 pi 
discarded. Medium was aspirated out of each well and cells washed with PBS 
twice to ensure all serum from the medium had been washed away. To each well, 
100 pi of corresponding virus dilution was added, each dilution had duplicate wells 
and two negative control wells containing 100 pi VTM were also included. Each 
plate was agitated every 10 minutes to ensure that the monolayer was covered by 
the virus inoculum at all times and virus adsorption was for a total of one hour at 
room temperature. To prepare the agar overlay, 2 ml aliquots of 5% indubiose 
(Biosepra, France) were heated in a boiling bath for approximately 15 minutes until 
the agar was molten. Overlay medium consisting of 100 ml MEM, 20 pi of DEAE 
dextran (10%; Pharmacia Biotech, Uppsala, Sweden), 400 pi of L-Glutamine (200 
mM; Life Technologies Ltd), 1.0 ml of non-essential amino acids (Biowhittaker),
1.0 ml gentamicin sulphate at a working strength of 50 mg/ml, 5 ml of 7.5% sodium 
bicarbonate (Life Technologies Ltd), and 300 pi of TPCK-trypsin was added to 5% 
indubiose (Biosepra, Cergy-Saint-Christophe, France) in a 9:1 ratio respectively, 
allowed to cool sufficiently and then 1.5 mis added to each well. Once set, plates 
were incubated at 37°C with 5% CO2 for 72 hours. After this time, cell monolayers 
were fixed with glutaraldehyde (SERVA, Heildelberg, Germany) and stained with 
carbol fuchsin solution (Merck Ltd, Lutterworth, UK). Virus infectivity titres were 
calculated from wells containing a dilution of virus that produced approximately 30 
to 100 plaques using Equation 2.1:
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EQUATION 2.1 Method for calculating virus infectivity titre (PFU/ml)
1 1
Infectivity titre = plaque count X -------------- X   PFU/ml
Dilution Inoculum volume
2.6 Antivirai Susceptibiiity Enzyme-Linked immunoassay (EiA)
MDCK cells in MEM (supplemented with 10% FBS) were seeded (5x10® cells per 
well) into 96-well sterile microtitre plates (Greiner Labortecknik Ltd., Stonehouse, 
UK) and incubated at 37°C with 5% CO2 overnight or until cell monolayers were 
confluent. Viruses to be screened were serial diluted 10'  ^ to 10 ® in MEM, and in 
MEM with amantadine (final concentration 1.0 pg/ml; Sigma chemical Co., MO, 
US). Amantadine was used at this concentration to enable direct comparisons of 
the results obtained from this study with other published reports that had used 
similar methods with amantadine at 1.0 pg/ml (23, 25, 147, 417). Growth medium 
was removed from the wells, cells were washed once with PBS and blotted dry. 
Dilutions of virus were added (100 pi) to corresponding wells. Controls included a 
known amantadine-resistant and sensitive virus and a negative control consisting 
of plain MEM. Plates were centrifuged at 700 x g for 45 minutes at ambient 
temperature and further incubated at 37°C for 15 minutes. Virus inoculum was 
removed and replaced with 100 pi MEM (1.25 mg/ml TPCK trypsin and 1.0 pg/ml 
amantadine where necessary) before the plates were incubated at 37°C with 5% 
CO2 for 16 hours. Following incubation, MEM was removed and plates were 
.washed once with PBS. Cells were fixed using industrial methylated spirit followed 
by washing in PBS (0.01% Tween20; PBST) using a platewasher. Plates were 
blotted dry and 100 pi mouse monoclonal antibody targeting the viral nucleoprotein 
(Harlan Sera Labs, Loughborough, UK; cat. no. MAS771 b) diluted 1/1000 in PBST 
(5% w/v fat free milk) was added. Following incubation at 37°C for 60 minutes, 
plates were washed 4 times using PBST. A secondary sheep anti-mouse IgG 
antibody conjugated with horseradish peroxidase (HRPO; Sigma Chemical Co; 
cat. no. A5096) diluted 1/10000 in PBST (5% w/v fat free milk) was added (100 pi) 
and incubated for 60 minutes at 37°C. Plates were washed 4 times using PBST 
and blotted dry. 3,3',5'5'-tetramethylbenzidine (TMB; Europa Bioproducts Ltd, 
Wicken, UK) was added to each well (100 pi) and incubated at room temperature
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for 5 minutes in the dark. To stop the reaction, 100 pi 2N H2SO4 (Fisher Scientific, 
Loughborough, UK) was added before the optical density (CD) of individual wells 
was read using a Multiskan RC plate spectrophotometer (Labsystems) at a dual 
wavelength of 450 and 620 nm. Dual wavelength measurements were used to 
reduce the background ‘noise’ created by scratches or particulate matter on the 
wells. This ensures a more accurate colorimetric reading of the contents of the 
wells. Viruses exhibiting less than 50% inhibition in presence of drug were 
classified as resistant. Inhibition was calculated using Equation 2.2:
EQUATION 2.2 Method for calculating percentage inhibition of infiuenza when grown in the 
presence of amantadine
CD with drug -  CD control
% Inhibition = 100 -   X 100
CD without drug -  CD control
2.7 Plaque Reduction Assay (PRA)
The plaque reduction assay (PRA) was similar to the virus titration method 
(section 2.5). To determine the susceptibility of virus replication to amantadine, 
duplicate sets of plates were set up and quadruplicate wells inoculated with each 
virus dilution. Two wells were subsequently maintained with amantadine (1.0 
pg/ml) and two wells without. Inhibition of the virus to amantadine was determined 
by counting mean plaque numbers per dilution in replicate wells in the presence 
and absence of the drug. The percentage reduction in plaque forming units per ml 
(PFU/ml) was then calculated. Viruses showing greater than 50 percent reduction 
were considered sensitive and those with less than 50 percent inhibition were 
resistant.
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2.8 Haemagglutination Assay (HA) for Influenza
Using a multichannel pipette, 80 pi PBS was added to the each well of the first row 
of a 96-well ‘U’ bottomed plate and 50 pi PBS was added to the remaining seven 
wells in each of the rows. Culture fluid (20 pi) was added to the first well of the 
appropriate row, this being repeated for all samples to be tested. The contents of 
the first row were mixed (five-fold dilution) using a multichannel pipette before 50 
pi was transferred to the next well. The mixing and transferring was repeated until 
the final row (ten-fold to 320-fold dilution) where the last 50 pi fluid was discarded. 
Fresh turkey erythrocytes were prepared by washing with PBS and a 0.5% 
suspension was made using PBS as the diluent. Turkey erythrocytes (50 pi; 0.5%) 
were added to each well and mixed by gently tapping the plate. Plates were 
incubated at room temperature for 50 minutes and then the haemagglutination titre 
read by identifying the well exhibiting approximately 50 percent agglutination. This 
end point was recognised as the point at which there was partial agglutination 
occurring, recognised as a “doughnut-shaped” agglutination of erythrocytes.
2.9 Haemagglutination inhibition (HAi) for infiuenza Serology
To analyse serum samples for evidence of previous influenza infection and to 
determine the nature of the subtype of virus involved in that infection, HAI tests 
were performed. The patients' sera and control sera were first treated to remove 
any non-specific inhibitors by using receptor-destroying enzyme (RDE). One 
volume of serum was added to 4 volumes of RDE and incubated for 18 hours at 
37°C. In order to inactivate the RDE, samples were incubated at 56°C for 1 hour. 
Relevant stock virus strains were chosen according to the requirements for the 
Test. For each virus, a dilution containing 8 agglutinating doses (AD) is prepared 
and confirmed by back-titrating to 1 AD.
Twenty-five pi of RDE treated serum (1/5 dilution in RDE) was added to the first 
well of a 96-well V  bottom microtitre plate and two-fold serial dilutions prepared 
across the plates using 25 pi volumes of PBS. The relevant virus (8 AD) was 
added in 25 pi amounts to every well of the serum titration and plates incubated at 
room temperature for one hour. Turkey erythrocytes (25 pi; 0.5%) were added to 
each well and incubated for 30 minutes at room temperature. The test was then
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read by tipping the plate so that non-agglutinated cells could be seen running 
down the bottom of the wells and the HAI titre was read as the last well exhibiting 
non-agglutination.
2.10 Haemagglutination Inhibition (HAI) for Extended Typing
HA subtype identification of viruses was done by HAI test using a panel of post 
infection ferret antisera raised to reference virus strains. Ferret antisera were RDE 
treated and diluted ten-fold to 640-fold in 96-well V ’ bottomed plates as described 
in section 2.9. The viruses to be analysed were adjusted to 8 HA units and 25 pi 
amounts added to every well of the serum titration. Following incubation and 
addition of turkey erythrocytes, plates were read as described in section 2.9.
2.11 Microneutralisation Assay
A microneutralisation assay had been developed and this was used in conjunction 
with an EIA to test serum samples for neutralising antibody (262, 308). A panel of 
viruses was constructed including A/Tawian/1/86, A/Texas/36/91, A/Thess/1/95, 
A/JHB/34/94, A/Shan/9/93 and B/Pan/45/90; viruses were diluted 1 x 10 ® in VTM. 
Serum samples were RDE treated and two-fold serial dilutions prepared in 80 pi 
volumes in 96-well microtitre plates. The appropriate volume of virus (80 pi) was 
added to each well, mixed and incubated for one hour at room temperature.
Confluent monolayers of MDCK cells in 96-well plates were washed and 75 pi of 
virus/serum mixture added to the appropriate well. Plates were centrifuged at 700 
X g for 45 minutes, inoculum replaced with MEM (1.25 pg/ml trypsin) and 
' incubated at 37°C with 5% CO2 for 16 hours.
Upon completion of incubation, wells were washed with PBST and cells fixed 
using methanol with 2% H2O2 . Primary mouse monoclonal antibody targeting the 
viral nucleoprotein (Harlan Sera Labs, Loughborough, UK; cat. no. MAS771b) was 
diluted in PBS containing 1% BSA (bovine serum albumen) to 1/1000, 100 pi 
added to each well and incubated at 37°C for 1 hour. Plates were then washed 
four times with PBST using an automatic platewasher (Labsystems) and blotted
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dry. A secondary rabbit anti-mouse antibody conjugated with HRPO (DAKO cat. 
no. P0260) was made to 1/500 in PBST, 100 pi added to each well and incubated 
for one hour at 37°C. Plates were washed four times using PBST and wells blotted 
dry. Substrate was prepared (1.25 ml citric acid (24.3 mM), 2.6 ml Na2 HP0 4  (100 
mM), 300 pi AEC (3.3 mg AEC in 1 mi dimethylsulphoxide), 10 pi 30% H2O2 , and 
1.15 ml distilled H2O) and 50 pi was added to each well and incubated at room 
temperature for 30 minutes. Plates were washed once with PBST and 100 pi PBS 
BSA 1% added to each well. Results were read using a light microscope counting 
the number of visible stained foci per well. End points were calculated by 
identifying the dilution where 50 percent stained infectious foci were observed 
when compared to the control wells.
2.12 Polymerase Chain Reaction
2.12.1 RNA Extraction
RNA extractions were performed using a method previously described (33, 86). 
Virus suspension or tissue culture fluid (150 pi) was added to 840 pi lysis buffer L6 
(Severn Biotech Ltd) and 10 pi silica extraction matrix (Severn Biotech Ltd). The 
mixture was vortexed and incubated at room temperature in a shaker for 10 
minutes. The mixture was then centrifuged at 13,500 RPM for 30 seconds and the 
supernatant carefully discarded. The pellets were washed twice with 1 ml of L2 
wash buffer (Severn Biotech Ltd), twice with 1 ml 70 percent ethanol (BDH) and 
once with 1 ml acetone (BDH). The resulting pellets were dried at 56°C for 10 
minutes. Thirty pi nuclease-free H2O (Promega) and 1 pi Rnasin (40 U/pl; 
Promega) was added to each pellet, vortexed and incubated at 56°C for 10 
minutes to elute the RNA. Each tube was vortexed to resuspend the silica pellet 
and centrifuged at 13,500 RPM for 5 minutes. Supernatant was carefully removed 
from the pellet, ensuring no carryover of silica.
2.12.2 Reverse Transcription
A reverse transcription mix (17.8 pi) was prepared containing 4 pi PCR buffer (20 
mM), 6 pi MgCl2 (50 mM), 6 pi dNTP (each dNTP 10 mM), 1 pi M-MLV Rtase (200
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U/pl; all Giboo BRL), 0.4 pi random hexamer mix (0.53 pg/pl; Pharmacia Biotech), 
and 0.4 pi RNasin (40 U/pl; Promega). The mix was added to 22.2 pi of extracted 
RNA and incubated at room temperature for 10 minutes, then 37°C for at least 45 
minutes and 95°C for 5 minutes. The cDNA product was then placed on ice for 5 
minutes until required.
2.12.3 PCR Amplification
PCR amplification of the influenza A matrix gene was performed using a single 
round amplification. Primers (MWG Biotech) used to amplify the coding region 
were designated AMP2 (forward; 5’-GCAAAAGCAGGTAGATATTG-3’) and 
AMP998 (reverse; 5 -AGGTAG i i i i i i ACTCCAGC-3 ). A reaction mix containing 
8 pi PCR buffer (20 mM), 2 pi MgCIa (50 mM), 1 pi AMP2 (25 pmol/pl), 1 pi 
AMP998 (25 pmol/pl), 63.7 pi nuclease free H2O (Promega), and 0.3 pi Thermus 
aquaticus (Taq) polymerase (5 U/pl; Gibco BRL) was prepared for each PCR 
reaction. The primary mix (80 pi) was added to 20 pi cDNA and amplification 
performed using a PTC-200 thermocycler (Perkin-Elmer) using the following 
cycling conditions: 94°C for 2 minutes, then 35 cycles of 94°C for 1 minute, 50°C 
for 1 minute and 72°C for 1 minute. Reactions were held at 15°C until required.
Amplification of the HAI region of the haemagglutinin gene of influenza A H3N2 
was performed using a nested PCR consisting of two separate rounds. Primary 
amplification was performed using primers designated AH3G (forward; 5’- 
AAGCAGGGGATAATTCTATT-3’) and AH3H (reverse; 5 -ATGCCTGAAACCGT- 
3'). A primary amplification mix consisting of 8 pi PCR buffer (20 mM), 2 pi MgCl2 
(50 mM), 1 pi AH3G (25 pmol/pl) and 1 pi AH3H (25 pmol/pl), 63.7 pi nuclease 
free H2O (Promega), and 0.3 pi Taq polymerase (5 U/pl) was prepared per 
reaction and 80 pi added to 20 pi cDNA. Amplification was performed using the 
following cycling conditions: 94°C for 2 minutes, then 35 cycles of 94°C for 1 
'minute, 50°C for 1 minute, and 72°C for 1 minute. PCR products were held at 
15°C until required.
Secondary amplification of the HAI primary PCR product was performed using the 
primers AH3B (forward; 5-AGCAAAGCTTTCAGCAACTG-3') and AH3CII 
(reverse; 5'-GCTTCCA I 1 iGGAGTGATGC-3’). A reaction mix containing 5 pi
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PCR buffer, 2.5 pi MgCl2 (50 mM), 1 pi dNTPs (10 mM), 1 pi AH3B (25 pmol/pl) 
and 1 pi AH3CII (25 pmol/pl), 33.3 pi nuclease free H2O, and 0.15 pi Taq (5 U/pl) 
per reaction (48 pi) was added to 2 pi of the primary PCR product. Amplification 
was performed using the following cycling conditions: 94°C for 2 minutes, then 35 
cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 1 minute. PCR 
products were held at 15°C until required.
2.12.4 Gel Electrophoresis
PCR products for analysis were loaded into a 1% SeaKem agarose gel (FMC 
Bioproducts) using Orange G loading dye (Severn Biotech). Gel electrophoresis 
was in IX  tris borate EDTA (TBE) buffer at 80 volts for 90 minutes. Amplicons 
were visualised by staining with ethidium bromide (10 pg/ml) and viewed using 
short wave ultraviolet light.
2.13 Sequencing Gel Electrophoresis
Sequencing of the influenza A matrix and haemagglutinin gene was performed 
using an Applied Biosystems 373 Sequencer. RNA extraction, reverse 
transcription and PCR amplification were performed as described above (sections
2.12.1 to 2.12.4). The PCR product was loaded into a 1% agarose gel and 
electrophoresed at 80 volts for 90 minutes. Gels were examined under long wave 
ultra violet light after staining with ethidium bromide and bands of the predicted 
size were excised using a clean scalpel.
Two methods were used for the purification of PCR products from agarose gels. 
Initially, a Gelex DNA Extraction Kit (Camgen) was used; this utilised a silica- 
based methodology. Gel slices were melted at 56°C with a 0.5 volume of Gelex 
Modifier and 4.5 volume of Gelex Salt wash buffer. Once the gel had completely 
'melted, 10 pi Gelex Resin (silica) was added and the reaction tube vortexed 
thoroughly. The reaction was incubated at room temperature for one minute and 
then centrifuged at 13,500 RPM for 30 seconds. The supernatant was discarded 
and the pellet washed twice with Wash Buffer. The pellet was dried at 56°C, 
resuspended in 10 pi of nuclease free H2O and incubated at room temperature for
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1 minute. Following centrifugation, the supernatant was carefully removed and the 
pellet discarded. To confirm the presence of the desired DNA, a 1 pi sample was 
electrophoresed on a 1% agarose gel and the remaining eluted DNA was stored at 
-20°C until required. Because this method proved unsatisfactory for samples 
containing low yields of DNA, an alternative method was used to ensure that 
samples containing low yields of DNA could be sequenced.
The QIAquick Gel Extraction Kit (Qiagen) utilised membrane technology (spin 
columns) and was more reliable than the Gelex DNA Extraction Kit. Gel slices 
were melted at 56°C in a wash buffer provided, vortexed and loaded into a spin 
column. The column was centrifuged at 13,500 RPM for 1 minute; the elution 
waste was then discarded. Further wash buffers were added to the column and 
eluted by centrifugation. The column was then placed into a clean ependorf tube 
and 30 pi nuclease free water loaded into the column which was centrifuged again. 
The eluted DNA was collected and a 1 pi sample was electrophoresed on a 1 % 
agarose gel to ensure that the correct amplicon was present and to estimate the 
quantity of DNA required for the sequencing reactions. The remaining eluate was 
stored at-20°C until required.
'Sequencing reactions for the matrix gene were prepared using the primers AMP2 
(forward; 5’-GCAAAAGCAGGTAGATATTG-3’), AMPB (forward; 5’-CAGAGACTT 
GAAGATGTCTT-3’), AMPCII (reverse; 5’-TGCTGGGAGTCAGGAATCTG -3'), 
AMPDII (reverse; 5’-GACCAGCACTGGAGCTAGGA -3’), AMP680 (forward; 5’- 
ATTGGGACTCATCCTAGCTC -3’) and AMP998 (reverse; 5’-AGGTAGTTT 
TTTACTCCAGC -3’). Sequencing of the influenza HAI region was performed 
using the primers AH3G (5'-AAGCAGGGGAAAATAAAAAC-3), AH3B (5’- 
AGGAAAGCTTTCAGCAACTG-3’), AH3G (5'-GGTTGGATTTGGAGTGATGG-3') 
and AH3I (5 -TGGGTGGGAAGGA i i i iGTA-3’). All sequencing primers were used 
at a concentration of 3.2 pmol/pl.
Individual reactions were prepared containing 1 pi each primer, 8 pi Ready 
Reaction mix (Perkin-Elmer), template DNA and nuclease free H2O. The quantity 
of DNA added to the reaction was estimated from the intensity of the band 
observed from electrophoresis of a 1 pi sample on an agarose gel; this usually 
ranged from 5 pi to 8 pi. The total volume of the reaction was made up to 20 pi 
with nuclease free H2O. Sequencing reactions were subjected to the following
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cycling conditions: 25 cycles of 96°C for 30 seconds, 50°C for 15 seconds and 
60°C for 4 minutes. Products were then held at 4°C.
Upon completion of cycling, products were purified immediately to avoid template 
degradation. The entire sequence product to be purified was added to a mix of 50 
pi cold ethanol (95-100%; BDH) and 2pl sodium acetate (3 M, pH4.6), cooled on 
ice for 10 minutes and then centrifuged at 13,500 RPM for 20 minutes. The 
supernatant was discarded and replaced with 250 pi cold ethanol (70%) and spun 
at maximum speed for 5 minutes. The supernatant was removed using a fine- 
tipped Pasteur pipette and pellets dried using a DNA Speed Vac (Savant, France) 
for 5 minutes. Pellets were stored at -20°C until further required for sequencing.
Sequencing was performed by the dideoxy chain termination method (315). The 
reactions were analysed by separation on polyacrylamide-urea gels using a 373 
sequencing machine (Applied Biosystems).
2.14 Sequence Analysis and Construction of Phyiogenetic Trees
Output files from the 373A sequencer were edited in the program Analysis 
' (Applied Biosystems) to remove waste sequence from the start and end of each 
sequence. Files were then transferred to SeqEd (Applied Biosystems) where the 
forward and reverse sequences were compared and aligned. The consensus 
sequence was converted to a text format and transferred to EditSeq (DNAStar). 
The EditSeq files were imported into MegAlign (DNAStar) and aligned using the 
Clustal algorithm option.
Phylogenetic trees were constructed using the PHYLIP shareware package on a 
Power Macintosh. Initially, alignments from MegAlign were modified to a 
compatible layout. The alignment files were exported in Paup format and 
converted into PHYLIP format using the program Readseq. This file format was 
then used in other programs within the PHYLIP package. Transition:transversion 
ratios (Ts:Tv) were calculated using Tree Puzzle 4.0. Maximum likelihood distance 
'matrices were calculated using the program DNADist (PHYLIP). The output file 
was then analysed by Fitch, which produced a tree in text format. The tree was 
viewed using the program Treeview.
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To determine the strength of nodes and branches within each tree, bootstrap 
values were calculated. Seqboot was used to create 100 datasets, the output file 
was then imported to DNADist, which calculated the maximum likelihood distance 
matrices for each dataset. The output file from DNADist was imported to Fitch 
where trees were produced for each dataset. Consence was used to produce the 
consensus or majority tree with bootstrap values on each branch. Trees and 
bootstrap values were viewed in Treeview. Completed phylogenetic trees were 
created by transposing bootstrap values onto the original trees. Values greater 
Than 70 were displayed although where nodes were considered of phylogenetic 
importance, bootstrap values were included irrespective of value.
2.15 Cloning
2.15.1 Transformation of Competent Cells
Cloning of the HAI gene of influenza A was performed using a TOPO TA Cloning 
Kit (Invitrogen). Briefly, a vial of competent Escherichia coii (E. coii) cells was 
thawed on ice. To each vial 2 pi p-mercaptoethanol was added and gently mixed. 
Two pi of a cloning reaction composed of 1 pi pCR-TOPO vector (Invitrogen), 2 pi 
PCR product and 2 pl sterile nuclease free H2O was added to the competent cells 
and incubated on ice for 30 minutes. The cells were heat-shocked for 30 seconds 
at 42°C and then incubated on ice for two minutes. SOC medium (250 pl; 
Invitrogen) was added and the cell suspension incubated in an orbital shaker 
(Gallenkamp) for 30 minutes at 37°C and 180 RPM. Agar plates were poured 
containing ampicillin sodium salt (20 mg/ml; Life Technologies) and allowed to 
cool. The plates were spread with 40 pl X-gal (40 mg/ml) and 40 pl IPTG (lOOmM) 
and incubated at 37°C for approximately one hour prior to use. One hundred pl of 
transformed cells was spread onto the plates which were incubated at 37°C 
overnight.
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2.15.2 Isolation of Colonies Containing PCR Product of Correct Size
Approximately 10 to 20 white colonies were picked using a sterile loop and spread 
onto a fresh agar plate (as above) and incubated at 37°C overnight. Ten new 
colonies were picked and the loop from each colony was immersed into a vial 
containing 5 ml broth; this was then incubated in a shaker at 37°C overnight. Each 
loop was also immersed into a vial containing 50 pl sterile H2O, which was then 
placed into a boiling water bath for 5 minutes. The vial was centrifuged at 13,500 
RPM for 1 minute and the supernatant carefully removed. A PCR mix containing 5 
pl PCR buffer (20 mM), 3 pl MgCb (50 mM), 1 pl dNTP (each dNTP 10 mM), 1 pl 
M l3 forward primer (20 pmol/pl; 5'- CAGGAAACAGCTATGAC-3’), 1 pl M l3 
reverse primer (20 pmol/pl; 5’- GTAAAACGACGGCCAG-3'), 28.8 pl sterile H2O 
and 0.25 pl Taq (5 U/pl) was added to 10 pl supernatant (total volume 50 pl) and 
amplified using the following cycling conditions: 29 cycles of 94° for 1 min, 55°C 
for 1 min, 72°C for 2 min and then 72°C for 5 min. Reactions were then held at 
15°C until required. Products were electrophoresed on a 1% agarose gel to 
identify bands of the correct size. The corresponding broths to these positive 
results were saved.
2.15.3 Sequencing of Cloned HAI Gene from Positive Colonies
To sequence the clones, 5 pl of broth was added to 50 pl sterile H2O and the 
above selection procedure carried out. The entire PCR product was run on a 1 % 
agarose gel and the corresponding band excised. Gel slices were cleaned and the 
DNA extracted using the QIAquick Gel Extraction method (section 2.13). 
Sequencing primers were identical to those used in routine sequencing of the HAI 
gene. The M l3 reverse primer (as above) was included (3.2 pmol/pl) in the 
sequencing reaction to ensure that the whole HAI region was sequenced.
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2.16 Epidemiological Analysis
Data collected by the Birmingham Unit of the Royal College of General 
Practitioners (RCGP) on the rates of influenza and influenza-like illness was 
presented as the number of new episodes of illness occurring per 100,000 
population (87). This set of data represents an accurate picture of the circulation of 
influenza activity within the community and was used to plot the incidence of 
influenza activity in the UK over the past 30 years. Isolates prior to 1995 were 
predominantly from hospital laboratories and hospitalised cases of influenza. 
Isolates post-1995 included a greater proportion (approximately 50%) of 
community-based specimens from general practitioners and virological 
surveillance studies. Isolates were received from sites all over the UK and 
therefore represented the circulation of influenza throughout the UK population in 
all seasons studied.
Any epidemiological or clinical data for viruses was extracted from national archive 
information consisting largely of laboratory records, EXCEL databases and where 
possible original patient forms. Details that were collected included the origin of 
each virus isolated, age and sex of patient and whether amantadine had been 
used to treat the infection.
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3.1 Introduction
3.1.1 Use of Amantadine
Until the recent launch of the neuraminidase inhibitors zanamivir and oseitamivir, 
the anti-M2 protein drug amantadine and its analogue derivative rimantadine were 
the only antiviral drugs licensed for the treatment of influenza infections. For over 
three decades they have been proven clinically useful in the treatment and 
prevention of influenza A (37, 74, 149, 165). Amantadine has been available for 
clinical use since 1966 but has been used only on a limited scale in some 
countries, especially the UK (277). The use of amantadine over the past three 
decades has not yet resulted in the appearance of epidemic strains of influenza A 
virus that are resistant to the compound (144). However, the circulation of 
resistance strains has been documented illustrating the need for further 
surveillance (156, 277, 417).
3.1.2 Previous Susceptibility Studies
3.1.2.1 Treatment Groups
Numerous studies have demonstrated how amantadine-resistant viruses are 
readily selected in animals and tissue culture when virus is grown in the presence 
of drug (10, 22, 51, 277, 350). From its early days, this was acknowledged as the 
main disadvantage of the drug but the significance of generation of resistance in 
vivo was not clear. There have been several previous studies to investigate the 
frequency and occurrence of amantadine-resistant viruses in clinical isolates. 
Drug-resistant viruses have been recovered from patients undergoing treatment 
with amantadine or rimantadine (130), patient-contacts (147) and in non-treated 
persons (156, 166). The groups where an increase in drug-resistant viruses is 
observed are from patients undergoing amantadine or rimantadine treatment or 
prophylaxis where selective pressure on the virus was greatest. The frequency of 
the recovery of these isolates has been determined in several cases (Table 3.1).
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TABLE 3.1 Frequency of resistance and documented transmission of amantadine- and 
rimantadine-resistant viruses from treatment/prophylaxis-based susceptibility studies
Study Year Subject
Group
Resistance Transmission Reference
Hall at al. 1987 Children 27% X (130)
Hayden at al. 1989 Families 29% / (147)
Hayden at al. 1991 Adults 50% X (152)
Mast at al. 1991 Elderly 60% / (238)
Houck at al. 1995 Elderly 50% X (166)
Gravenstein at a i 2000 Elderly 33% X (119)
A study by Hall et al. (1987) to investigate the efficacy and acceptability of 
rimantadine in the treatment of children with acute influenza A infections observed 
that of 37 children treated with drug, 27% were shown to shed resistant isolates 
and 45% of children who had received rimantadine were still shedding resistant 
virus on day 7 after treatment (130). This work provided good evidence that under 
the influence of drug therapy, resistant viruses were frequently isolated from 
children and were apparently shed for relatively long periods after treatment had 
ceased. Hayden at ai. (1989) investigated the efficiency of rimantadine in 
protecting family members from influenza A infection and the emergence of 
resistant viruses during therapy (147). The study found 29% of adults or children 
undergoing therapy shed resistant virus on day 5 of treatment. It was concluded 
that rimantadine was ineffective in protecting household members from influenza A 
infection due to the close proximity of patients. When rimantadine was used for 
both treatment and post-exposure prophylaxis, resistant viruses were rapidly 
selected and transmitted between family members. From other similar studies, it 
can be concluded that amantadine- and rimantadine-resistant viruses have been 
recovered from 30-60% of adults and children treated for influenza A infections. 
The findings from Hall at a/. (1987) and Hayden at al. (1989) had important 
implications in patient-care management (130, 147). The apparent shedding of 
resistant viruses after the completion of treatment and the transmission of resistant 
viruses between patients and contacts demonstrated that in situations where 
patients were in close proximity there was a probability that disease could spread
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rapidly. This was especially important in respect to ‘at-risk’ groups where the 
acquisition of a resistant influenza A virus could be life-threatening.
When compared with neuraminidase inhibitors, the limiting factors associated with 
anti-M2 protein inhibitors are highlighted. An investigation into seasonal 
prophylaxis of nursing home residents compared the efficacy of zanamivir and 
rimantadine at preventing disease (119). Analysis of viruses shed from patients 
revealed that in the rimantadine-treated group, 38% of viruses isolated were 
resistant and 44% of cases from this group were drug-prophylaxis failures. Within 
the zanamivir-treated group there was no resistance detected and efficacy was 
improved (119). It is apparent that the emergence of amantadine- and 
rimantadine-resistant viruses can cause the failure of drug treatment and 
prophylaxis. The apparent transmission of resistant viruses can result in illness 
among household contacts and nursing home residents (147, 238). The resistant 
viruses appear to emerge rapidly and cause typical influenza in human contacts 
suggesting that wild-type sensitive strains exhibit no selective advantage over 
resistant strains.
Other important findings from the study of resistant viruses have helped in 
understanding their properties so that preventative measures might be initiated. 
The rapid emergence of resistant viruses has been documented; in the avian 
model this can be from 2-9 days (22, 384) and in humans is typically 4-5 days 
post-treatment (130, 147). It is apparent that once drug-resistant virus has 
emerged from a subject, the genotype of subsequent isolates remains resistant or 
comprises a mix of resistant and sensitive viruses (22).
3.1.2.2 Populations
The emergence of amantadine-resistant viruses in hosts undergoing drug therapy 
provides valuable data for improving patient care. However, it is equally important 
to understand the occurrence of amantadine-resistant viruses within the general 
population, where the use of amantadine is significantly lower. This type of 
research has been less frequent but several groups have documented the 
occurrence of amantadine- and rimantadine-resistant viruses in larger samples of
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virus isolates (Table 3.2). An early study by Heider etal. (1981) tested strains that 
had been collected from the 1980 Berlin epidemic; 2/21 strains of H3N2 virus were 
' resistant to amantadine and rimantadine (156). The exact origin of these resistant 
strains was unknown but anti-influenza treatment had not been practised in the 
former G DR at that time and therefore it was concluded that the strains had been 
imported from countries where use of the drug had been utilised for several years, 
e.g. the former USSR (418). This provided evidence for the first time that resistant 
strains circulated in nature (156). In the former USSR, where rimantadine 
treatment had been in long-term use since 1969, Kuber et al. (1989) noted 
differences in resistance between different subtypes of influenza A viruses (196). 
The percentage of drug-resistant variants isolated was 4.7% for MINI and 40.1% 
for H3N2. These figures might have been influenced by the proportion of subtypes 
circulating in the population i.e. H3N2 subtypes were predominantly circulating the 
population, but they also might have indicated differing sensitivities between 
different subtypes. The study by Kubar et al. (1989) concluded that despite the 
'prolonged use of rimantadine (two decades) the efficacy of the drug was 
undiminished (196).
TABLE 3.2 Frequency of resistance of amantadine- and rimantadine-resistant viruses from 
population-based amantadine/rimantadine susceptibility studies
Study Date N* Study Period Resistance Reference
Heider at al. 1981 21 1980 9% (156)
Pemberton at al. 1983 39 1978-1981 15% (277)
Belshe at al. 1988 248 1978-1988 2% (23)
Valette at al. 1993 105 1988-1990 0% (364)
Prud’homme at al. 1997 50 1991-1994 0% (287)
Ziegler at al. 1999 2017 1991-1995 0.8% (417)
Elliot & Zambon 2001 2309 1958-1999 2.2% (85)
^Number of patients studied.
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Other previous studies screening clinical isolates for amantadine-resistance have 
been limited. Two of the most significant were studies by Belshe et al. (1989) and 
Zeigler et al. (1999). Belshe’s group screened 248 viruses from clinical isolates 
originating in the US over a period of ten years (1978-1988). Of these, 5 (2%) 
were resistant to amantadine and rimantadine (23). However, the resistant viruses 
were all isolated from members of one family undergoing rimantadine treatment 
and therefore did not represent a true figure of resistance within the population. 
This study demonstrated the absence of naturally-occurring resistant viruses and 
concluded that the emergence of new influenza strains may have prevented the 
widespread emergence of resistant influenza A virus. The most recent 
susceptibility screening study was by Zeigler etal. (1999) who tested isolates from 
43 different countries around the world (417). Resistant viruses were detected at a 
frequency of 0.8%. Of the resistant viruses found, 12/16 were isolated from cases 
where there had been no apparent exposure to amantadine or rimantadine (417). 
This study concluded that although the circulation of resistant strains was rare, 
there was evidence to suggest that resistant strains were emerging without the 
selective pressure of drug. Studies by Prud’homme etal. (1997) and Valette etal. 
(1993) screened 50 Canadian isolates from 1991-1994 and 105 French isolates 
from 1988-1990 respectively using an El A similar to the one described for this 
study (287, 364). Data resulting from this work demonstrated that all isolates were 
sensitive to amantadine, further evidence for the low frequency of naturally 
occurring resistance.
Accumulated data from previous studies shows the importance of continuing 
surveillance for naturally-occurring influenza A viruses, especially in the advent of 
widespread use of antiviral compounds. In untreated patients it has been reported 
that approximately 0.8% of clinical isolates recovered from patients are resistant 
(144). The predominance of resistant strains in drug-treated patients and the low 
frequency of naturally-occurring drug-resistant strains suggests that drug- 
resistance does not confer any selective advantage.
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3.1.3 Transmission of Resistant Viruses
In the avian model there have been studies that have demonstrated the ability of 
, amantadine-resistant viruses to be transmitted between birds. Webster et al. 
(1985) studied the control of a highly pathogenic influenza virus among chickens 
(384). Infected chickens were administered with amantadine or rimantadine both 
prophylactically and by treatment. The drugs were found to be effective in the 
prevention of disease but did not stop virus shedding. In an attempt to mimic 
natural conditions, infected birds were put in contact with susceptible birds and all 
were administered amantadine. It was found that the susceptible birds all 
succumbed to disease, direct evidence for the transmission of resistant virus and 
its potential for causing disease (384). Again, using the avian model. Bean et al. 
(1989) infected chickens with virus and treated the birds with amantadine (22). 
After exposure to drug, the infected birds shed resistant virus and continued to 
shed after treatment had stopped. When birds carrying resistant virus were mixed 
with birds infected with wild-type sensitive virus for which no amantadine treatment 
,had been administered, resistant virus was isolated from the sensitive birds within 
one passage. This further demonstrated the potential for transmission of resistant 
viruses between close contacts in animal populations (22).
Transmission of resistant viruses in human populations has been limited. Some 
evidence to support the case for transmission was produced by Hayden et al. 
(1989) where the emergence of resistant viruses among family members treated 
with amantadine was studied (147). Within families treated with amantadine, 
illness in contacts was apparently caused by the transmission of a resistant virus 
from the index case (147). Another study providing evidence for the transmission 
of human resistant viruses was Mast et al. (1991) who investigated outbreaks of 
influenza A disease in nursing homes (238). Within the homes, patients 
contracting influenza were treated with amantadine two days after the onset of 
\ symptoms and general amantadine prophylaxis was initiated shortly after the 
onset of the outbreak. Resistant viruses were isolated from several patients. The 
viruses isolated had identical genetic changes and the patients were living in 
adjacent rooms providing further evidence for the transmission of resistant viruses 
in humans (238).
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Population studies of amantadine susceptibility have not yielded any documented 
cases of the transmission of resistant viruses without the selective pressure of the 
antiviral drug. This suggests that resistant viruses emerging in nature do not have 
any obvious selective advantage over sensitive viruses that allow them to be 
transmitted. This theory alone may be partly responsible for the absence of a 
circulating epidemic human influenza strain that is resistant to amantadine or 
rimantadine.
3.1.4 Viruses to be Screened (UK 1958-1999)
Over the last century there have been several different influenza A subtypes that 
have circulated the globe (Figure 3.1). Evidence for circulation of certain subtypes 
from the earliest periods of the last century has been gathered from serological 
evidence. This data has revealed that MINI viruses emerged in approximately 
1918 and circulated until 1958. The first isolation of influenza viruses occurred in 
the early 1930s (335) and from this point in history there is a relatively accurate 
' record of the viruses and subtypes in circulation. H2N2 viruses superseded MINI 
viruses in 1958 and caused the worldwide pandemic of Asian influenza (81). The 
circulation of H2N2 viruses spanned approximately ten years after which they 
were replaced in circulation by another newly emerging subtype. The winter of 
1969 saw the emergence of H3N2 viruses, a novel subtype that heralded another 
worldwide pandemic (Hong Kong influenza) (52). H3N2 remained the only 
circulating subtype in the UK until 1977 when viruses of HI N1 subtype re-emerged 
(197). Over the past decade, there have been no major epidemics observed within 
the UK and currently influenza B, and influenza A H3N2 and HI N1 co-circulate.
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FIGURE 3.1 Circulation and recycling of influenza tfiroughout the last century
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Sporadic cases of animal to human transmission of various influenza A subtypes are 
highlighted in stars. Boid boxes are present where there is direct evidence i.e. virus 
isoiation of circuiating subtypes; white boxes represents subtypes where serologicai data 
provided evidence for the circuiation of virus. Adapted from (342).
The circulation of influenza over 40 years (1958-1999) in the UK is summarised in 
Figure 3.2. This illustrates the viruses that were circulating the UK over the study 
period and is very similar to the worldwide pattern of circulation of subtypes. The 
earliest subtype of influenza A available to be screened were H2N2 viruses. The 
actual number of viruses screened from this period was low due to poor archiving 
at the time of isolation and therefore did not represent proportional sampling. 
Within the UK, H3N2 viruses emerged in the season of 1968/69 causing 
widespread infection throughout the population. Evidence for the effect of this 
wave of disease on the UK population can be seen in the Royal College of 
General Practitioners (RCGP) index where there is a large peak in the rate of 
General Practitioner (GP) consultations per 100,000 population (Figure 3.2). H3N2 
and MINI co-circulated the UK with influenza B viruses although the isolation rate 
for H3N2 viruses was predominant in most seasons. Other virological events of 
interest within the UK include two large epidemics during the seasons of 1975/76 
and 1989/90 that can be identified by peaks in the RCGP index.
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3.1.5 Antiviral Susceptibility Assays
Several methods used to assess the susceptibility of influenza to antiviral drugs 
have been developed over the years. Hamzawi etal. (1981) used an egg-bit assay 
to culture viruses in the presence and absence of drug (132). Influenza viruses 
were inoculated onto allantois-on-shell cultures in varying concentrations and 
incubated: haemagglutination was used to detect antigen (132). Heider et al. 
(1981) assayed the susceptibility of strains from the 1980 Berlin epidemic using a 
haemadsorption reduction test in mouse Ehrlich ascites cells (156). These two 
early methods were superseded by the plaque reduction assay that was 
developed by Appleyard (1975) to study inhibitors of influenza viruses (11). This 
assay was then commonly used in several susceptibility studies and is still widely 
used and considered to be the “gold standard” for antiviral susceptibility testing of 
influenza (31,148, 242). The plaque assay has been used for antiviral drug testing 
,of other viruses including herpes simplex virus (355), human immunodeficiency 
virus (295) and cytomegalovirus (386).
The enzyme-linked immunoassay (EIA) was first utilised by Belshe etal. (1989) to 
screen viruses for amantadine susceptibility (23). The assay that the group 
developed has been modified and used in several other studies including the 
present one demonstrating its usefulness for such work (256, 287, 364, 417). 
Molecular biology has allowed the development of methods that can be used 
either as screening tools or to directly analyse the amino acid sequence of viruses. 
Polymerase chain reaction-restriction analysis has been used to detect mutations 
within M2 known to confer resistance (193). This has been used as an alternative 
to the plaque reduction assay to confirm resistance detected by an EIA (417) but 
the method can only detect viruses carrying mutations at positions previously 
. reported to confer resistance, any viruses with changes outside of these positions 
would not be detected. Direct automated sequencing has been used as a tool to 
screen viruses for amantadine-resistance but is more commonly used to 
determine the sequence of the M2 gene and identify mutations arising.
To enable the collection of data within the current study, an antiviral susceptibility 
screening protocol had to be established. The options available for determining 
amantadine susceptibility of viruses were tissue culture (plaque reduction assay), 
EIA or molecular techniques e.g. polymerase chain reaction-restriction analysis.
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The assay was to be used as a tool to screen viruses collected and archived from 
the UK over the past 40 years, therefore it was essential that it was quick, with 
relatively low labour input and with the capability to screen large numbers of 
isolates. Although considered the gold standard for antiviral susceptibility testing, 
using the plaque reduction assay to screen isolates was unrealistic because it was 
extremely labour intensive resulting in a low throughput of isolates; polymerase 
chain reaction-restriction analysis was also considered too labour intensive. 
Therefore, it was decided that an EIA would be used initially to screen the large 
number of virus isolates and any resistant viruses detected would be confirmed 
resistant and further characterised by plaque reduction assay. These resistant 
viruses would then be genotypically characterised by sequencing the M2 gene to 
determine the drug genotype (Figure 3.3).
The plaque reduction assay has been described as the gold standard for 
assessing the susceptibility of influenza to antiviral compounds (409) and has 
been used with amantadine for many years (11, 148). The advantage of the 
plaque assay over the EIA is that growth of the virus is calculated as individual 
infectious particles or plaque forming units (PFU). It is considered to have greater 
accuracy in determining the infectivity of a virus, compared to EIA. A recent study 
that outlined the optimisation of a cellular EIA for screening antiviral agents found 
that results from the EIA correlated strongly with the plaque reduction assay (256). 
However, even with comparable susceptibility data, the plaque reduction assay 
has the advantage that valuable data concerning the phenotypic characteristics of 
a virus can be determined through studying plaques produced from infection. 
These data include the general size and number of plaques, and the 
morphological characteristics of individual plaques. This can provide evidence for 
the growth potential of the viruses tested and for the presence of viral 
quasispecies within the isolate.
64
Chapter 3 -  Amantadine Susceptibility Screening
FIGURE 3.3 Antiviral susceptibility screening protocol
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Flowchart illustrates the antiviral susceptibility testing protocol used in the determination of 
frequency of amantadine-resistance in this study.
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3.2 Aims
The aim of this work was to assess the frequency and pattern of occurrence of 
amantadine-resistance in influenza viruses circulating within the UK. Amantadine- 
resistance within the UK population has not previously been studied; as a 
consequence of the low use of the drug within the population, results should 
indicate the level of naturally-occurring resistance within circulating strains. With 
access to an archive of isolates collected over the past 50 years it was possible to 
screen a large number of viruses including periods when amantadine was not in 
use. An assay was designed and optimised which enabled efficient collection of 
data. The biological and phenotypic properties of resistant isolates were 
characterised by plaque reduction assay that provided data on growth and 
resistance characteristics. From collected data, several questions were posed:
• What was the frequency of amantadine-resistance in the UK through the 
period 1958-1999?
• Is there variation in amantadine susceptibility between influenza different 
antigenic subtypes?
• Was there evidence that susceptibility varied between influenza seasons?
• Did the transmission of resistant viruses occur within the population?
• What was the potential for the emergence of an epidemic strain resistant to 
amantadine?
6 6
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3.3 Results
3.3.1 Design of an Enzyme-Linked Immunoassay (EIA)
The final protocol for the susceptibility EIA is described in Chapter 2 (section 2.6; 
page 41) but during the development and optimisation of the assay several 
important parameters were assessed including the optimisation of both primary 
and secondary monoclonal antibody (MAb) concentrations, the incubation times 
for Mab and substrate, and the composition of antibody diluents. The incubation 
time for propagating viruses prior to antibody staining was an important 
consideration. The length of time would determine whether single cycle or multiple 
cycle replication had occurred. Results demonstrated that following an incubation 
period allowing single cycle replication only the strength of signal produced 
(representing antigen released) was weak and would not permit the detection of 
viruses with low infectivity titres. Signal produced after a multiple cycle incubation 
of 16 hours was significantly stronger and allowed detection of viruses with both 
low and high titres.
Finally, controls for the assay had to be included to validate results. A reference 
virus strain (A/Tawain/1/86) was used for the amantadine-sensitive control and a 
known amantadine-resistant virus (GS10) used as the resistant control. To monitor 
background negative values, cells were infected with sterile virus transport 
medium (+ / - drug) and stained as normal to highlight changes within the quality of 
the cell monolayer or toxicity to the drug. A set of controls was included with each 
batch of assays performed and the susceptibility of the sensitive and resistant 
controls monitored. If either control appeared to have failed validation criteria (i.e. 
resistant control demonstrating >50% inhibition) the results were discarded and 
the assay repeated. The EIA susceptibility assay is summarised in Figure 3.4.
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FIGURE 3.4 Diagrammatic representation of the ElA-antiviral susceptibility assay
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Cells were infected with virus and incubated in the presence and absence of amantadine. 
Two monoclonal antibodies were used to detect the presence of viral nucleoprotein. The 
level of protein expression was measured colourimetrically using HRPO and TMB.
3.3.2 Frequency of Amantadine-Resistance in the UK 1958-1999
The viruses used in this study were all influenza A isolates that had been 
characterised at the Influenza Laboratory based at the Central Public Health 
Laboratory (OPHL), Colindale, which is the national influenza laboratory. A range 
of specimens consisting mainly of throat and nose swabs and tissue culture fluid 
was sent to the laboratory from regional public health laboratories, hospital 
laboratories and general practitioners. Viruses had been predominantly isolated in 
mammalian tissue culture (>75%) while viruses isolated prior to 1985 had been 
isolated in both the allantoic cavity of fertile hens eggs and tissue culture. Viruses 
were stored at -70°C or freeze-dried at time of isolation. The origin of isolates prior 
to 1995 was predominantly from hospital laboratories and hospitalised cases of 
influenza. Isolates following this date included a greater proportion (approximately 
50%) of community-based specimens from general practitioners and virological
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surveillance studies. Isolates were received from sites all over the UK and 
therefore represented the circulation of influenza throughout the UK population in 
all seasons studied.
A total of 2309 influenza A isolates were tested using the susceptibility EIA. Of the 
viruses tested, positive signal was detected in 2130 (92.2%). Viruses that did not 
grow sufficiently for analysis were generally not used, except in seasons when the 
number of archived viruses was low, isolates failing to produce signal were 
inoculated into MDCK cells. After incubation for 7 days at 37°C in an attempt to 
amplify antigen, antiviral screening using the EIA was repeated; if insufficient 
signal was still produced the virus was discarded. The number of viruses archived 
limited the proportion of subtypes available for testing but the number of H3N2 and 
MINI tested represented an approximation of the predominant circulating strains 
over the last 40 years. In total, positive signal was detected for 1559 (72.5%) 
H3N2, 531 (25.6%) MINI and 40 (1.9%) H2N2 viruses. Viruses were categorised 
into defined seasons depending on their date of isolation to enable data to be 
compared between each influenza season. Officially, for UK surveillance 
purposes, the influenza-monitoring season starts in the UK on October 1st and 
lasts until March 31st although the actual duration of influenza epidemics is 
probably 8-12 weeks between these dates (98). Approximately 95% of viruses 
used in this study were isolated during the time of influenza epidemics each year, 
the remainder were isolated from sporadic cases and outbreaks occurring in 
months when there was very limited influenza circulation in the country. Viruses 
that were isolated out of season were assessed according to the date of isolation 
and their antigenicity and grouped into an appropriate season.
Viruses demonstrating less than 50% inhibition to amantadine were classified as 
drug-resistant and collected for further analysis. Initial results revealed that the 
susceptibility EIA had detected resistant viruses in H3N2 and MINI subtypes but 
the small group of H2N2 viruses tested lacked any resistance. The frequency of 
detection of resistant viruses by EIA for H3N2 and MINI was 17.8% and 15.8% 
respectively. When these resistant viruses were further tested using plaque 
' reduction assay it was found that only a small number were confirmed resistant. 
The subsequent frequency of resistance for H3N2 and MINI was 2.4% and 2.1% 
respectively. The overall frequency of amantadine-resistance between H3N2, 
MINI and H2N2 viruses (1958-1999) was 2.3% (Table 3.3).
69
Chapter 3 -  Amantadine Susceptibility Screening
TABLE 3.3 Summary of influenza A susceptibility screening
Subtype Circulation
(years)
N Resistant by EIA Resistant by 
Plaque Assay
H3N2 1968-present 1559 278 (17.8%) 37 (2.4%)
MINI 1977-present 531 87 (15.8%) 11 (2.1%)
H2N2 1958-1968 40 0 0
TOTAL 1958-present 2130 365 (17.1%) 48 (2.3%)
N -  number of viruses tested.
When seasonal data were analysed, the results indicated that the occurrence of 
resistance was not constant from season to season. There appeared to be ‘bursts’ 
of resistance present in some seasons and very low levels of resistance in others. 
This phenomenon was observed in both H3N2 and H1N1 viruses. The pattern of 
varying resistance by EIA within the H3N2 viruses (Table 3.4) was extremely 
pronounced. Of 27 seasons screened, 8 contained proportionally larger numbers 
of resistant viruses to other seasons. Between these peaks of high frequency 
resistance there were interspersed periods where no resistant viruses had been 
isolated. This phenomenon was demonstrated when data from 1982/83 to 1985/86 
was analysed. There were 25 resistant viruses detected by EIA during the 1982/83 
season followed by two seasons where there was a low occurrence of resistance; 
however, the next season (1985/86) produced 50 resistant viruses, the highest 
detected for any season. Examining resistance from plaque reduction data, this 
trend was less pronounced but the season of 1985/86 remained as containing a 
significantly higher number of resistant viruses than any other season. Data from 
MINI subtypes was similarly analysed and it was again found that several 
seasons contained proportionally higher numbers of resistant viruses by EIA and 
were interspersed with seasons lacking any detectable resistance (Table 3.5). For 
example, 18 resistant viruses were found by EIA in the 1983/84 season but during 
the following two seasons no resistance was detected. Then, in the 1986/87, 
1987/88 and 1988/89 seasons 24, 8 and 9 resistant viruses were isolated 
respectively. This again demonstrated the sporadic bursts of resistance appearing 
followed or interspersed with periods of relatively high sensitivity in viruses 
isolated. Data from plaque reduction assay revealed the 1983/84 season as
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containing the highest number of resistant H1N1 viruses. The susceptibility 
screening of H2N2 viruses revealed a total lack of resistance (Table 3.6).
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TABLE 3.4 Amantadine susceptibility screening data for infiuenza A H3N2 viruses
Season No. 
Isolated ^
No.
Tested^
No. Tested Virus 
Analysed (%) ®
No. Resistant 
by EIA
No. Resistant by 
Plaque Assay
1999/98 886 96 76 (79) 19 2
1998/97 453 52 43 (83) 3 1
1997/96 504 251 251 (100) 16 1
1996/95 532 3 3(100) 1 0
1995/94 40 39 39 (100) 1 0
1994/93 515 148 111 (75) 6 1
1993/92 86 45 33 (73) 3 0
1992/91 367 260 223 (86) 27 2
1991/90 0 0 0 0 0
1990/89 849 169 130 (77) 24 1
1989/88 145 75 58 (77) 10 1
1988/87 46 24 21 (88) 9 1
1987/86 1 1 1 (100) 0 0
1986/85 396 139 136 (98) 50 19
1985/84 395 34 34 (100) 1 0
1984/83 49 25 24 (96) 7 2
1983/82 684 128 126 (98) 25 4
1982/81 399 90 83 (92) 19 2
1981/80 208 19 16(84) 6 0
1980/79 317 46 46 (100) 20 0
1979/78 0 0 0 0 0
' 1978/77 692 10 5(50) 1 0
1977/76 926 19 9(47) 5 0
1976/75 1923 24 24 (100) 19 0
1975/74 941 4 3(75) 1 0
1974/73 575 3 3(100) 2 0
1973/72 1290 2 2(100) 0 0
TOTAL 13219 1771 1559 (88%) 278 (18%) 37 (2.4%)
Represents the actual number of Influenza A H3N2 viruses isolated In the National 
Influenza Laboratory, Colindale over that particular influenza season.  ^ Represents the 
number of viruses from that season tested by the drug susceptibiiity EIA in this study.  ^
Represents the number of viruses that produced sufficient signal in the EIA to be analysed 
for drug susceptibility.
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TABLE 3.5 Amantadine susceptibiiity screening data for influenza A H1N1 viruses
Season No. 
Isolated ^
No.
Tested^
No. Tested Virus 
Analysed (%) ^
No. Resistant 
by EIA
No. Resistant by 
Plaque Assay
1999/98 0 0 0 0 0
1998/97 262 53 50 (94) 3 0
1997/96 8 3 3(100) 0 0
1996/95 119 19 15(79) 0 0
1995/94 8 4 4(100) 0 0
1994/93 0 0 0 0 0
1993/92 73 34 22 (65) 2 0
1992/91 70 39 31 (79) 5 3
1991/90 3 1 1 (100) 0 0
1990/89 0 0 0 0 0
1989/88 257 97 75 (77) 9 1
1988/87 33 24 21 (88) 8 0
1987/86 315 102 97 (95) 24 1
1986/85 178 0 0 0 0
1985/84 16 10 9(90) 0 0
1984/83 196 100 100 (100) 18 6
1983/82 182 81 80 (99) 8 0
1982/81 4 3 3 (100) 0 0
1981/80 177 10 3(100) 3 0
1980/79 10 0 0 0 0
1979/78 72 11 5(45) 2 0
1978/77 297 31 12(39) 5 0
TOTAL 2280 622 531 (85%) 87 (17%) 11 (2.1%)
 ^ Represents the actual number of Influenza A H1N1 viruses Isolated In the National 
Influenza Laboratory, Colindale over that particular influenza season.  ^ Represents the 
number of viruses from that season tested by the drug susceptibility EiA in this study.  ^
Represents the number of viruses that produced sufficient signal in the EIA to be analysed 
for drug susceptibility.
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TABLE 3.6 Amantadine susceptibility screening data for influenza A H2N2 viruses
Season No. 
Isolated ^
No.
Tested^
No. Tested Virus 
Analysed (%) ^
No. Resistant 
by EIA
No. Resistant by 
Plaque Assay
1967/68 ND 3 2(66) 0 0
1966/67 ND 1 0 0 0
1965/66 ND 1 1(100) 0 0
1964/65 ND 7 7(100) 0 0
1963/64 ND 6 6(100) 0 0
1962/63 ND 23 22(96) 0 0
1961/62 ND 3 2(66) 0 0
TOTAL ND 44 40(90.9%) 0 0
 ^ Represents the actual number of influenza A H2N2 viruses isolated in the National 
Influenza Laboratory, Colindale over that particular influenza season.  ^ Represents the 
number of viruses from that season tested by the drug susceptibility EIA In this study.  ^
Represents the number of viruses that produced sufficient signal In the EIA to be analysed 
for drug susceptibility. ND -  no data available.
3.3.3 Phenotypic Characterisation of Amantadine-Resistant Strains
Susceptibility testing by plaque reduction assay was performed on isolates that 
had been determined as resistant from the EIA screening. Of the 365 viruses 
resistant by the EiA, 48 (13.2%) were confirmed using plaque reduction assay. 
Aithough labour intensive, it provided valuable data concerning the phenotypic 
properties of the viruses.
The number of plaques formed in the presence and absence of amantadine by 
each virus was counted and the plaque forming units per ml (PFU/ml) calculated 
(Equation 2.1 ; page 41). It was then possible to determine the reduction in PFU/ml 
caused by the presence of amantadine; this figure was used to confirm the 
susceptibility of the virus (Table 3.7).
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Initial analysis of the results indicated that there were wide ranges in infectivity 
titres of the viruses tested, from 3.5 x 10  ^ PFU/ml (A/ENG/692/98) up to 8 x 10  ^
PFU/ml (A/ENG/277/86). This observation was predicted because the viruses had 
been isolated from original archived material that contained different titres of virus. 
Of greater importance was the antiviral effect of amantadine on the PFU/ml of 
each virus. When the percent reduction in PFU/ml was calculated there was a 
range in the degree of resistance shown by the viruses. Resistance could be 
defined into two categories, high resistance and partial resistance. There were 
15/48 viruses that appeared to be partially resistant (26-50% reduction PFU/ml) to 
amantadine and 21/48 viruses with high resistance (1-25% reduction PFU/ml). The 
remaining viruses (6/48) had negative values for percent reduction in PFU/ml 
indicating that there had been an increase in the PFU/ml in the presence of drug. 
This result had not been expected; the increase of viral growth in the presence of 
amantadine had not previously been reported.
The phenotypic characteristics of each virus were analysed and recorded. The 
diameter of each plaque formed was measured and any interesting morphological 
features noted. The mean plaque size in the presence and absence of amantadine 
and the percent reduction in size of plaque in the presence of drug were calculated 
for each virus (Table 3.7). From these results it was possible to estimate the 
growth potential and look for the presence of heterogeneous populations of 
infective virus particles within the isolate. Plaques were noted for 45/48 viruses 
(94%). The remaining viruses could not be analysed because of poorly defined 
plaques however it was possible to identify endpoints of viral growth and therefore 
estimate the susceptibility of the virus to amantadine. Results indicated that for the 
majority of viruses (80%), plaque size was reduced in the presence of amantadine. 
The reduction in diameter of plaques ranged from 7.1% to 69.6%. This suggested 
that resistant viruses growing in the presence of amantadine had a reduced 
growth potential when compared to the sensitive population of virus, causing the 
formation of smaller plaques. A small group of viruses (7/48) had plaques that 
were identical in size in the presence and absence of amantadine. This implied 
that although amantadine had reduced the PFU/ml, the growth characteristics of 
the resistant viruses were identical to the sensitive. In order to further investigate 
this observation, it is proposed that piaques grown in the presence of amantadine 
could be picked and used in one-step growth curve experiments to determine the 
rate of replication and virus yield. This would ascertain whether the sensitive and
78
Chapter 3 -  Amantadine Susceptibility Screening
resistant viruses with similar plaque morphologies were indeed similar in 
replication and virus yield.
An interesting observation was made where several viruses had formed larger 
plaques in the presence of amantadine (Table 3.7). In total 10/48 (21%) viruses 
demonstrated this phenomenon but some showed a more substantial increase 
than others. The viruses A/ENG/116/84, A/ENG/629/86 and A/ENG/39/92 had an 
80%, 88.9% and 220% increase in plaque size respectively. This was interesting 
because it suggested that in the presence of drug, the resistant population of virus 
that had been selected had much greater growth potential than the sensitive 
population in presence of drug.
Another interesting morphological feature observed was the formation of opaque 
plaques; two viruses (A/SCOT/62/92 and A/SCOT/59/92) displayed this 
phenomenon. In the absence of drug the plaques appeared normal with complete 
removal of the cell sheet but growing virus in the presence of drug appeared to 
form a mixed population of clear and opaque plaques. Closer inspection of the 
individual plaques revealed that although the majority of the cell monolayer within 
the boundary of the plaque had been infected, the virus had not caused the cells 
to be completely removed leaving a layer of cells that gave the plaque its opaque 
appearance. The plaques formed in the presence of drug were identical in size for 
A/SCOT/59/92 and 45.5% smaller for A/SCOT/62/92 to plaques formed in the 
absence of drug. A selection of resistant viruses from the current study displaying 
the above phenotypic and morphological characteristics is presented in Table 3.8.
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TABLE 3.8 Observed phenotypic characteristics of selected resistant viruses
Virus Observed Characteristic Plaque Morphology
Drug + Drug*
A/ENG/14/87 Reduction in plaque size
A/ENG/207/86 Selection of plaques from 
heterogeneous population
A/ENG/395/86 Small plaque size -/+ drug
A/SCOT/18/88 Large plaque size -/+ drug
A/ENG/357/96 Increase in plaque number 
+ drug
A/ENG/39/92 Increase in plaque size 
+ drug
A/SCOT/62/92 Opaque plaques + drug
* Amantadine added to agar overlay at I.Opg/mi (final concentration), f  Opaque plaques are 
difficult to visualise.
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3.3.4 Epidemiological and Clinical Analysis of Amantadine-Resistant Strains
Initial analysis of data from laboratory reports revealed that the origins of the 
resistant isolates were spread over the UK. The majority of isolates had been 
spread over England with several originating from areas around Scotland (Table 
3.9). There was evidence to show that some individual areas were associated with 
more resistant viruses than others, e.g. Guildford and Bath. It was hypothesised 
that these clusters of resistant viruses might have originated from small outbreaks. 
Further analysis of the data revealed that there were some viruses that could be 
grouped, and classed as outbreak cases. The most significant example was a 
group of 1985/86 viruses that originated from Guildford Public Health Laboratory. 
Examination of laboratory details determined that the patients from which samples 
had been taken were all adolescent males suggesting that they may have 
originated from a school or institution. Dates of sampling from this specific case 
showed that eight isolates had all been received within approximately 10 weeks. 
Three of the samples had been collected within a period of 14 days and four had 
been received on two dates, with two viruses isolated on each day. Further 
investigation revealed that this case was a boarding school outbreak.
Another interesting case involved four viruses that were isolated from Scotland 
(Table 3.9). Initially, it was hypothesised that these strains would all have 
originated from the same location at approximately the same time suggesting an 
outbreak case involving the transmission of a resistant strain. However, analysis of 
laboratory details revealed that all of the isolates had been separately isolated 
from different regions of Scotland at different times indicating that these were 
unrelated, sporadic cases.
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TABLE 3.9 Epidemiological analysis of amantadine-resistant strains
Virus Season Subtype Origin Date of 
Isolate
Original
Specimen
. A/ENG/798/98 98/99 H3N2 Maidenhead 29/12/98 TS
A/ENG/692/98 98/99 H3N2 Plymouth 22/12/98 TS
A/ENG/424/98 97/98 H3N2 London 19/03/98 TCP
A/ENG/357/96 96/97 H3N2 Bristol 17/12/96 TCP
A/ENG/280/93 93/94 H3N2 Preston 27/10/93 TS
A/SCOT/87/92 91/92 H3N2 Glasgow 01/05/92 TCP
A/SCOT/77/92 91/92 MINI Aberdeen 05/03/92 TCP
A/SCOT/62/92 91/92 H1N1 Glasgow 18/02/92 TCP
A/SCOT/59/92 91/92 MINI Edinburgh 14/02/92 TCP
A/ENG/39/92 91/92 H3N2 Leeds 13/01/92 TCP
A/ENG/327/90 89/90 H3N2 Leicester 20/02/90 TCP
A/ENG/129/89 88/89 H3N2 Preston 31/01/89 TCP
A/ENG/128/89 88/89 H3N2 Manchester 31/01/89 TCP
A/SCOT/18/88 88/89 H3N2 Edinburgh 05/05/88 TCP
A/ENG/14/87 86/87 MINI Chelmsford 23/01/87 TCP
A/ENG/638/86* 85/86 H3N2 Nottingham 16/05/86 TCP
A/ENG/637/86* 85/86 H3N2 Nottingham 16/05/86 TCP
A/ENG/632/86* 85/86 H3N2 Guildford 09/05/86 TCP
A/ENG/629/86* 85/86 H3N2 Guildford 09/05/86 TCP
A/ENG/589/86 85/86 H3N2 Newcastle 22/04/86 TCP
A/ENG/588/86 85/86 H3N2 Stoke 22/04/86 TCP
A/ENG/586/86 85/86 H3N2 Newcastle 17/04/86 TCP
A/ENG/557/86 85/86 H3N2 Manchester 09/04/86 TCP
' A/ENG/550/86* 85/86 H3N2 Guildford 09/04/86 TCP
A/ENG/549/86* 85/86 H3N2 Guildford 09/04/86 TCP
A/SCOT/49/86 85/86 H3N2 Edinburgh 26/03/86 TCP
A/ENG/395/86* 85/86 H3N2 Guildford 13/03/86 TCP
A/ENG/400/86* 85/86 H3N2 Guildford 14/03/86 TCP
A/ENG/277/86* 85/86 H3N2 Guildford 03/03/86 TCP
A/ENG/310/86 85/86 H3N2 Bath 04/03/86 TCP
A/ENG/268/86 85/86 H3N2 Preston 03/03/86 TCP
A/ENG/207/86 85/86 H3N2 Guildford 26/02/86 TCP
A/ENG/168/86 85/86 H3N2 Nottingham 19/02/86 TCP
A/ENG/50/86 85/86 H3N2 Bath 24/01/86 TCP
A/ENG/221/84 83/84 MINI Newcastle 16/04/84 TCP
A/ENG/136/84* 83/84 MINI Bath 02/04/84 TCP
A/ENG/134/84* 83/84 MINI Bath 02/04/84 TCP
A/ENG/116/84 83/84 H3N2 Birmingham 30/03/84 TCP
A/ENG/147/84 83/84 MINI Guildford 02/04/84 TCP
A/ENG/118/84 83/84 MINI Coventry 30/03/84 TCP
A/SCOT/76/84 83/84 MINI Glasgow 05/06/84 TCP
A/ENG/907/83 83/84 H3N2 Manchester 18/10/83 TCP
A/ENG/627/83 82/83 H3N2 Bath 17/03/83 TCP
A/SCOT/16/83 82/83 H3N2 Edinburgh 15/02/83 TCP
A/ENG/259/83 82/83 H3N2 Nottingham 14/02/83 TCP
' A/ENG/1/83 82/83 H3N2 Newcastle 05/01/83 TCP
A/ENG/640/82 81/82 H3N2 Sheffield 07/04/82 TCP
A/ENG/551/82 81/82 H3N2 Leicester 01/04/82 TCP
TCP - tissue culture fluid; TS - throat Swab; * - possible outbreak cases.
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3.4 Discussion
This study documented amantadine-resistance in human influenza A viruses 
isolated over the last century. The viruses circulated within a geographically- 
contained location with defined seasonal influenza. Previous studies have been 
concerned with the isolation of viruses during and after treatment (25, 71, 147, 
166, 193, 238) but few have been able to ascertain the frequency of resistance in 
non-treated individuals (156, 277, 417). Here, an estimate of amantadine- 
resistance in a geographically discreet population was made. The use of 
amantadine within the UK had been limited, therefore this provided a more 
accurate representation of natural emergence and variation of amantadine 
susceptibility in influenza A viruses.
3.4.1 Methodology Conclusions
All various methods described to assay antiviral drugs are based on measuring the 
viral growth, and inhibition of viral growth in the presence of the inhibitor, but this 
can be achieved in several ways. The plaque reduction assay measures the 
production of progeny infectious virus particles detected by the formation of 
plaques. The EIA is designed to detect the presence of virus-specific antigens 
produced during the replication cycle of the virus. The use of EIA in determining 
the susceptibility of viruses to antiviral compounds is acceptable as long as there 
is a direct relationship between the production of virus-antigen and infectious virus. 
For example, an antiviral compound targeting a late stage of the virus replication 
cycle will not affect the synthesis of antigens produced early in the cycle. 
Therefore, when designing an antiviral susceptibility testing strategy, it is important 
to understand the different interactions of virus and drug.
The methodology used in this study involved the design and optimisation of an EIA 
to determine susceptibility of influenza isolates to amantadine. The ability of the 
assay to perform this task was validated by the results gained however it was 
apparent from the discrepancy between the EIA and plaque reduction assay 
results that the EIA was selecting a large number of ‘false-resistant’ viruses. The 
percentage of H3N2 and HI N1 viruses selected by the EIA as resistant that were 
confirmed resistant by plaque reduction assay was 13.3% and 12.6% respectively.
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The apparent low fidelity of the amantadine-susceptibility screening EIA suggests 
that further work is required to fully optimise the assay. The aim of this section of 
the work was to design and utilise an assay that would enable a large number of 
viruses to be screened for drug susceptibility. The antiviral testing ‘gold-standard’ 
(plaque reduction assay) was then used to confirm the drug phenotype of EIA- 
resistant viruses. It was possible that in an attempt to fully maximise the efficiency 
of the EIA, i.e. increase the number of viruses per assay and reduce the test 
turnaround time, the specificity of the assay had been compromised, the overall 
specificity of the assay was estimated to be approximately 87%. In order for the 
assay to be efficiently used within a routine diagnostic laboratory, where high 
throughput of samples for drug-resistance testing would possibly not be a priority, 
further optimisation is required to reduce the rate of false-resistant results. 
Therefore, it might be concluded that in this respect the assay was successful, it 
tested over 2300 clinical samples and selected amantadine-resistant strains, but in 
order to improve the overall specificity more time would have to be invested to ‘fine 
tune’ certain components of the assay.
The reasons why the specificity of the assay was relatively low were not clear but 
it was possible that the assay had become over-sensitive at detecting resistant 
viruses. To perform the test, virus samples were serially diluted from a ten-fold to 
1000-fold dilution. It was concluded that this dilution was not sufficient for viruses 
with extremely high titres. It appeared that the viruses were growing equally in 
both media supplemented with and absent of drug. It was possible that the EIA 
was over-sensitive and where virus had been inoculated onto cells in the presence 
of drug at a high multiplicity of infection, there was a high proportion of non- 
infectious viral debris that remained attached to and within the cells after washing 
stages. This material would have provided a substrate for antibody to bind to 
throughout stages of the assay resulting in a falsely high optical density reading 
that implied that the virus had undergone infectious cycles in the presence of the 
drug. To overcome this limitation, viruses should have been diluted further to 
enable a lower multiplicity of infection to be achieved. In this situation there would 
have been sufficient quantity of virus to infect the cell monolayer without having an 
excess of non-infectious virus remaining in association with the cells throughout 
the test. Unfortunately, to modify the assay in this way would have reduced its 
capability of having a high throughput of viruses.
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The methodology involved with the drug-susceptibility screening EIA used in this 
study was compared to other EIA methods from similar studies (23, 25, 147). 
Overall, the different methodologies used were comparable, however, there were 
some small discrepancies. For example, in the present study an anti-influenza A 
nucleoprotein antibody was used to detect viral antigen, other studies used 
polyclonal ferret antiserum raised against either H3N2 or MINI virus. It is unclear 
how this might affect the overall specificity of the assay, but it is a viable option for 
future work to optimise the assay. Interestingly, one of the studies using a similar 
drug-susceptibility EIA diluted viruses 10'^  to 10 ® in ten-fold serial dilutions (23). 
As discussed above, it was possibie that the apparent low specificity of the EIA 
from the present study was a result of viruses at high titres that had not been 
sufficiently diluted when used in the assay. Therefore, the methods used by 
Belshe et al. (1989) confirm that if the assay is to be further optimised, dilution of 
viruses to 10'® might improve the specificity of the test.
3.4.2 Frequency of Resistance
The frequency of amantadine-resistance of influenza A viruses screened in this 
study was 2.4%, 2.1% and 0% for H3N2, MINI and H2N2 subtypes, respectively. 
This resuited in an overall frequency of 2.25% for influenza A viruses. Due to the 
nature of the study and subjects, this figure was considered to represent an 
approximation of the level of resistance occurring in the UK in non-treated 
individuals. There was evidence to suggest that some of the isolates tested were 
from small outbreaks arising as a result of amantadine use. In order to calculate 
the natural frequency as accurately as possible, the data for these suspected 
viruses were omitted and the figure recalculated; this adjusted figure was 
caiculated to be 1.7% for all subtypes. When compared to the most recent 
susceptibility study published, where the frequency of amantadine-resistance was 
determined to be 0.8%, the figure generated from the present study both including 
and excluding suspected outbreaks was higher (417). The majority of resistant 
viruses (14/16) isolated by Zeigler at al. (1999) could not be associated with any 
form of drug treatment and it was concluded that these viruses had emerged as a 
result of the high mutation rate of the virus, generating the changes within M2 
necessary to confer resistance. However, the study investigated the occurrence of 
resistance in 43 countries globally and therefore did not give a true picture of
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susceptibility in one population. When the results from the study were broken 
down into the different countries there were some interesting observations. The 
majority of isolates tested originated from the US (n=991); the frequency of 
resistance was calculated at 0.8%. There was no resistance detected in viruses 
isolated in China (n=150), but the most interesting finding was isolates that had 
originated from Australia. In total, 94 isolates were tested and 5 (5.3%) were 
detected as resistant. All five resistant isolates were found to be from unrelated 
individual cases, similar to the majority of the viruses isolated in the present study. 
Further data by Zeigler et al. (1999) revealed that over a total of 6 years in 
Australia, 9/198 (4.5%) isolates were found to be drug-resistant (417). This was a 
relatively high figure for resistance but more significantly Australia was very similar 
to the UK in respect of the extremely limited use of amantadine within the 
population for treating influenza. Within this relatively small, contained population 
there was evidence that resistant viruses had circulated without significant 
selective pressure from amantadine or rimantadine. This finding correlated with 
the results presented here for the UK where unrelated individual cases of resistant 
viruses were isolated. Therefore, using data from this present study and previous 
investigations (156, 417) it was concluded that the occurrence of resistant viruses 
in an environment where the use of amantadine or rimantadine for the treatment of 
influenza infections was limited were predominantly as a result of the high 
mutation rate of the influenza virus, but with a small proportion resulting from 
individual isolated cases of amantadine use. This was true of the UK where 
amantadine has been limited to treatment within residential homes and schools 
and is rarely used even in these situations. Therefore selective pressure from the 
drug on the virus was extremely low meaning that there must have been some 
other mechanism i.e. spontaneous mutation, to force the emergence of the 
resistant viruses.
Results from the screening of viruses by the susceptibility EIA demonstrated that 
within the H3N2 and H1N1 subtypes there was variation in the susceptibility of 
viruses to amantadine (data not shown). Viruses that were drug-sensitive (<50% 
reduction growth) showed a range in susceptibiiity in the presence of drug as 
demonstrated by a variety of differing OD readings. These varied from highly 
susceptible, to viruses of intermediate susceptibility that were only slightly above 
The cut-off for resistance. This demonstrated that the H3N2 and MINI influenza
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viruses tested varied in some way that determined their susceptibility to 
amantadine.
These results correlated with findings from a previous study conducted by 
Pemberton et al. (1986) who tested the susceptibility of MINI and H3N2 viruses 
against amantadine (277). They found viruses had a range of susceptibilities when 
titrated against amantadine. The biological cloning of a highly resistant virus 
produced a set of clones that were found to have a range of susceptibilities to 
drug. It was suggested that this was as the result of the presence of 
heterogeneous populations within any one virus isolate. It has previously been 
demonstrated that any single influenza virus preparation can contain a complex 
heterogeneous population of variants (quasispecies) that wiil include viruses of 
both resistant and sensitive genotype (193). It was therefore proposed that 
sensitive strains of influenza A could contain differing proportions of resistant 
genotypes within the quasispecies. A strain containing a relatively high proportion 
of resistant genotypes would have a lower susceptibility to amantadine compared 
to a strain containing a population of predominantly sensitive genotypes. This 
quasispecies theory may provide an explanation for the difference in susceptibility 
of viruses observed in this study. The H3N2 and MINI subtypes have been in 
circulation during a period when amantadine has been in use worldwide, but in 
limited use within the UK. This limited exposure to the drug may have had some 
influencing effect on the levels of susceptibility experienced in this study. Any 
selective pressure from amantadine might have had an effect on the balance of 
genotypes within the viral quasispecies. This might not have been initially obvious 
because the overall phenotype of the virus would remain the same, i.e. sensitive, 
but the actual susceptibility of the virus would be reduced.
Evidence to support this hypothesis was evident within some of the phenotypic 
data collected by plaque reduction assay. It was noted that several virus 
preparations produced different sizes of plaques when grown without drug e.g. 
A/ENG/207/86 but when the virus was grown in the presence of amantadine small 
plaques were selected (Tables 3.7 and 3.8). This suggested that without the 
selective pressure of drug, a viral quasispecies existed that consisted both of 
sensitive and resistant genotypes, where the sensitive genotypes maintained a 
selective advantage over the resistant genotype. However, when a selective 
pressure was applied to the quasispecies in the form of amantadine, it suppressed
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replication of the sensitive genotypes and allowed the resistant genotype to grow 
resulting in the selection of a single plaque size. These results suggested that 
some virus preparations were composed of mixed heterogeneous populations 
containing differing genotypes that contributed to the variation in susceptibility 
observed.
In comparison, H2N2 viruses showed less variation with the actual level of 
susceptibility being significantly higher. This might be explained by the absence of 
amantadine use in the late 1960s when H2N2 viruses were circulating. There was 
no resistance detected in the H2N2 group indicating that there was very little 
selective pressure, if any, on the viruses causing them to specifically mutate within 
the M2 proteins and accumulate resistant genotypes within the quasispecies. 
However, one must be careful in drawing any conclusions from this set of viruses 
because only a small number of isolates were tested in proportion to the total 
number isolated. If the frequency of resistance determined for H3N2 and H1N1 
viruses (2.3%) was the same for H2N2 viruses then in theory a minimum of 
approximately 50 viruses would need to have been screened before a resistant 
virus was discovered. It was also very difficult to generate conclusions because 
H3N2 viruses superseded H2N2 viruses in 1968/69; if H2N2 viruses had 
continued circulating within the population it would have been interesting to see 
whether their susceptibility to amantadine would have decreased as they gained 
more exposure to the drug. The hypothesis that H2N2 viruses were more 
susceptible to amantadine because they were less exposed to the drug is not 
supported by other data (175). Some infiuenza viruses e.g. A/WSN/33 and 
A/PR/8/34, with parental strains isolated before the use of amantadine have been 
shown to be drug-resistant (175). The exact mechanism by which these viruses 
acquired resistance is not ciear but it provides evidence that resistant viruses can 
be generated without the selective pressure of drug.
3.4.3 Variation of Amantadine Susceptibility Between Influenza Seasons
The screening results for H3N2 and H1N1 viruses demonstrated that there were 
different levels of resistance between influenza seasons. This was evidence to 
support the hypothesis that variation in susceptibility had occurred. An interesting 
pattern observed in the screening results was the occurrence of clusters of
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resistance within certain seasons. These clusters suggested that there was some 
natural variation within the susceptibility of viruses circulating in the population 
each influenza season. An influencing factor to be considered was the proportional 
sampling of viruses each season; the number of viruses screened was dependent 
on the available viruses in the archive. From Tables 3.4 and 3.5 it can be seen that 
the number of viruses tested for each season varies greatly. This might have 
significantly influenced the results; the greater the number of isolates tested each 
season the more probable the isolation of a greater number of resistant viruses. 
The presence of amantadine-resistant strains was first detected (by plaque 
reduction assay) in the 1981/82 and 1983/84 influenza seasons for H3N2 and 
MINI subtypes, respectively. It was possible that this was a consequence of the 
relatively small number of viruses tested in the seasons leading up to the first 
isolation of drug-resistant viruses. Therefore, it was possible that the apparent lack 
of resistance preceding these dates was simply because the probability of isolating 
resistant viruses was lower. Unfortunately, all viruses available for testing over this 
period were analysed so there was no method of avoiding this sampling bias.
From data previously published it was hypothesised that viruses put in 
chronological order would display a gradual increase in levels of resistance. This 
evidence for this hypothesis originated from a study by Pemberton et al. (1986) 
who found an apparent increase in the level of resistance in viruses tested from 3 
consecutive years (277). The proposed explanation for this finding was that the 
viruses had evolved in an environment where amantadine was present and 
therefore had become less susceptible over time, although it was conceded that 
the study had tested a significantly small collection of viruses compared to the 
number circulating the community. However, findings from the study presented 
here do not support this hypothesis. Levels of resistance, season to season, 
appeared to be irregular with spontaneous bursts or peaks at random times. The 
period that could be associated with a higher incidence of resistance was the 
1980s where the most resistant viruses were isolated. The reasons behind this 
finding however were unclear.
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3.4.4 Variation of Amantadine Susceptibility between Influenza Subtypes
There appeared to be no significant variation in resistance between H3N2 and 
H1N1 subtypes from amantadine-susceptibility screening; resistance was 
determined to be 2.4% and 2.1% respectively. There was however variation in 
susceptibility when these two subtypes were compared with the H2N2 viruses.
The contribution of virus subtype to the frequency of resistance to amantadine or 
rimantadine occurring in influenza A viruses has not been previously ascertained. 
A study by Kubar et al. (1989) investigated the efficacy of rimantadine in the 
treatment of outbreaks of influenza in the former Soviet Union (196). The aim of 
the work was to determine whether the development of resistant viruses had 
diminished efficacy of the drug. Over a period of seven years the study isolated 
rimantadine-resistant MINI (4.7%) and H3N2 (40.1%) variants (196). This finding 
illustrated that there were differences in the isolation of resistant viruses within 
influenza A subtypes.
Using results from the study presented here, it was possible to hypothesise the 
processes that might lead to variation in amantadine susceptibility between 
different antigenic subtypes of influenza A. The length of time that a virus 
circulated within a population would theoretically increase the number of 
replication rounds. This would increase the probability that mutations conferring 
amantadine-resistance would occur and therefore that the susceptibility to the drug 
would decrease. This might have explained the results from Kubar et al. (1989) 
where the H3N2 viruses tested had a high level of resistance (196). If the 
circulating strains had been predominantly H3N2 in the former Soviet Union then 
this would have allowed a greater duration of replication for the H3N2 viruses to 
accumulate mutations.
The present study indicates that the frequency of resistance was slightly higher for 
H3N2 viruses when compared to MINI viruses. Although this difference was 
small, the predominant circulation of H3N2 viruses within the UK may explain the 
finding. After the reappearance of the MINI subtype in 1977/78 there has been 
cocirculation of H3N2 and MINI viruses (Figure 3.2). However, the cocirculation 
has not been balanced; in the majority of seasons there was a predominance of 
one subtype, sometimes completely lacking any activity of the other. In general,
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the number of isolations of H3N2 was greater within the UK indicating that the 
duration of circulation has been more prolonged. In effect this has increased the 
length of time the virus has been in circulation and therefore the time for the virus 
to evolve in respect to amantadine susceptibility.
The seasons where the greatest number of resistant viruses had been detected 
were characterised by a dominant subtype circulating and limited activity from the 
other. This trend was true except for the 1985/86 season where the distribution of 
circulation was approximately 69% and 31% for H3N2 and HI N1, respectively. All 
other seasons e.g. 1981/82 and 1983/84 where resistant viruses had been 
isolated had a predominance of either H3N2 or H1N1 circulating. Therefore it 
appeared that one influencing factor in the selection of resistant viruses of certain 
subtypes was the actual balance of subtypes within the season in question.
3.4.5 Phenotypic Analysis of Resistant Viruses
Data collected from plaque reduction assays were valuable in characterising the 
resistant viruses selected. Previous data collected from the EIA screening had 
suggested that there was variation in the level of susceptibility shown by sensitive 
viruses to amantadine. From infectivity data it appeared that resistant viruses had 
high and partial levels of resistance to amantadine. The presence of highly 
resistant strains suggested that these viruses contained heterogeneous 
populations that were predominantly comprised of resistant genotypes. It was 
.speculated that the partially resistant strains would contain lower proportions of 
resistant genotypes mixed with sensitive particles that would result in a greater 
reduction in PFU/ml in the presence of amantadine. The plaque reduction assay 
results supported the theory that resistant viruses were also heterogeneous in 
their susceptibility to the drug. Overall, there was variation in the susceptibility of 
sensitive viruses, and within amantadine-resistant viruses, ievels of resistance 
also varied.
An extremely interesting group of viruses was identified where certain viruses 
displayed an increase in PFU/ml in the presence of drug. This observation could 
not be found in any other previously published studies, although the phenomenon 
of drug dependence has been observed in influenza A viruses treated with the
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neuraminidase inhibitor drug zanamivir (30, 242). Within other viruses, including 
poliovirus and human rhinovirus, data have also been reported indicating that drug 
dependence can occur (107, 377).
Results presented for the size of plaques produced by resistant viruses in the 
presence and absence of drug gave similar results to that from the PFU/ml data. 
There was variation in plaque size as a consequence of the presence of drug; 
viruses could be grouped into categories of high and partial resistance depending 
on the degree of inhibition shown by treatment of amantadine. Similar to the 
infectivity data there was a group of viruses that appeared to have larger plaques 
in the presence of amantadine indicating that the viruses were growing at 
increased rates. It was speculated that the virus populations contained within the 
larger plaques formed in the presence of drug had increased fitness in respect to 
growth properties. This was an interesting observation because the majority of 
viruses tested had an overall reduction in plaque size indicating that the resistant 
viruses able to propagate in the presence of drug had reduced growth potentials 
compared to the sensitive genotypes.
The data from PFU/ml and plaque size were analysed to determine whether there 
were any correlations between the figures. This analysis revealed that several 
viruses had distinct properties when grown in the presence of drug (A/ENG357/96, 
A/SCOT/59/92, A/ENG/39/92, A/ENG/129/89, A/ENG/632/86, A/ENG/629/86 and 
A/ENG/550/86). They all had increased PFU/ml and plaque size indicating that 
they had a preference for growing in ‘drug-rich’ conditions (Table 3.7).
It may be that the Ml species within these viruses differed in their biochemical 
properties. When amantadine blocks the M2 ion channel, it reduces the flow of 
protons from the acidic endosome into the interior of the virion (137). This process 
inhibits the low-pH disassembly of the ribonucleoprotein/M1 (RNP/M1) complex 
and therefore prevents the uncoating and release of the RNP into the host cell 
cytoplasm. If the Ml species of a virus had an altered pH tolerance, then this may 
have facilitated the dissociation of the RNP/M1 compiex at a iess acidic pH that 
would compensate for the blockage of the ion channel by amantadine. As a result 
of this, when the virus was propagated in the absence of amantadine, the internal 
pH of the virion would be too acidic and therefore not at the optimum pH for the 
dissociation of the RNP/M1 complex. The overall result would appear as an
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increase in the PFU/ml and possibly the plaque size between viruses grown in the 
absence and presence of drug. Although only hypothetical, this theory could be 
tested by analysing the dissociation of the RNP/M1 complex at different pH values. 
Results from this experiment would give an indication of the optimum pH at which 
dissociation occurred. It would be interesting to perform this work using resistant 
viruses displaying different extremes of resistance, i.e. high reduction in PFU/ml 
and plaque size (e.g. A/ENG/168/86) and increase in PFU/ml and plaque size in 
the presence of drug (e.g. A/ENG/39/92).
3.4.6 Epidemiology of Resistant Viruses
The available clinical data associated with resistant viruses was extremely limited 
which unfortunately restricted the possible analysis. However, details of location, 
age and sex of isolates and patients were available. It was not possible to 
ascertain whether patients had exposure to amantadine either through treatment 
or contacts but evidence was gathered to predict where such cases had occurred.
The initial analysis revealed that the distribution of resistant viruses within the UK 
appeared to be random, viruses originated from locations in both the North and 
South of the country. However, it was important to consider that there was a 
certain bias in these findings; the distribution of the viruses was restricted to areas 
containing either a public health or hospital laboratory. This was certainly the case 
for older isolates where the majority were sent from such establishments, it was 
only in approximately the last five years studied that viruses were more evenly 
distributed as a result of community-based surveillance schemes being 
implemented (6, 97). This random distribution of resistance indicated that the 
majority of resistant viruses were sporadic, unrelated cases which was 
corroborated by conclusions drawn from the data presented concerning the 
frequency of resistance. There were groups of resistant viruses that were 
clustered into certain seasons. When epidemiological data was linked to these 
clusters it provided further evidence for the unrelated and sporadic nature of the 
majority of cases. Within a single season containing a cluster of viruses, e.g. 
1983/84, viruses appeared to have a random distribution iilustrating that they were 
unrelated cases. This was further supported by the analysis of four isolates 
originating from Scotland. Epidemiological data demonstrated that the viruses all
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originated from separate hospital laboratories in Scotland. Due to the fact that the 
viruses were isolated from patients in hospitals, the viruses could have emerged 
as a result of individual treatment cases of amantadine or were unrelated cases 
from non-treated individuals. Unfortunately, laboratory reports did not specify any 
amantadine treatment that patients had undergone, therefore the reasons why 
these four viruses emerged can only be speculated.
There were however several interesting groups of viruses. Within the 1985/86 
influenza season, which contained the largest collection of resistant viruses, there 
was evidence to suggest that a group of viruses were related. In particular, 8/19 
viruses collected from 1985/86 originated from Guildford Public Health Laboratory. 
They were all H3N2 viruses, isolated within a period of approximately 10 weeks 
between February and May 1986. Analysis of laboratory reports revealed that the 
patients from whom viruses had been isolated were all adolescent males aged 12- 
16 years. This was interesting because it suggested that the viruses originated 
from a school or similar establishment. Evidence to support this theory was found 
in several reports documenting influenza outbreaks in boarding schools. Davies et 
al. (1988) studied an outbreak at Christ’s Hospital boarding school where 
amantadine had been used prophyiactically to control an outbreak of influenza 
(64). The first case was reported on 29/01/86 and laboratory confirmation of 
influenza H3N2 was provided by Guildford PHL. The outbreak persisted for 
approximately 56 days until the last confirmed isolation on 23/03/86. This data 
correlated with the epidemiological results presented in the present study. Viruses 
sent to Guildford for laboratory confirmation would only have been reported as 
infiuenza positive. To type the virus isolates, tissue culture fluid was forwarded to 
the Influenza Laboratory, CPHL where the subtype and antigenic profile of virus 
were determined. Therefore, this was evidence that the group of Guildford strains 
originated from a single school outbreak. In total, approximately 86 influenza 
viruses were isolated at CPHL from samples sent from Guildford; 8 viruses (9.3%) 
were determined as amantadine-resistant by plaque reduction assay when 
screened during this study.
The study by Davies et al. (1988) had revealed that a programme of amantadine 
prophylaxis had been initiated approximately one week after the first confirmed 
case of influenza at the school (64). Amantadine was taken by 79.2% of pupils; 
prophylaxis lasted for 14 days. During this period of amantadine use, 36 pupils
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were diagnosed as having clinical influenza; 23 (64%) had been taking 
amantadine. Therefore, a number of pupils were receiving amantadine 
prophyiactically for a two-week period succumbed to an influenza infection (64). 
The evidence suggested that the prophylaxis failures within the school had been 
caused by the emergence of resistant viruses as a consequence of exposure of 
the virus to amantadine. It is possible that this could have been as. a result of the 
emergence of an index resistant virus, e.g. (A/ENG/207/86) that was then 
transmitted to other pupils, or the emergence of several unique resistant viruses 
that then spread through the school population. The study by Davies et al. (1988), 
and the findings from the present study illustrate the difficulty of using amantadine 
in situations where there is close contact between individuals (64). The occurrence 
and transmission of resistance within similar environments has been documented 
and demonstrates the limitations of the drug (130, 147, 166). Matrix gene 
sequence analysis of the resistant strains associated with known and suspected 
outbreak cases will provide evidence for the transmission of the viruses. If all 
strains appear to be homogeneous in amino acid sequence then this would 
suggest that transmission of resistant viruses had occurred.
There was also some evidence that several of the viruses that had been received 
from Bath PHL could have originated from a boarding school. An earlier report had 
described the policy of treating pupils at the school with amantadine in preference 
to the trivalent vaccine; results during the study had demonstrated that superior 
protection was provided by amantadine (306, 307). This study showed that a 
proportion of pupils who had received amantadine had developed symptoms of 
influenza, which had subsequently been confirmed by laboratory analysis. This 
suggested that resistant viruses originating from Bath may have been as a direct 
consequence of amantadine treatment. It was unfortunate however, as the clinical 
^details relating to the isolates received from Bath were extremely limited and the 
ages of the patients could not be found. This, with the available evidence above 
demonstrated that although the use of amantadine in the UK has been extremely 
limited, there have been isolated cases where it has been used to control 
outbreaks and small epidemics.
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3.4.7 Transmission of Resistant Viruses
It has been documented that amantadine-resistant viruses can be transmitted 
person to person (147, 238) and it was hypothesised that the set of viruses 
originating from Guildford during the 1985/86 season supported this theory. The 
remaining results from this study however suggested that the frequency of 
transmission of resistant viruses in the general population was low. Evidence for 
this was apparent when seasonal data were examined. If the transmission of 
resistant viruses was a common event, then it would be expected that resistant 
viruses would spread quickly through a localised population similar to the pattern 
of wild-type sensitive viruses. The results from the screening suggested that 
resistant viruses emerged and then disappeared from the population. A good 
example could be seen where four viruses were isolated in Scotland from 
individual unrelated cases. Each virus had originated from a hospital laboratory 
and therefore it was concluded that the isolates would have originated from 
hospital wards. If there had been general transmission of the resistant viruses then 
it would have been expected that more resistant viruses would have been isolated. 
The confines of a hospital ward would have provided the ideal conditions for viral 
transmission between patients and therefore, the apparent lack of evidence for 
these events would indicate that transmission did not occur frequently.
In general, the pattern of emergence of resistance from this study did not support 
transmission of resistant viruses within a population. If resistant viruses were 
generally spread though a community or population then there should have been 
more evidence for this, especially during the more recent seasons screened. 
These periods contained a much higher proportion of viruses that originated from 
community-based surveiliance schemes. If there was transmission of resistant 
viruses then these schemes should have identified more isoiates of such viruses. 
.This was not the case though; in the later years of the study, which included more 
community-based schemes, the frequency of resistance was lower than previous 
seasons. Therefore, the evidence would indicate that the population-based 
transmission of resistant viruses was extremely low. The transmission of resistant 
viruses has previously been documented, but only in situations where amantadine 
or rimantadine have been used in treatment or therapy (147, 238). These cases 
have also originated in either family or residential homes where there has been 
close contact between index cases and contacts. Therefore, in comparing results
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from this study and previous investigations it would appear that the ideal 
conditions for transmission would be an environment where drug was in use, 
exerting a selective pressure on the virus, and where there is extremely close 
.contact between patients. The transmission of resistant viruses amongst a 
population, it would appear, occurs at a low frequency.
3.4.8 Concluding Remarks
The overall level of amantadine-resistance in the UK 1958-1999 was calculated to 
be 2.25%. There was variation in susceptibility between seasons with 
spontaneous bursts of resistance interspersed with low levels of resistance. 
Frequency of resistance for H3N2 and MINI was very similar but there was no 
resistance detected within the H2N2 subtype. Within the H3N2 and MINI 
antigenic subtypes there was variation in susceptibility. It was hypothesised that 
this was due to the presence of quasispecies within the viruses containing 
.populations of sensitive and resistant genotypes. Changes within the environment, 
allowing the resistant population a selective advantage over the sensitive, would 
have allowed the formation of a predominantly resistant population within a virus 
isolate. There was evidence to support the hypothesis that resistant viruses were 
not transmitted throughout the population, but within confined populations there 
was evidence to suggest that these events occurred. It was concluded that the 
emergence of resistant viruses within the UK was primariiy a result of the mutating 
genome of influenza A viruses and less significantly from the use of amantadine to 
treat patients.
Surveillance of the drug susceptibility of isolates needs to be maintained. It is not 
fully known whether in the absence of selective drug pressure during multiple 
cycles of transmission resistant human viruses are capable of competing with wild- 
Types (144). Results from this study would suggest not, but it is known that 
resistant viruses are equally virulent in animal models (350). This raises the 
possibility that if conditions were suitable, with sufficient selective pressure e.g. 
during an epidemic period where drug prophylaxis was widespread, resistant 
strains could outcompete wild-type strains to create an epidemic strain with a 
resistant genotype. It is interesting to note that unpublished findings from a recent 
study have demonstrated the persistence of amantadine-resistance within certain
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swine influenza viruses (A. Hay, 2001; unpublished results). It is reported that in 
Europe, around 1986/87, an amantadine-resistant virus emerged in the swine 
population that has been maintained to present day. The exact reason for the 
emergence of this resistance is not known. The matrix genes from these resistant 
Viruses have evolved along a separate lineage to their sensitive counterparts. The 
significance of these findings is twofold; firstly, it demonstrates the ability of an 
amantadine-resistant virus to be transmitted and maintained through an animal 
population for a long period of time without any selective pressure from drug. 
Secondly, pigs have been defined as a possible mixing vessel for the 
reassortment of influenza viruses from different animal species to form novel 
strains that have the ability to cause pandemic disease in humans. If the 
reassortment event occurred in a pig carrying an amantadine-resistant virus, there 
is the possibility that the novel virus might carry the matrix genes from the swine. 
This would result in a virus with novel antigenic properties that is able to infect a 
iarge number of hosts and also contain mutations conferring amantadine- 
resistance. This illustrates the importance of maintaining surveillance of 
amantadine-resistance in viruses from all host species
With the recent introduction of anti-neuraminidase drugs it is becoming evermore 
important to use population-based screening studies such as this to continually 
investigate the emergence of resistant viruses. The inevitable launch of additional 
drugs targeting influenza will exert an ever-increasing pressure on the virus to 
evolve and generate resistance. Protocols developed here can be used as 
templates for antiviral testing in the future in an attempt to monitor the spread of 
drug susceptibility.
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Chapter 4
Genotypic Characterisation of 
Amantadine-Resistant Strains
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4.1 Introduction
4.1.1 The Influenza A M2 Protein
The M2 protein of influenza A was implicated in having an essential role in the 
replication cycle of the virus during early studies of the antiviral drug amantadine 
(142). The influenza M2 protein is a small homotetramer consisting of 97 amino 
acids (204). It has three distinct regions; the extracellular, transmembrane and 
cytoplasmic domains, each of which contain 24, 19 and 54 amino acid residues, 
respectively (136). The M2 protein is greatly under-represented within the 
influenza virion when compared with other viral proteins e.g. Ml, NR, HA1 or HA2, 
yet it is produced abundantly during infection and is expressed at the infected cell 
membrane in large quantities (411). M2 is coded by RNA segment seven of the 
influenza A genome. The segment contains two open reading frames (ORF), one 
encodes the Ml protein and the other ORF codes for the M2 protein in a 4-1 
reading frame (204). The M2 mRNA contains a leader sequence of approximately 
51 nucleotides that is covalently linked to the main body sequence (nucleotides 
740-1011) and identical to the 5’ end of the Ml mRNA (204) (Figure 4.1).
FIGURE 4.1 Coding strategies for M1 and M2 from influenza A gene segment 7
I in I # 11', r, 1 j AAA
AAA
4-1 frameshlft
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The orientation of the M2 protein within the virus membrane has been determined. 
The hydrophobic transmembrane domain of 19 amino acids (residues 25-43) 
anchors the protein to the virus membrane (206). The 54 amino acid COOH- 
terminal (C-terminal) domain is orientated on the cytoplasmic side of the 
membrane with the remaining NH2-terminal (N-terminal) domain (24 residues) 
showing at the surface of the membrane with a minimum of 18 amino acids 
residues exposed (206). The actual function of the C-terminal domain of the M2 
protein remains unknown although it has been shown to undergo post-translational 
modifications implying that it has some important role in the replication cycle (162, 
348, 371). It has been suggested that the extracellular domain (N-terminal) of the 
M2 protein plays an important role in interacting with other membrane proteins, 
e.g. HA, NA and Ml. Park et al (1998) constructed chimeric M2 mutants 
containing various combinations of the M2 domains and different regions from 
Sendai virus F protein (272). Results demonstrated that the only M2 chimeric 
mutant to be incorporated into influenza virions contained the M2 extracellular 
domain in combination with other regions of Sendai F protein. These findings 
suggested that the extracellular domain of M2 was important for its incorporation 
into virions (272).
4.1.2 The Influenza A M2 Ion Channel
The M2 protein forms a membrane channel that permits the flow of protons (282). 
The ion channel theory was initially hypothesised by Sugrue et al. (1990) who 
investigated the control of pH during the influenza infectious cycle (346). Results 
from this early study provided evidence that M2 played a part in pH regulation by 
counteracting the acidic conditions of certain compartments of the exocytic 
pathway, in particular the TON (346). It was proposed that M2 was able to regulate 
pH because it formed an ion channel within the virus membrane. Although there 
was no direct evidence at the time to support this theory, a further study by Sugrue 
and Hay (1991) presented data that indicated the M2 protein existed as two 
dimers, non-covalently held together by disulphide linkages at cysteine residues 
17 and 19 (348); residue 17 was found to be conserved in all influenza A viruses 
(411). This proposed arrangement of two dimers forming a tetramer structure 
facilitated the ion channel theories; it created a structure that could resemble a 
channel with an inner pore lying within the virus membrane (348).
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Two subsequent studies both independently provided evidence for the ion channel 
function of M2. Pinto etal. (1992) performed experiments where M2 mRNAs were 
microinjected into the oocytes of Xenopus laevis resulting in the expression of M2 
protein (282). Membrane currents were measured using a two-electrode voltage- 
damp procedure. Current readings across the membranes expressing M2 were 
Taken in the presence and absence of amantadine, which was known to target the 
M2 protein. It was found that the M2 protein could be associated with ion channel 
activity and that the presence of amantadine attenuated the flow of current across 
the membranes expressing the protein. However, when the same procedure was 
repeated with oocytes expressing M2 proteins carrying mutations known to confer 
resistance to amantadine the drug did not block conductance (282). These data 
provided direct evidence that the M2 protein functioned as an ion channel and that 
the transmembrane domain of M2 formed the channel pore. Duff and Ashley 
(1992) corroborated these findings when they created a synthetic 25-residue 
peptide that corresponded to the predicted sequence of the transmembrane 
domain of the M2 protein (79). This peptide was incorporated into voltage-clamped 
planar lipid bilayers and a current passed across, again the results demonstrated 
the occurrence of proton conduction across the membrane. Similar studies using 
electrophysiological measurements of ionic current across different membranes 
expressing M2 including mammalian cells (46, 376), lipid vesicles and bilayers 
(320, 360) and in yeast (198) provided further evidence that M2 formed an ion 
channel and the transmembrane region of the protein formed the basis of the ion 
channel pore.
Previous studies have indicated the importance of certain amino acid residues 
within the pore and their effect on the structure and function of the channel. The 
histidine residue found at position 37 (His-37) has been established to have 
essential properties for controlling the “gating” of the channel (281, 321, 329, 416). 
The 3-dimentional structure of the inner pore of the channel has been predicted, 
revealing that His-37 occludes the channel, preventing the flow of protons (Figure 
4.2) (281). Analysis of the structure of histidine (carrying a side-chain imidazole 
ring) suggests that within the tetramer structure, imidazole rings from two histidine 
molecules face each other and block the channel completely, resulting in the 
channel forming a closed state (Figure 4.3) (416).
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FIGURE 4.2 Axial view of the predicted structure cf the M2 icn channel
Panels A-E illustrate successive slices through the M2 ion channel in the direction of N- 
terminal to C-terminal. Amino acids thought to be essential for the function of the channel 
are characterised by ball-and-stick representations: (A) Val-27, (B) Ala-30, (0) Gly-34, (D) 
His-37 and (E) Tyr-41. It can be seen that His-37 (D) represents the only residue forming an 
occlusion within the channel. Taken from (281).
FIGURE 4.3 Representation cf the side view cf the M2 icn channel
e
His-37
The figure represents two helices of the M2 tetrad, with the N-terminal at top and C-terminal 
at bottom. The only major occlusion of the channel, His-37 is illustrated with the imidazole 
side-chain rings clearly visible. Taken from (329).
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A mechanism for proton transportation within the M2 ion channel has been 
hypothesised (Figure 4.4). The ion channel is composed of four helices of M2 
subunits that form a narrow pore that is occupied with water molecules (316). This 
channel of water spans the entire pore from the N-terminal mouth to the C-terminal 
end and consists of two to three parallel chains of “water wires” at any one time 
(99); this provides the basis for the transfer of protons along the channel. It is 
hypothesised that protons “hop” from one water molecule to the next and so move 
,along the length of the ion channel from the N-terminal to C-terminal mouth (316). 
However, in order for the flow of protons to be complete through the entire 
channel, the pore must be in an open state i.e. the arrangement of the His-37 
imidazole rings must be such that water molecules can span the entire channel. 
Within the closed channel, it has been proposed that the imidazole rings of His-37 
residues remain in the lumen of the pore, thus the water molecules extend into the 
lumen of the pore from the N-terminal mouth to the point at which His-37 occludes 
the channel (316). Modelling studies have demonstrated that for the ion channel to 
open, protonation of the His-37 residues within the transmembrane tetramer 
structure must occur although it has been shown that only one His-37 residue 
needs to be protonated to facilitate the conduction of protons (281). This event 
results in a “tilting or flipping” of the ring structures of His-37, vacating the lumen of 
the pore and thereby facilitating a column of water to span the pore region fro the 
,N-terminal to C-terminal mouth (Figure 4.4) (281, 416). Evidence for the 
importance of His-37 in the gating of the channel has been provided by studies 
where the His-37 residue was replaced with other amino acids (375). Resultant 
mutant ion channels, where the His-37 residues were replaced with residues that 
could not be protonated e.g. glycine or glutamate, were not activated when 
exposed to low pH (375). This demonstrated that the His-37 residue was vital in 
the gating of the channel and therefore, in the replication cycle of the virus.
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FIGURE 4.4 Predicted water wire model for proton transduction through the M2 ion channel
H* H* OOJOO
a O J P
« 3 »
f W
The channel Is viewed from the side with only His-37 showing; water molecules are 
represented by solid blue circles. (A) Pore in closed state; (B) lowered extracellular pH 
promotes protons (H^ ) to “hop” along water wires occupying the lumen of the pore from N- 
terminai mouth to histidine occlusion; (C) protonation of the histidine causes imidazole 
rings to tilt or flip allowing column of water to fill pore from N-terminal to C-terminal mouth. 
Transfer of protons along length of pore promotes acidification of cytoplasmic domain. 
Predicted pH values of Rostock M2 ion channels expressed in Xenopus laevis ooccytes for 
the extracellular and cytoplasmic domains at different stages of ion channel activity are 
included below (324).
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The M2 ion channel is found exclusively in the surface membranes of influenza A 
viruses. This is the fundamental reason why amantadine and rimantadine, anti-M2 
protein drugs are effective only against infections caused by viruses of influenza A 
subtype. There is however, evidence to show that within influenza B and C viruses 
there are structural proteins analogous to the M2 ion channel that have similar 
functions. The NB protein is coded by influenza B gene segment six in an 
overlapping reading frame; NB is coded by the same mRNA as the NA surface 
glycoprotein (323). Studies to elucidate the structure and function of the NB 
protein were similar in nature to those described for the M2 ion channel (349, 394). 
The protein was found to be post-translationally modified by palmitoylation, the 
formation of disulphide linkages to form dimers and glycosylation of the N-terminai 
of the protein (38, 394). When the protein was expressed in E. coli and added to 
artificial lipid bilayers it was found that the protein produced ion channel activity. In 
comparison to M2, NB ion channels appeared to conduct other cations (Cl ) in 
addition to protons, a finding that has not been fully explained (349). This finding 
was supported by results that demonstrated that the channel activity was blocked 
by the addition of an antibody targeting the C-terminal end of the protein. Influenza 
B viruses are inhibited by amantadine in vitro when virus is exposed to 
concentrations approximately 100 times that required to inhibit influenza A viruses 
(10, 349). Although it has not been proven that amantadine at such high 
concentrations specifically inhibits the NB ion channel of influenza B viruses, it is 
probable that this is the case. Therefore, the available evidence indicates that the 
NB protein forms a cation-selective ion channel in influenza B viruses.
The influenza C M2 protein (CM2) is a 139 amino acid protein that is translated 
from a full length mRNA from segment six of the influenza C genome (164). 
Studies suggest that the CM2 protein is modified post-translation; it forms 
disulphide-linked dimers and trimers, and undergoes palmitoylation, a 
characteristic analogous to M2 (163, 164, 218). Another post-translational 
modification that CM2 shares in common with NB, but not M2, is glycosylation of 
the N-terminal domain of the protein (163, 394). The function of CM2 has not yet 
been determined and it remains to be seen whether it shares the ion channel 
activity of M2 and NB. A hydrophobic region within the protein has been identified 
that may serve as a transmembrane domain (276); considering this and the 
degree of homology between CM2 and the ion channels of influenza A and B it is
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likely that CM2 does have a role in the control of pH within the replication cycle of 
influenza C viruses.
4.1.3 Post-Translational Modifications of M2
During the replication cycle of the influenza A virion the M2 protein undergoes 
several post-translational modifications. One modification is the addition of long 
chain fatty acids (acylation) to the M2 protein. An example of acylation is the 
addition of a palmitate moiety to the M2 protein (371). It has been determined that 
this event occurs during the transport of M2 to the cell surface and involves the 
majority of M2 molecules (347). The actual position of the palmitoylation has been 
determined through labelling of various influenza-infected cells with pH] palmitic 
acid. It was found that several equine viruses lacked an acyl group, which was 
correlated to the replacement of cysteine 50 with a phenylalanine residue (347). 
This demonstrated that the cysteine residue found at position 50 was the site of 
attachment for the palmitate fatty acid and therefore it was the cytoplasmic domain 
that was modified. The data also suggested that the linkage between the cysteine 
residue at position 50 and the palmitate moiety was a thioester linkage (347). 
Although the exact role of this modification was not clear, it was thought that the 
addition of the palmitate moiety to the cytoplasmic tail helped influence the stability 
of the M2 structure and possibly the formation of the M2 dimer (347).
Another post-translational modification that has been previously identified is the 
modification of the cytoplasmic tail by phosphorylation. There are five serine 
residues at positions 64, 71, 82, 89 and 93 found within the M2 protein that are 
possible targets for phosphorylation. Studies have shown that the serine residue 
residing at position 64 is the predominant phosphorylated residue within M2 (162). 
Serine residue 71 was not modified by the addition of phosphate, but the other 
serine residues at positions 82, 89 and 93 were all phosphorylated to a minor 
extent (162). The effect of phosphorylation on ion channel function was assessed 
and it was found that it had no discernable effect on membrane currents of M2 
expressed in Xenopus laevis oocytes (162). Other hypotheses of how 
phosphorylation affects the virus have included the control of the intracellular 
transport of M2 and the incorporation of M2 into virus particles. However, recent 
experimental evidence has shown that unphosphorylated M2 is incorporated into
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virus particles as efficiently as the phosphorylated form (358). This study also 
provided evidence that the phosphorylated cytoplasmic tail did not have any 
significant control on the intracellular transport of the M2 protein. Although the 
exact function of phosphorylation of the cytoplasmic tail is not fully understood, the 
conserved nature of serine residue 64 would suggest that phosphorylation at this 
position on M2 provides some evolutionary advantage to the virus (358).
The formation of disulphide bonds within the M2 tetramer structure represents 
another post-translational modification. The three possible sites for the disulphide 
linkages to form were identified as cysteine residues 17, 19 and 50. The cysteine 
residue at position 50 had previously been shown to be the target for covalent 
attachment of palmitate (347). It had been demonstrated that residues 17 and 19 
were conserved in all influenza A viruses, which made them primary targets for the 
linkages (411). Evidence for the formation of disulphide linkages originated from 
^^C-cysteine labelling of virus-infected cells and subsequent immunoprécipitation 
of virus peptides (161, 348). It was hypothesised that disulphide linkages held the 
two dimer structures together forming the tetramer which was the basis for the ion 
channel (348). Evidence has suggested that the formation of disulphide linkages 
has no effect on the function of M2 i.e. ion channel activity but the formation of 
disulphide linkages is thought to play a role in stabilising the M2 structure during 
stages of the replication cycle of the virus, although the exact role has not been 
fully characterised (162).
,The incorporation of post-translational modifications within the C-terminal 
cytoplasmic tail region suggests that this region of the M2 protein would be 
essential for virus viability. Mutant viruses formed with truncated cytoplasmic tails 
have been shown to lose viability in correlation to the extent of truncation (45). 
Recombinant viruses containing M2 proteins lacking 5 and 10 residues from the 
cytoplasmic tail region could not be recovered by reverse genetics techniques, and 
viruses lacking only one residue from the C-terminal end had reduced growth 
potential in plaque assay. Similar experiments to determine the effect of C-terminal 
truncations on ion channel activity determined that several viruses carrying mutant 
M2 genes with certain truncations had reduced activity although some had activity 
that resembled the wild-type channel (359). It was hypothesised that the C- 
terminal of the M2 protein could have secondary structure, which in truncation 
mutants would might destabilise the protein and decrease the ion channel activity
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of the virus. However, it has also been hypothesised that the M2 C-terminal 
domain may be important for sustaining interaction with other viral proteins; 
interactions with the M1 protein have previously been established (410, 411).
4.1.4 Function of the M2 Ion Channel
The M2 ion channel has been shown to have an essential role within the 
replication cycle of the virus. The two main functions of the channel are associated 
with its ability to transport protons and therefore regulate pH. Following the initial 
process of virus binding to the host cell receptors, the virion is internalised by 
receptor-mediated endocytosis (406). Cellular proton pumps within the endosomal 
membranes cause a gradual increase in the acidity of the internal environment 
within the endosome (136). The decrease in pH causes the HA to undergo a 
conformational change which promotes the fusion of viral and endosomal 
membranes (235). At the same time, the lowering of the internal endosomal pH 
stimulates the M2 ion channel and the pore “opens”, allowing the flow of protons 
through it to occur (282). This process lowers the pH within the virion interior, 
which subsequently promotes the dissociation of the M1/RNP complex liberating 
the RNP for transport to the host cell nucleus (414).
A second function of the M2 ion channel was discovered during studies of certain 
avian influenza A HA subtypes. Through studying the effect of amantadine on viral 
replication, it was found that the drug had an indirect affect on the structure of the 
avian HA (346). Certain avian HA species e.g. H7 and H5 contain a sequence of 
multi-basic amino acids at the cleavage site between HA1 and HA2 (182); this 
facilitates the proteolytic cleavage of the HA precursor HAO into the HA1 and HA2 
subunits in the TGN by the protease furin (341). The cleavage within the TGN 
renders the avian HA susceptible to structural conformational changes upon 
exposure to low pH (346, 392). In the late stages of the replication cycle, it was 
found that M2 was transported to the infected cell membrane via the TGN 
following synthesis in the endoplasmic reticulum (168). During the co-transport of 
the M2 and HA proteins from the site of synthesis in the endoplasmic reticulum to 
the infected cell membrane, the lumen of the TGN was maintained at an acidic pH 
by cell-mediated proton pumps. It was postulated that the M2 ion channel 
counteracted the acidity of the TGN by facilitating the flow of protons out of the
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TGN via the ion channel thus increasing the pH. The effect of this pH regulation 
was that the pH-susceptible HA contained within the TGN was maintained in its 
native form; however, if the activity of the ion channel was suppressed, the HA 
was converted to a low pH form (346). The consequence of this transformation of 
native HA to a low pH form was not fully understood; the formation and distribution 
of budding particles from the cell surface were not significantly different between 
control and drug-treated cells but the release of particles was blocked (310). It was 
postulated that the presence of low pH HA inhibited a final stage in virus 
maturation e.g. pinching off of budding particles.
4.1.5 Molecular Basis for Mode of Action of Amantadine
Amantadine has been shown to have two concentration-dependent inhibitory 
actions on influenza A viruses (143). Early studies demonstrated that high 
concentrations inhibited early stages of infection and virus uncoating (39, 40, 143, 
179), and low concentrations of drug indirectly affected the fusion activity of the 
viral haemagglutinin (143, 346). Therefore, the two inhibitory actions of 
amantadine correlate to the two defined functions of the M2 ion channel i.e. virus 
uncoating and HA maturation. Through the study of recombinant viruses 
composed of sensitive and resistant parental strains, the direct target of 
amantadine within the influenza A virion was initially shown to be the matrix 
protein (140, 224). The Ml and M2 proteins of resistant viruses were sequenced 
and the mutations conferring resistance were found to lie within a hydrophobic 
, sequence of 19 amino acids that corresponded to the transmembrane domain of 
the M2 protein (142). Resistant viruses were determined as containing a single 
point mutation within M2 at one of five amino acid positions; 26, 27, 30, 31 or 34 
(118,142) but the mechanism behind the inhibition was unclear (Figure 4.5).
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FIGURE 4.5 Diagrammatic representation of blockage of the M2 ion channel by amantadine
M2 IonExtracellular
Channel
Lipid Bilayer
Cytoplasmic
The figure represents the transmembrane domain of the M2 protein positioned within the 
lipid bilayer. Only two chains of the M2 tetramer are illustrated for clarity. Amino acid 
residues highlighted in green have been associated with amantadine-resistance. A molecule 
of amantadine (red) is shown lying within the ion channel pore. Adapted from (136).
There have also been reported cases of viruses carrying dual mutations within the 
M2 transmembrane domain that confer resistance (22, 118). Studies to assess 
amantadine-resistance in viruses recovered from both animals and humans have 
revealed a range of different substitutions that can occur at the five positions within 
the M2 transmembrane domain (Table 4.1). To date mutations in human viruses 
have been found at four amino acid positions, 26, 27, 30 and 31 (25, 147, 152, 
166,193).
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TABLE 4.1 Amino acid substitutions in the M2 protein of amantadine-resistant viruses
Virus M2 Transmembrane Amino Acid Position and Number
26 27 30 31 34
A/New/York/83
(H3N2)
Val ->Ala Ala ^Val Ser ->Asn
A/Virginia/88
(H3N2)
Vai ->Ala Ala ->Val
->Thr
Ser ^Asn
A/Shanghai/87
(H3N2)
Val ^A la Ala ^Val
->Thr
Ser ->Asn
A/USA/90
(H3N2)
Leu -^Phe
Ser ^Asn
Ck/Penn/83
(H5N2)
lie —>Ser 
-^Thr
Ala ->Ser
-^Thr
Ser ^Asn
Ck/Germany/27
(H7N7)
Val ->Ala
->G!y
->Asp
Ala -»Thr
->Pro
Ser -»Asn Gly -^Glu
Only amino acid residues within the M2 transmembrane region known to be important in 
amantadine-resistance are shown. Under each residue, the sensitive wild-type is shown on 
the left of the arrow, and the resistant mutants on the right. All resistant viruses were 
isolated in vivo except Ck/Germany/27 that were isolated by plaque selection in the 
presence of amantadine. Taken from (137).
It is apparent that resistant viruses isolated from humans during or following 
therapeutic treatment with amantadine or rimantadine predominantly carry a Ser to 
Asp substitution at position 31 (Ser31Asn) (90, 144, 147, 166, 417). It has been 
postulated that this mutation may provide the best fitness to viruses carrying it with 
regard to transmission, and therefore survival. Studies of resistant viruses within 
the avian model have revealed that mutations can be found at all five positions but 
several mutations reported are different from ones emerging in resistant human 
viruses e.g. Leu26His and Val27Asp (118). Within the avian model, resistant
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mutations appear to be dependent on the virus strain, e.g. in viruses of Rostock 
strain (H7N1), mutations were found to be exclusively at position 27 but in the 
Weybridge strain (H7N7) viruses mutations were predominantly found at position 
34 (142). Therefore, it appears that the occurrence of mutations within influenza A 
viruses are dependent on the host species and the virus strain. There are other 
potential factors affecting selection of different resistant genotypes that are not yet 
fully understood.
The occurrence of mutations within the transmembrane region of the M2 ion 
channel can influence different functional aspects of the virus. It has been reported 
that mutations at different positions within M2 have increased or decreased the 
activity of the protein resulting in corresponding changes in viral inf activity and 
growth (118). This was observed in avian strains of influenza where amino acid 
substitutions at positions 26, 30, 31 and 34 caused an increase in the expression 
of the low-pH form of HA as a result of suppression of the M2 ion channel activity. 
In contrast, viruses that carried a substitution at position 27 (He to Thr or Ser) were 
shown to have greater growth and inf activity compared to wild-type virus indicating 
a possible increase in M2 activity (118). These results are interesting as they raise 
the question of whether a resistant mutant could gain a selective advantage over 
sensitive wild-type strains by acquiring amantadine-resistance at certain positions 
in the M2 transmembrane domain. To date, studies concerning this aspect of 
resistance have been limited to avian influenza; the implication for the virulence 
and transmissibility within human strains and therefore the general population 
requires further investigation.
Molecular dynamics studies have revealed the predicted orientation of the M2 ion 
channel and the pore (281, 329). This has enabled the mapping of the location of 
important residues, which form the face of the lumen of the channel pore. Data 
from such studies may explain why certain residues within the channel have more 
structural significance, and are associated with amantadine-resistance. Modelling 
has revealed that certain residues known to confer amantadine-resistance were 
located on the lumen face of the M2 ion channel pore (Figure 4.6). It has been 
hypothesised that the positioning of the residues facilitate the interaction of the 
respective amino acids with amantadine molecules and therefore represent 
positions where amantadine can interact and block the channel. Mutations at any 
of the five positions have been shown to confer resistance and it is thought that
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substitutions of the residues may result in changes in the channel structure and 
neutralise the binding of amantadine within the pore region.
FIGURE 4.6 Helical wheel diagram representing one heptad of the four-helical bundle of the M2 
protein
C
b
25
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a d
The dashed line represent the boundaries between three different regions; the central pore 
of the ion channei, the middle region where the helix-helix interface lies, and the outer 
region representing the lipid bilayer. The transmembrane sequence below (residues 25-43) 
illustrates the heptad repeat of residues a and d, which corresponds to Val-27, Ala-30, Gly- 
34 and Tyr-41. Adapted from (281).
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4.2 Aims
The aim of this work was to characterise the amantadine-resistant viruses that had 
'been selected through amantadine susceptibility screening performed by El A and 
plaque reduction assay. It was hoped that this would reveal the relative frequency 
of M2 mutations in human populations and influenza subtypes. The objectives 
were to determine the underlying molecular changes conferring resistance in the 
viruses and therefore their resistance genotype. Primarily, this involved 
sequencing M2 and analysing the transmembrane domain, the region that was 
known to be the target of amantadine and where substitutions conferring 
resistance occurred. With the resulting data, amino acid sequences were aligned 
to identify changes within M2 and also to determine the presence of any changes 
within M1 that might have contributed to changes in virus function. A selection of 
amantadine-sensitive viruses was chosen from the susceptibility screening and M2 
sequenced to determine whether there were any significant amino acid 
substitutions within the proteins of the sensitive strains.
Understanding the consequence of amino acid changes within M2 on the 
biological properties of the viruses was important because the matrix genes have 
been implicated in controlling virus growth. It was hoped that comparisons of 
sequence data and phenotypic results from Chapter 3 would reveal whether 
specific mutations within M2 conferred any selective advantage to the viruses.
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4.3 Results
4.3.1 PCR Amplification of Resistant Strains
RNA was extracted from tissue culture fluid containing the resistant viruses, 
reverse transcribed into cDNA and amplified by PCR as described in Materials and 
Methods (Chapter 2, page 45). The PCR primers used to amplify the entire M 
gene were designated AMP2 and AMP998 (Figure 4.7). PCR amplicons were 
detected by agarose gel electrophoresis and ethidium bromide staining. The 
correct size for bands corresponding to the amplified M gene was 996 base pairs 
(Figure 4.8). The presence of a band of this size indicated that the M gene had 
been successfully amplified from the specimen; the PCR product was then stored 
for further analysis.
FIGURE 4.7 Oligonucleotide primer positions for (A) PCR amplification and (B) sequencing of gene 
segment seven
A
5’ 1 M Gene 1127-5’
AMP2 ^ ^ AMP998
B
5' PCR P ro d u c t.................. ...............  3 ’
AMP2 ^ AMP680 .►
AMPB
W'
_ AMPCII _ AMPDII
. AMP998
Green bars represent the target gene and PCR amplicon. Primers used for PCR 
amplification are designated with arrows and represent the approximate position of 
amplification.
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FIGURE 4.8 A typical gel image produced by M gene PCR amplification
1 2 3 4 5 6 7 8 9 10 11 12 13
500 bp
1.6 Kb
996 bp 
product
Gel electrophoresis of samples A-F. Lanes 1&2, 3&4, 5&6, 7&8, 9&10, 11&12 were replicates 
of resistant samples A-F. Lane 13 contained a negative control consisting of virus transport 
medium. Samples A (lanes 1&2), 0 (lanes 5&6), E (lanes 9&10) and F (lanes 11&12) were all 
positive for influenza M gene; samples B (lanes 3&4) and D were negative for M gene. M -  
DNA molecular weight marker.
In cases where the PCR did not amplify the M gene and the 996 base pair product 
could not be visualised on the agarose gel, the original virus isolate was inoculated 
into tubes separately seeded with confluent MDCK and RMK mammalian 
monolayers. After incubation for seven days at 37°C the tissue culture fluid was re­
extracted and the PCR repeated.
From EIA and plaque reduction testing, 48 viruses were selected as phenotypically 
resistant to amantadine. PCR amplification was performed on 48/48 resistant 
viruses; results showed that 47/48 contained a product of 996 base pairs 
corresponding to the M gene. The only virus from which genetic material could not 
be extracted was A/ENG/424/98; even after attempted re-amplification in tissue 
culture there was still no positive PCR result. Therefore, this virus could not be 
processed any further and thus the total number of resistant viruses that were 
analysed by genotypic methods was 47.
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4.3.2 M2 Genes Originating from Resistant viruses
Automated sequencing was performed on M gene PCR products of resistant 
viruses as described in Materials and Methods (section 2.13). The positions of the 
primers used in the sequencing reactions are illustrated in Figure 4.7. The majority 
of viruses were sequenced using an Applied Biosystems 373 automated 
sequencer although a proportion of viruses were sent to Durham University DNA 
sequencing service to be analysed.
Raw data extracted from the Applied Biosystems 373 sequencer was analysed 
using the sequence analysis software package, SeqEd (Applied Biosystems). 
Nucleotide sequences from each primer were checked, bases were called, and 
then the sequence aligned to produce a nucleotide sequence corresponding to the 
whole matrix gene. In order to produce a nucleotide sequence for the entire M2 
gene, two sections of the matrix sequence had to be cut and then spliced. 
Nucleotides 26-51 and 740-1004 were spliced together in EditSeq (DNAStar) to 
form a sequence 291 bases in length for each virus; this corresponded to the 
known size of M2 (204). Sequences were then imported into MegAlign (DNAStar) 
where nucleotide and amino acid alignments were created. Changes within the 
nucleotide or amino acids were compared to the majority sequence calculated by 
MegAlign.
Initially, nucleotide sequences for M2 were prepared for all of the resistant viruses 
and aligned against the majority sequence calculated by MegAlign (Figure 4.9). 
From initial analysis of the nucleotide alignments it was apparent that there were 
numerous nucleotide substitutions occurring in the resistant viruses. There were 
only two viruses that had sequences homologous to the majority, A/ENG/627/83 
and A/ENG/259/83. The sequences were divided into the three known functional 
domains of M2 to determine whether the substitutions were more prevalent in 
certain regions. The extracellular domain (residues 1 -72) contained relatively few 
sites where nucleotide substitutions occurred. At residues 6, 27 and 72 there were 
12/47, 10/47 and 10/47 viruses that had mutations from C ^T , A ^G  and C->T 
respectively; 10/12 viruses that carried a mutation at one of these three positions 
carried all three mutations. In addition, there were two viruses (A/ENG/357/96 and 
A/ENG/327/90) that carried a single G ^A  mutation at positions 35 and 47 in the 
extracellular domain.
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In order to determine whether the substitutions found within the extracellular 
domain were silent, or coding for amino acid changes, an amino acid alignment 
was prepared for H3N2 and H1N1 viruses using MegAlign (Figures 4.10 and 
4.11). From these alignments it was clear that there were only two amino acid 
substitutions that had occurred, both within H3N2 viruses. One mutation was a 
Gly^Glu at position 16 (Gly16Glu) and the other an Arg12Lys. It was deduced 
that these amino acid substitutions had been caused by the single G->A 
nucleotide substitution at residues 35 and 47 (Figure 4.9). Therefore, the 
remaining nucleotide substitutions within the extracellular domain were all 
synonymous (silent) suggesting that non-synonymous changes causing amino 
acid mutations within this domain were detrimental to the function of the 
extracellular region.
The nucleotide and amino acid alignments for the transmembrane domain 
(nucleotide residues 73-129) of M2 were analysed (Figures 4.9 to 4.11). In 
comparison, there were significantly more mutations in the transmembrane region 
than the extracellular region. Analysis of both nucleotide and amino acid 
substitutions revealed that approximately 26% of the nucleotide changes found 
within the transmembrane region were non-synonymous i.e. coding for an amino 
acid change. This figure was relatively high when compared to the percentage of 
non-synonymous nucleotide changes within the extracellular domain (6%). When 
the non-synonymous changes within the transmembrane region were analysed, it 
was found that they comprised of 12 transitions and 15 transversions. The amino 
acid changes within the transmembrane domain were analysed and compared to 
previous studies where amantadine-resistant viruses had been characterised. 
From a total of 47 viruses that had been sequenced, 22 carried a mutation within 
the transmembrane region. The most frequent mutations found were Ser31Asn 
(9/22) and Leu36Val (8/22). The remaining viruses had Val27Ala (1/22), Val27lle 
(3/22) and He32Met (1/22) substitutions. In addition, several viruses carried dual 
mutations within the transmembrane region; three viruses carrying a Leu36Val 
also had a Leu43lle mutation. Similarly, two viruses with Ser31Asn had an 
additional Pro25Ser. These results obtained from sequencing M2 confirmed 
previous findings that the Ser31Asn mutation was commonly found in resistant 
H3N2 viruses isolated from humans. The Val27Ala mutation that was found in 
A/ENG/357/96 had also previously been described in human resistant strains. The 
remaining viruses carrying mutations in the transmembrane domain were
1 2 2
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interesting because there had been no previous documentation of their occurrence 
in human resistant viruses. The Leu36Val mutation was discovered in eight H1N1 
viruses originating from the 1983/84 and 1991/92 seasons. Three viruses from 
1991/92 carried an additional Leu43lle mutation. Four viruses were found to have 
mutations at position 27; one Val27Ala and three Val27lle substitutions. The 
Val27Ala had been previously found in human viruses but the Val27lle 
substitutions could not be found in the M2 transmembrane sequences of any 
human viruses. The M2 transmembrane mutations are summarised in Table 4.2.
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The nucleotide and amino acid sequences of the cytoplasmic domain (nucleotide 
residues 130-291) were analysed; between the 47 resistant viruses sequenced 
there were 121 nucleotide changes observed (Figure 4.9). In relation to the size of 
the domain (162 nucleotides) mutations occurred at a frequency of approximately 
1.6 nucleotide changes per site per virus compared to 1 and 3.9 for the 
extracellular and transmembrane domains respectively. This demonstrated that 
the cytoplasmic region was more conserved than the transmembrane domain but 
not to the degree of conservation shown by the extracellular domain. 
Approximately 33% of the nucleotide changes were non-synonymous. This 
indicated that the cytoplasmic domain had the highest rate of non-synonymous 
mutations throughout the three functional domains of M2. All of the molecular 
changes observed in the domains of M2 of the resistant viruses are summarised in 
Table 4.3.
TABLE 4.3 Summary of M2 sequence mutations within 47 resistant viruses analysed
M2 Domain (No. Nucleotides)
Extracellular (72) Transmembrane (57) Cytoplasmic (162) 
Ntchanges 34 103 121
Synon (Ts/Tv) 32 (32/0) 76 (64/12) 81 (60/12)
Non-synon (Ts/Tv) 2 (2/0) 27 (12/15) 40 (33/7)
' No. nt changes/
0.01 0.03 0.02
site/virus
Nt -  nucleotide; Synon -  synonymous; Non-synon -  non-synonymous; Ts -  transition 
(purine to purine / pyramidine to pyramidine); Tv -  transversion (purine to pyramidine / 
pyramidine to purine).
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4.3.3 M2 Genes Originating from Sensitive Viruses
In order to determine whether the mutations found within the M2 gene were 
exclusive to resistant viruses, a selection of viruses that were sensitive to 
amantadine by EIA were sequenced. The amino acid sequences of H3N2 and 
H1N1 were aligned separately against A/Aichi/2/68 and A/USSR/90/77 
respectively (Figures 4.12 and 4.13). The H3N2 alignment revealed that out of 26 
sensitive viruses sequenced, two contained mutations within the transmembrane 
region (Figure 4.12). Eleven sensitive MINI viruses were sequenced and there 
were seven viruses carrying M2 transmembrane mutations, three viruses each 
contained two separate mutations (Figure 4.13). The amino acids changes found 
within all viruses were at positions that had not previously been associated with 
amantadine-resistance but several shared mutations with viruses that had been 
found to be phenotypically resistant in this present study. Seven MINI viruses 
carried an amino acid substitution at position 36; the majority (6/7) contained a 
Leu36Val mutation, identical to the mutation found within the eight resistant 
viruses (Figure 4.11 and Table 4.2). The other mutation at this position was a 
Leu36Met; this mutation had not been found in the resistant strains. There were 
other mutations found in the transmembrane region of the sensitive strains that 
were in common with mutations found in the resistant strains. Two viruses carried 
a Pro25Ser and two carried a Leu43lle, both mutations had been found in the 
resistant strains (Figures 4.10 and 4.11).
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4.3.4 M1 Genes Originating from Resistant Viruses
The remaining viruses that had been sequenced did not contain any mutations 
within the transmembrane domain of M2. This was interesting because the viruses 
were phenotypically resistant but genotypically they appeared to be sensitive. In 
order to determine whether there were any changes within M1 that might have 
influenced the sensitivity of the virus to amantadine, the M1 of all resistant viruses 
were sequenced. The only virus that could not be used for M1 analysis was 
A/SCOT/77/92 because the AMPB and AMPCII primers (Chapter 2, page 48) used 
in the sequencing of the gene failed. It was not possible from the available 
fragments to piece together the M1 sequence therefore the virus was omitted from 
the analysis. Alignments were prepared for both nucleotide and amino acids; 
viruses were grouped into those containing mutations within the M2 
transmembrane region (+M2 TM) and those without (-M2 TM). It was hoped that 
by analysing the alignments for both sets of viruses, anomalies between them 
would identify possible mutations that might be the alternative cause of resistance 
other than M2 transmembrane mutations. Alignments of the 759-nucleotide M1 
sequence (residues 26-784) were prepared and analysed (Figure 4.14). Initially, it 
was apparent that within both sets of viruses, the N-terminal third of Ml was highly 
conserved compared to the C-terminal third of the gene where there was much 
greater variability between the viruses. When the two groups of viruses were 
compared, only six amino acid substitutions at five different positions were 
discovered in the +M2 TM viruses that were absent in the -M2 TM. The majority of 
these mutations were found at separate amino acid positions in a small proportion 
of viruses lacking mutations within the transmembrane region of the M2 protein. All 
other mutations present within Ml could be found in strains of either of the two 
sets of viruses demonstrating that the mutations were not affecting the 
susceptibility of the viruses to the drug. Therefore, these results suggested that -  
M2 TM viruses did not contain mutations within Ml that were responsible for 
causing resistance to amantadine.
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4.3.5 Analysis of Phenotypic and Genotypic Data from Resistant Strains
The phenotypic results obtained from Chapter 3 (Tables 3.7 and 3.8; pages 75 
and 80, respectively) were analysed in collaboration with the sequence data of the 
resistant viruses. Viruses carrying mutations within the transmembrane domain 
were confirmed to be phenotypically resistant (Table 4.4). The group of viruses 
that were found to lack mutations within the transmembrane domain of M2 were 
also phenotypically resistant (Table 4.4; only one virus, A/ENG/588/86, from this 
group is illustrated). The data collected in Chapter 3 concerning the morphology of 
plaques was compared to the genotypic results to identify any homology between 
characteristics.
One interesting observation made was that when viruses carrying a Ser31Asn 
substitution were grown in the presence of amantadine, the level of inhibition of 
these viruses was less compared to other resistant genotypes. It was apparent 
that a relatively large proportion of them (4/9) demonstrated an increase in PFU/ml 
in the presence of drug although these experiments were not repeated and 
therefore were treated with some caution. However, based on the available data, it 
did appear that the presence of the Ser31Asn mutation conferred a selective 
advantage when grown in the presence of amantadine.
There did not appear to be any other correlations between the resistant genotype 
and the relative growth properties of the virus. To substantiate these findings and 
confirm the current results, the plaque reduction assays for each virus would have 
to be repeated, ideally in the presence of a wider range of concentrations of 
amantadine. However the results obtained were considered to be reliable enough 
to postulate on the effects of different mutations on functions of the virus.
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TABLE 4.4 M2 transmembrane mutations and associated plaque morphology
Amino acid position 
and mutation
Virus Plaque morphology
- Drug + Drug
No Mutation (sensitive) A/ENG/290/87
Val27Ala
Val27i!e
Ser31Asn
Leu36Val
Leu43lle
Leu36Val
A/ENG/357/96
A/ENG/586/86
A/ENG/268/86
A/SCOT/77/92
A/ENG/134/84
No Mutation (resistant) A/ENG/588/86
Only five viruses with M2 transmembrane mutations from the present study are illustrated. 
Viruses were grown in MDCK cells in the absence and presence of 1.0 pg/ml amantadine 
and stained after 72 hours.
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4.4 Discussion
The genetic characterisation of the matrix genes from viruses that had been 
determined as phenotypically resistant to amantadine contained several 
interesting features. Nucleotide sequencing of M2 revealed the amino acid 
sequence of each virus tested; this data was also analysed for each functional 
domain of M2 to correlate findings with functions of the gene.
4.4.1 Extracellular Domain
The extracellular domain of M2 from amantadine-resistant viruses was highly 
conserved at the amino acid level. This was in agreement with previous studies 
(175, 412). At the nucleotide level there was a high proportion of synonymous 
changes (silent) and this has been previously described in other RNA viruses as 
indicative of proteins that are not under any selective pressure (301). The 
conserved nature of this domain suggested that its function was critical in the 
.replication cycle of the virus. Within the extracellular domain, two important 
residues, Cys-17 and -19 were absolutely conserved (411). They have been 
proposed as the sites where cysteine linkages are formed, holding the structure of 
the M2 tetramer together (348, 411). Therefore, the results from this study provide 
further evidence for their importance in the structure and function of the virus.
4.4.2 Transmembrane Domain
Analysis of the transmembrane domain revealed there were higher levels of 
mutation than in the extracellular domain. There was a higher frequency of non- 
synonymous changes suggesting an increased selective pressure on this region of 
the protein. This was expected because it was known that the transmembrane 
\ domain of the M2 protein was the target of amantadine and therefore this positive 
selective pressure would force the virus to mutate, possibly creating a resistant 
genotype. The ratio of transitions to transversions in the transmembrane region 
was higher than the other two domains. The significance of this finding was not 
absolutely clear but it was possible that it provided evidence for the ability of M2 
gene to withstand mutations that may have caused structural or conformational
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changes to the protein. This may have provided further evidence for the selective 
pressure on this region; a higher rate of transversion mutations would be indicative 
of changes occurring that might have provided an advantage to the virus.
Amantadine-resistance is conferred by mutations occurring within the M2 
.transmembrane domain at one of five amino acid positions (118,142). Sequencing 
M2 from the resistant viruses in this study revealed that 22/47 viruses carried 
mutations within the transmembrane domain with 13/22 carrying a mutation at an 
amino acid position known to confer resistance. The most common mutation found 
in H3N2 M2 was Ser31Asn; this correlated with previous studies that had 
determined that this mutation was frequently isolated in resistant human viruses 
(90, 144, 147, 166, 417).
Another mutation found during the present study that had been previously reported 
in resistant human strains was Val27Ala (147, 166, 238). However, at this same 
residue another mutation was discovered, a Val27lle substitution that was present 
in three viruses. The amino acids Ala and lie are relatively similar in structure; both 
are non-polar hydrophobic molecules with aliphatic side-chains and a molecular 
.weight of 89 and 131 Daltons respectively (314). Therefore, the similarity between 
the two molecules in respect to their biological nature suggests that the 
consequence of substituting the wild-type Val-27 with either Ala or lie would have 
a similar effect on the structure/configuration of the ion channel, i.e. resistance to 
amantadine.
The Val27lle mutation was interesting because it had not been previously 
observed in human resistant strains, but is present in some avian strains of 
influenza A e.g. A/CK/GERM/34 (Rostock) that has a naturally occurring lle-27 
(118, 142). It was known that mutations occurring at position 27 conferred 
amantadine-resistance in both human and avian strains (25, 118, 147, 166) but it 
was interesting that the mutation found in the three resistant human viruses 
(Val27lle) did not appear to confer resistance in Rostock. The sequence 
divergence between the matrix genes of avian and human viruses is reportedly in 
the range of eleven to 22 percent (88). In order to confirm that the M2 of the 
human strains containing lle-27 had not been the result of laboratory 
contamination e.g. through reassortment, an alignment of the whole M2 amino 
acid sequence of three avian strains and the three human viruses carrying the
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Val27lle substitutions was prepared. This, together with a phylogenetic 
comparison determined that there were sufficient differences between the two 
species of M2 to conclude that they were of separate origins (Figure 4.15). It was 
found that the remaining residues within the transmembrane sequence of M2 were 
homologous between Rostock and the human viruses, therefore differences 
between the two strains of virus were put down to other mutations within M2. If any 
of the other mutations within Rostock M2 had altered the structure or configuration 
of the channel this might have resulted an amantadine block resulting in a 
sensitive virus. It would have been interesting to take gene segment seven from 
the resistant human strains discovered in the present study, and engineer it into a 
Rostock virus using reverse genetics to investigate whether the progeny virions 
were of sensitive or resistant phenotype and genotype.
Another aspect that had to be considered was the possible influence of the 
mutations within the haemagglutinin gene of the Rostock virus. It had been 
previously demonstrated that mutations within the HA gene affected the 
susceptibility of Rostock viruses to amantadine (118). Therefore, it was postulated 
that there could have been interactions between the M2 and HA of Rostock strains 
which could have maintained the susceptibility of the virus to amantadine.
138
____________________________________ Chapter 4 -  Genetic Characterisation
FIGURE 4.15 (A) Amino acid alignment and (B) phylogenetic analysis of M2 sequences from avian 
and human influenza viruses
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The mutation Leu36Val was found in 8/22 H1N1 resistant viruses with mutations in 
the transmembrane domain of M2. There is no previous evidence to suggest that 
this mutation had occurred in either human or animal influenza A strains and 
therefore it was considered to be novel. It was interesting to note that the 
Leu36Val mutation was situated in close proximity to the His-37 molecule located 
within the transmembrane pore. His-37 has been implicated as having an essential 
role in the gating of the M2 ion channel (281). Therefore, it was possible that a 
'mutation occurring immediately next to the His-37 residue might have indirectly 
affected the function of the channel by interfering with this residue. It was thought 
that this mutation might have been the cause of the amantadine-resistance 
observed in the viruses that carried it, but upon sequencing a selection of H3N2 
and H1N1 sensitive viruses it was apparent that the mutation was found in both 
sensitive and resistant H1N1 strains (Figure 4.13). This finding was interesting 
because it disproved the initial hypothesis. It appeared that the presence of the 
mutation was not the determining factor in these viruses that was controlling their 
susceptibility to amantadine. The substitution of the Leu residue for a Val residue 
at position 36 was examined. The structures of the two amino acids were similar; 
both are hydrophobic molecules with aliphatic side chains, each with a molecular 
weight of 131 and 117 Daltons respectively (314). This suggested that the 
structural differences between the two substituted amino acids at this position 
'were unlikely to cause a significant conformational change within the channel at 
that position which might have affected the gating function of His-37.
In order to further explore this finding, a series of experiments would need to have 
been performed. Initially, inserting gene segment seven carrying the Leu36Val 
mutation into a known amantadine-sensitive parent strain, and screening the 
progeny for resistance would have confirmed whether the mutation was 
responsible for conferring resistance. In order to ascertain whether the mutation 
had any affect on the configuration of His-37 and therefore the function of the 
channel, viruses with the Leu36Val mutation could have been used in experiments 
similar to those previously described (253, 281) and the currents across the 
channel measured. Results from these proposed experiments would have 
revealed whether the close proximity of the Leu36Val mutation to the His-37 
residue affected the function of the ion channel.
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An observation made during the analysis of the M2 amino acid alignments 
revealed that between all of the resistant viruses, the His-37 residue was 
absolutely conserved. The significance of this finding was important when related 
to previous studies that have investigated the function of His-37 within the 
regulation of protons across the channel (281, 321, 375). When the sensitive 
viruses were sequenced, it was also found that His-37 was absolutely conserved. 
These data were further evidence of the importance of His-37 in controlling the 
maintenance of pH during specific areas of the virus replication cycle. Mutant ion 
channels with His-37 substituted for other amino acids do not become protonated 
and are not activated by low pH (375).
There were a relatively large number of viruses selected from this study that were 
amantadine-resistant by phenotypic assays but when characterised genotypically, 
they lacked any mutations within the M2 transmembrane domain. The reasons for 
this phenomenon are unclear but several theories may be postulated. From the 
phenotypic testing of the resistant strains in Chapter 3, it was apparent that some 
viruses were composed of mixed populations of genotypes (Table 3.8, page 80). It 
seemed possible that upon PGR amplification of the mixed population, a sensitive 
virus was the template amplified, which would have resulted in the amplified 
product consisting of an M2 protein lacking the mutations known to confer 
resistance. A way of avoiding this situation would have been to titrate the virus in 
the presence of amantadine and pick individual plaques from the progeny of 
viruses produced. This process would have ensured that any genetic material 
used would have originated from a virus that had grown in the presence of drug. 
Performing PGR amplification on the plaque-purified material would have made 
certain that the amplicons that were produced originated from a resistant virus.
Another possible source of error was from the growth of the resistant viruses in 
tissue culture. After the initial testing of the viruses by EIA and plaque reduction 
assay, it was necessary to grow each strain in tissue culture to produce enough 
material for genetic characterisation. Therefore, between the phenotypic and 
genotypic testing the viruses were subjected to a passage without the selective 
pressure of drug. This may have resulted in a shift in the proportion of sensitive 
and resistant genotypes within a given mixed population of one virus strain. 
Ideally, to characterise the exact genotype of the virus it would have been 
necessary to test original material obtained from the patient. To enable the
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detection of the virus within the laboratory, the process of amplification in tissue 
cuiture was necessary and this process may have altered the balance between 
resistant and sensitive genotypes within each virus culture. Unfortunately, for the 
majority of viruses screened in this study, the original isolates were not available. 
Previous work has shown that resistant strains can either maintain resistance or 
revert to the sensitive wild-type when the selective pressure of amantadine is 
removed (22, 118). An option would have been to grow the resistant viruses in 
medium containing drug but it was thought that this might have altered the natural 
resistant genotype of the viruses. Each virus upon amplification in tissue culture, 
prior to genetic characterisation should have been tested phenotypically to confirm 
that the resistant phenotype had been maintained during the passage. However, 
this would have been extremely labour intensive and therefore was not practical to 
perform.
Other proteins closely linked to M2 during the replication cycle of influenza A 
include Ml and HA. It was thought that changes within these proteins might have 
had an indirect effect upon the susceptibility of the viruses to amantadine. During 
the initial stages of replication, the M1/RNP complex dissociates releasing the 
RNP into the host cell cytoplasm and subsequently the host cell nucleus (136). 
The dissociation of the complex is triggered when the endosomal pH is reduced; 
reduction in pH is caused by the influx of protons into the endosomal interior 
Through the M2 ion channel (414). When amantadine blocks the M2 ion channel 
the pH remains relatively stable and therefore the Ml/RNP complex cannot 
dissociate. It was postulated that changes within the Ml protein might raise the pH 
threshold at which the dissociation event occurred, thereby allowing the release of 
RNP without the requirement of low pH. However, sequencing the Ml from all 
resistant strains revealed that there were no sequence differences between + M2 
TM viruses and -  M2 TM viruses, suggesting that -  M2 TM viruses did not contain 
mutations within Ml that were responsible for causing resistance to amantadine 
(Figure 4.14). Therefore, to further test this hypothesis concerning the dissociation 
of the Ml/RNP complex, other aspects of the event would need to be investigated.
Another possibility for the absence of M2 transmembrane mutations in 
phenotypically resistant viruses involved the close association of the activities of 
.HA and M2 during the influenza A replication cycle. Previous findings had reported 
that mutations within the HA2 region of the HA gene complemented mutations
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within the M2 transmembrane domain (118). The mutations within HA2 were found 
to affect the fusion properties of the protein to the extent that the HA precurser 
could undergo normal fusion events, even when the M2 ion channel was blocked 
by amantadine therefore lowering the pH of some of the compartments of the TGN 
involved with HA maturation (118).
In a study of amantadine-resistant strains of the avian influenza virus Rostock, 
Steinhauer et al. (1991) found that when the resistant viruses were characterised, 
three viruses were genetically distinct due to an absence of any mutations within 
the M2 transmembrane domain (340). The HA of these viruses were analysed and 
it was found that they all shared a common mutation within the HA2 region. This 
mutation (Lys58lle) was found to generate a HA species that was more acid-stable 
resulting in a protein with a lower fusion potential than the wild-type (Figure 4.16). 
This finding suggested that in these viruses, the fusion potential of the HA was 
lower to compensate for the blockage of the M2 ion channel caused by 
amantadine. This phenomenon had not previously been reported in human 
viruses. However, it may be that several of the viruses from this study, which had 
no mutations within the M2 transmembrane region but were resistant by 
phenotypic methods, might have contained mutations within the HA to 
compensate for increased acidity in the TGN. A drawback with this theory was that 
the previous work was carried out on avian strains of influenza; these strains had 
HA species that were cleaved proteolytically within the TGN by the protease furin. 
The avian HA was therefore susceptible to acidic conditions and upon exposure to 
lowered pH within the TGN, it was converted to a low pH form which prevented the 
release of progeny particles from the infected cell (310, 346). The primary effect of 
amantadine on human influenza A viruses is preventing the dissociation of the 
M1/RNP complex during the initial stages of the replication cycle (143, 184). The 
HA of human influenza A viruses do not contain the multibasic cieavage site that is 
present within certain avian strains (182). The precursor of HA (HAG) does not 
undergo the proteolytic cleavage into the HA1 and HA2 subunits intracellularly, 
therefore if the pH of the TGN was lowered this should not affect the formation of 
native pH. Therefore, theoretically, if mutations existed within the human HA2, 
similar to those found in Rostock HA2 it would not have the same compensating 
effect on the human viruses. To investigate this phenomenon further, it was 
proposed that the HA, in particular the HA2 domain, of the resistant viruses lacking 
'M2 transmembrane mutations would be sequenced to identify any common
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mutations at positions that were known to be important in the fusion activity of the 
protein. Comparisons of these sequences with the HA of known amantadine- 
sensitive viruses should also help to identify mutations that might have occurred.
FIGURE 4.16 Structure of the influenza A HA monomer
HA2 58 % (
NH2 — HA1
The figure represents the structure of the HA monomer, showing the location of the 
mutation found at residue 58 of HA2 that can indirectly confer amantadine-resistance. Also 
shown are the amino terminals of HA2 and MAI. Taken from (340).
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4.4.3 Cytoplasmic Domain
Analysis of the sequence data for the M2 cytoplasmic domain demonstrated that it 
was relatively conserved in relation to the size of the domain, but not to the same 
degree as the extracellular domain (Figure 4.10 and 4.11). The relatively high 
proportion of non-synonymous changes observed suggested that in common with 
the transmembrane domain, this region was subject to some form of selective 
pressure that was driving the amino acid changes. The transition to transversion 
ratio was much lower than the transmembrane domain. The cytoplasmic domain 
was previously shown to contain several important sites for post-translational 
modifications to occur. The addition of long chain fatty acids had been reported to 
occur at Cys-50 (347). Results from this study illustrated that Cys-50 was 
absolutely conserved in all resistant and sensitive viruses demonstrating the 
importance of this residue in the function of M2.
Within the cytoplasmic domain of M2, three Ser residues, Ser-64, -89 and -93 
have been identified as sites where phosphorylation can occur (162). Interestingly, 
only 1/3 of these Ser residues (position 64) was absolutely conserved between the 
resistant and sensitive viruses from the present study. The other sites, Ser-89 and 
-93 were not conserved; 14/47 resistant and 12/37 sensitive viruses (Ser-89), and 
1/37 sensitive virus (Ser-93) carried mutations at these positions (Figures 4.10 to 
4.13). The Ser-89 residue had been substituted by a Gly (10/14) and an Asn (4/14) 
in H3N2 and MINI resistant strains. Sensitive strains lacking the phosphorylation 
sites had Ser-89 substituted by Gly (11/12) and Asn (1/12), and the Ser-93 residue 
substituted by Asn (1/1). These data indicate that although the three Ser residues 
at positions 64, 89 and 93 had all been implicated as sites for post-translational 
phosphorylation, it appeared that only Ser-64 was essential for this role. Viruses 
were isolated lacking Ser at residues 89 and 93 indicating that it was not an 
absolute requirement for the proteins to be phosphorylated at these sites. 
However, Castrucci et al. (1995) demonstrated that virus mutants containing 
truncated M2 proteins lacking five and ten residues at the C-terminal end could not 
be rescued using a reverse genetics system (45). It is possible that the five- 
residue deletion mutant illustrated the importance of Ser-93, which might explain 
why only a single virus was found with a mutation at this Ser residue in the present 
study.
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When the viruses lacking phosphorylation sites were further analysed, it was 
apparent that a high proportion of both resistant and sensitive viruses contained 
mutations within the transmembrane domain. In total, 27/84 resistant and sensitive 
viruses lacked a phosphorylation site at either Ser-89 or Ser-93. Of these viruses, 
19 had mutations within the transmembrane domain of M2. This was an interesting 
finding because it appeared as if mutations occurring in the transmembrane region 
were being complemented by substitutions of Ser residues at either position 89 or 
93 in the cytoplasmic tail. In another study of M2 cytoplasmic tail truncation 
mutants, Tobler et al. (1999) demonstrated that truncated M2 proteins had 
reduced ion channel activity (359). For most truncated mutants it was shown that 
the observations were a possible consequence of reduced protein expression at 
the infected cell surface, thereby reducing the total capacity for conductance to 
occur. However, one mutant demonstrated good expression while maintaining 
reduced ion channel activity (359). It was concluded that the truncation of the M2 
cytoplasmic tail at position 82 had caused an alteration in the structure of the ion 
channel formed by this mutant, which consequently reduced the potential for ion 
flow through the channel. It is interesting that this mutant did not contain either the 
Ser-89 or -92 residues. Therefore, it is possible that the loss of one or more 
phosphorylation sites within the C-terminal third of the virus has an effect on the 
ion channel activity of the protein. In the present study, the mutations found in the 
transmembrane region of viruses containing a Ser-89 substitution might have been 
compensating for structural changes in the ion channel caused by the Ser 
substitutions. Therefore, the M2 transmembrane mutations were possibly acting to 
stabilise the channel and maintain normal activity and the function of the protein. 
This is an interesting idea that could be further investigated using site-directed 
mutagenesis and ion channel conductance studies to assess the possible 
relationship between Ser-89 and -93 substitutions and ion channel activity.
Evidence for the previous occurrence of human influenza A viruses lacking the 
Ser-89 or Ser-93 residues was found. The two ancestral H1N1 reference strains, 
A/WSN/33 and A/PR/8/34 were both found to contain a Gly residue at position 89 
within the M2 cytoplasmic tail (233, 397). This was interesting because it 
demonstrated that human viruses lacking this phosphorylation site had circulated 
previously. The resistant viruses found in the present study carrying a substitution 
at Ser-89 were predominantly HI N1 subtypes but there were two viruses of H3N2 
subtype demonstrating that this trait was not exclusive to H1N1 viruses. Another
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interesting observation was that A/WSN/33 and A/PR/8/34 both had mutations 
within the transmembrane domain of M2 that caused amantadine-resistance in 
both strains; how these viruses acquired resistance was unclear because their 
parental origins were isolated before the use of amantadine or rimantadine. 
Therefore, these two early H1N1 strains were amantadine-resistant and lacked the 
Ser-89 phosphorylation site, a feature in common with 14 resistant viruses isolated 
from the present study. It is possible that there may be a connection between the 
two processes of phosphorylation and generation of amantadine-resistance 
through mutations in the transmembrane region. It is possible that the substitution 
of the Ser-89 with other amino acid residues, which resulted in an overall reduction 
in phosphorylation of the protein, in some way altered a functional or structural 
.aspect of the ion channel, the domain primarily responsible for conferring 
amantadine-resistance.
4.4.4 Genotypic and Phenotypic Correlation
The findings from the analysis of both genotype and phenotype of resistant viruses 
produced an interesting result. Although the data needed to be repeated to provide 
more substantial evidence, it was possible that the viruses with a Ser31Asn 
substitution replicated at higher rates in the presence of amantadine. If this finding 
could be confirmed it would support previous evidence for the prevalence of the 
Ser31Asn mutation in resistant human influenza A viruses (90, 144, 147, 166, 
417). It suggested that viruses of this resistance genotype had a selective 
.advantage over others and therefore could out-compete other genotypes where 
conditions were favourable. However, the data presented here represents the 
growth of the viruses in vitro, further work would be required to confirm this in vivo. 
A possible way of investigating this might be to infect ferrets with viruses 
containing wild-type M2, and M2 with a Ser31Asn mutation. The viruses could be 
constructed by simple reverse genetics techniques to ensure that no other variable 
influenced the results i.e. viruses would have the same backbone, but contain 
sensitive and resistant mutations within M2. This type of experiment should 
provide data on the growth potential of viruses carrying the Ser31Asn mutation 
compared to wild type sensitive strains in vivo.
147
Chapter 4 -  Genetic Characterisation 
It is difficult to postulate why viruses with the Ser31 Asn mutation had an apparent 
evolutionary advantage over other resistant viruses. It is possible that the mutation 
occurring at that specific position within the M2 ion channel brought an added 
stability or rigidity to the channel, making the whole protein structure more stable 
and therefore less likely to fail in its function to control the pH of certain cellular 
compartments. Viruses that became resistant through mutations at other positions 
within the ion channel might have contained inherently unstable channels that 
would have reduced the ability of the virus to replicate and therefore compete with 
other genotypes. It is certain from previously published evidence that viruses with 
the Ser31Asn mutation have an increased ability to survive in, and transmit 
between humans but the underlying mechanisms remain unclear (90, 144, 147, 
166, 417).
4.4.5 Concluding Remarks
In summary, the genotypic characterisation of the resistant viruses selected from 
EIA and plaque reduction assay revealed mutations within the transmembrane 
domain of M2 that could be implicated in drug-resistance, or were present in both 
sensitive and resistant viruses. The group of viruses lacking mutations within the 
domain suggested that interactions with other viral gene products might influence 
the susceptibility of the virus to the drug. Sequence data confirmed that the 
extracellular domain was highly conserved in all viruses used in the study but the 
transmembrane and cytoplasmic domains showed differing degrees of variation. 
Important residues previously reported to be involved in post-translational 
modification of M2 were conserved demonstrating that certain regions of the M2 
protein are essential for replication of the virus.
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5.1 Introduction
As described earlier (section 1.6.3) RNA viruses are unique with respect to the 
high rates of mutation occurring during replication. The RNA polymerase molecule 
present in these viruses has low fidelity (it lacks 3’-> 5’ exonuclease activity) that 
results in the occurrence of a high error rate during the process of genomic 
transcription (338). The rate of mutation in RNA viruses can range from 1x10'^ to 
1 X 10'^ misincorporations per base site per round of copying (78) compared to the 
low mutation frequency associated with DNA replication, which can be as low as 1 
X 10'® to 1 X 10'^^  (159). The high error rate and relatively high levels of replication 
demonstrated by these viruses can lead to the formation of a population of viruses 
containing diverse variants which are all phenotypically related but carry distinct 
genomic sequences as a result of mutation. The phenomenon of diverse RNA 
populations has been referred to as “quasispecies” (83).
5.1.1 Evolution of Influenza A Genes
Influenza A viruses are able to undergo rapid evolution due to the high error rate 
during the replicative processes of the virus. This property allows the virus to 
continually change its genetic makeup to evade such selective pressures as the 
immune response and antiviral drug treatment. The rate of change for different 
influenza A proteins is dependent on the function and the location of the protein 
within the virion structure (Table 5.1).
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TABLE 5.1 Evolutionary rates of change for influenza A genes
Gene
Segment
(Subtype)
Host Rate of Change 
(site/year X 10'^ ) 
Nt aa
N Period Reference
HA (HA)* Human 3.65 5.83 183 1968-1994 (59)
HA (H3)* Human 7.00 - 14 1968-1980 (34)
HA (H3)* Human 5.7 9.7 254 1984-1996 (96)
HA (H3) Equine 2.80 - 2 1963-1979 (63)
HA (HI)* Human 4.30 - 14 1977-1983 (294)
NA (N2) Human 2.28 2.56 38 1968-1995 (401)
NA (N2) Human 3.7 4.7 6 1957-1979 (313)
NS Human 1.94 - 9 1942-1985 (41)
NS Human 1.83 - 15 1933-1977 (180)
NP Human 2.18 0.42 16 1933-1983 (111)
NR Swine 2.12 0.22 11 1930-1988 (111)
NP Avian 1.21 0.00 19 1927-1982 (111)
PA Human 1.32 - 4 1934-1968 (264)
PB1 Human 0.87 - 3 1957-1968 (181)
PB2 Human 1.82 7 1933-1988 (114)
M Human 1.08 - 13 1933-1988 (175)
Ml Human 0.83 0.03 13 1933-1988 (175)
M2 Human 1.36 0.46 13 1933-1988 (175)
M Swine 1.30 - 8 1930-1988 (175)
Ml Swine 1.43 0.05 8 1930-1988 (175)
M2 Swine 0.91 0.48 8 1930-1988 (175)
* Based on the rate of change within the HA1 region of the HA moiecuie. Adapted from (113, 
383). N -  number of viruses anaiysed.
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5.1.1.1 Haemagglutinin (HA)
The protein reported to be undergoing the most rapid rate of change is the HA 
molecule, located at the surface of the influenza A virus envelope. There has been 
some controversy associated with the evolution of this molecule; several theories 
have been postulated as to how the HA of human viruses can change so rapidly. 
One such hypothesis supports the neutral theory of evolution where it is believed 
that the mutation rate of HA is simply higher than other genes: consequently, the 
rate of neutral changes is high, with a proportionally high frequency of coding 
changes (110). This theory is supported by evidence that shows within all 
influenza A genes the rate of synonymous changes is always higher than non- 
synonymous (110).
.Alternatively, it could be that the HA molecule has a higher rate of mutation, but in 
addition as there is positive selection for coding changes that are beneficial to the 
virus and confer a selective advantage (345). Evidence to support this hypothesis 
can be found when the distribution and frequency of silent and coding changes are 
analysed within the HA1 subunit. The rate of non-synonymous changes is much 
higher, and synonymous changes lower within antigenic regions of HA1 (173). 
Therefore, this suggests that positive pressure has forced the selection of viruses 
containing coding changes within the HA1 antigenic regions, most probably 
because these changes confer a selective advantage to the virus (Figure 5.1).
152
Chapter 5 -  Evolution of Matrix Genes
FIGURE 5.1 Antigenic variation in influenza A H3 strains from 1968-1995
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Residues that have changed over this time are represented by a dot surface. Antigenic sites 
located on HA1 are represented by designated coiours; A, red; B, yeilow; C, magenta; D, 
cyan; E green; and positions not assigned to an antigenic site in white. (A) The HA 
polypeptide is illustrated and (B) the distal globular head domain of the H3 HA with the 
receptor binding pocket represented by the white mesh grid. Adapted from (59).
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The overall rate of change of HA is higher compared to the other external and 
internal influenza A genes (Table 5.1). An estimate of the rate of change of the 
HA1 subunit of the HA molecule ranges from 4.3 to 7.0 x 10'  ^ changes per 
nucleotide site per year with the average value around 5.7 x 10'® changes per 
nucleotide site per year (34, 96, 294). The HA has been identified as the main 
determinant of immunity to influenza in man; it is thought to stimulate the initial 
development of neutralising antibody, which provides the first stage in the 
immunological response to infection (286). Therefore, the selective pressure 
applied upon the HA, especially within the main antigenic sites located within the 
HA1 subunit, is sufficient to force the selection of antigenic variants. This gradual 
accumulation of mutations within the HA causes subtle variations within the 
antigenicity of the virus, enough to enable the virus to evade the immune 
response; this process is referred to as antigenic drift (59).
5.1.1.2 Neuraminidase (NA)
The NA molecule represents the second major glycoprotein located on the surface 
of the influenza A lipid envelope. In comparison to the HA molecule there have 
been relatively few studies to determine the evolution of this gene. Early work had 
demonstrated that drift could be observed in the NA and it appeared to be as a 
result of similar processes affecting the HA (209). Although anti-NA antibodies 
reportedly do not neutralize virus activity, it is thought that they do play an 
important role in the evolution of NA (189).
Studies of the evolution of human NA have extensively focused on the N2 subtype 
(209, 237, 401). The rate of evolution of N2 is reported to be in the range of 2.28 
To 3.70 X 10'^ changes per site per year for nucleotides and 2.56 to 4.7 x 10'  ^
changes per site per year for amino acids (313, 401). It has also been reported 
that the NA gene of human H3N2 viruses has evolved in two separate lineages 
(401). Work to determine species-specific lineages for NA has been performed by 
Saito et ai. (1993) who studied the N8 influenza viruses (313). It was found that N8 
had evolved into three distinct lineages; equine, Eurasian avian and North 
American avian. The rate of evolution for N8 in equine viruses was estimated to be 
2.06 X 10'^ and 1.75 x 10'  ^ changes per site per year for nucleotides and amino
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acids, respectively (313). When compared to the rate of human N2 evolution, 
equine N8 was lower suggesting that within humans the selective pressure 
exerted on the NA was higher than in equine viruses. Studies of the N8 found in 
avian lineages demonstrated that, as with studies of other influenza A genes, there 
was a high degree of conservation of amino acids within the protein suggesting 
that the NA in avian strains was at an evolutionary optimum and that changes 
were detrimental to the survival of the virus. It was also proposed that that the 
reported differences between human and equine NA were possibly attributed to 
the length of immune response following vaccination in both respective species. 
The effect of the vaccine in horses is short-lived, as little as three months 
compared to the human response, which lasts significantly longer (313). Therefore 
it was proposed that the increased length of immune pressure exerted on the virus 
in humans might have produced the observed results i.e. higher rate of NA 
evolution in humans compared to horses (313).
5.1.1.3 Non-structural (NS)
There have been several studies involved with predicting the evolution of the NS 
gene of influenza A. Similar to gene segment seven, the NS gene (RNA segment 
8) encodes two overlapping proteins, NS1 and NS2 (201). NS1 has been shown to 
interact with host nuclear proteins and evidence suggests that NS2 interacts with 
the Ml protein (288, 403).
Phylogenetic analysis has shown that influenza A NS is categorised into species- 
specific lineages: human, equine and distinct avian lineages (180, 226). Within 
human influenza A viruses, the NS gene evolved as a single lineage until 1977 at 
which point MINI viruses re-emerged. Following this event, human NS genes 
have evolved independently in the H3 and HI subtypes (226). The evolutionary 
rates of NS and its gene products follow similar species-specific rates of change 
when compared to other influenza A internal proteins e.g. the NR gene. In terms of 
the nucleotide rate of change, the fastest is observed in the human lineage and 
slowest in the equine lineage (180). The rate of change of amino acids for NS was 
lowest in the avian lineages compared to human and equine (180).
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It has been shown that analogous to the Ml and M2 proteins, the two gene 
products of NS evolve at different rates. Interestingly, it appears that the rates at 
which NS1 and NS2 evolve are dependent on species lineage (180). It has been 
.proposed that differences observed may be attributed to the functions of both 
proteins. NS1 interacts with host nuclear proteins and therefore in different species 
undergoes different changes in order to achieve optimal interaction (180). 
Estimates of the rate at which the human NS gene is evolving range from 1.83 to 
1.94 X 10'^ changes per nucleotide per year (41, 180). This rate is comparable to 
other internal genes of influenza A, but lower than the surface glycoproteins (Table 
5.1).
5.1.1.4 Nucleoprotein (NP)
The NP gene of influenza A viruses has been previously shown to be a major 
determinant of host specificity (318). The important role of this gene has led to 
several studies that have investigated its evolution. It is interesting to note that the 
NP gene has undergone a relatively constant rate of change that has remained, 
even during the antigenic shift events of 1957 and 1968 (328). The rate of change 
of the NP gene is estimated to be in the range of 1.62 to 2.2 x 10'^ changes per 
nucleotide site per year for the human lineages, 1.21 to 1.39 x 10'^ changes per 
nucleotide site per year for avian and 0.78 x 10'  ^ changes per nucleotide site per 
year for the equine lineage (5, 111, 112). Analysis of amino acid changes 
demonstrates that evolution within the avian lineages is virtually static with 
practically no changes occurring over a period of approximately 50 years (-0.02 x 
10'^ changes per amino acid site per year) with human and equine viruses 
undergoing slightly higher rates of 1.14 x 10'^ and 0.66 x 10'^ changes per amino 
acid site per year respectively (112).
The NP gene has been shown to exist in different lineages at both the nucleotide 
and protein level (112). Similar to other influenza A proteins, host specific lineages 
appear to evolve at different rates. Nucleotide sequences of NP from human and 
swine viruses have demonstrated that they share a common ancestor. It has also 
been shown that these two lineages have evolved at a higher rate than the avian 
NP gene (111). Therefore, as with other influenza genes, it has been hypothesised
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that within avian lineages, the NP gene is maintained at an adaptive peak because 
this lineage represents the ancestral origin of the gene. However, rates are higher 
within human and equine lineages because the virus has had to adapt its host 
specificity and immune response.
5.1.1.5 Polymerase Complex (PA, PB1, PB2)
The three subunits comprising the polymerase complex in influenza A viruses 
have each been studied to estimate the origin and evolution of these genes. It has 
been reported that the PA gene of human influenza A is evolving at a rate of 1.32 
X 10'^ changes per nucleotide site per year (264, 383). Findings indicated that PA 
has evolved into at least five different lineages. Human, equine and swine lineages 
have evolved independently and avian viruses have evolved into two separate 
lineages. The gene is relatively conserved in humans and appears to have 
remained in a single lineage despite two major antigenic shifts (1957 and 1968) 
(264).
The PB1 gene has evolved along four distinct lineages comprising human, avian, 
equine and swine (181). Interestingly, the single human lineage is comprised only 
of the H1N1 subtype of viruses; H3N2 and H2N2 viruses were found to be more 
closely related to the avian lineage providing evidence that prior to the 1957 
antigenic shift, avian PB1, together with HA and NA was introduced into humans 
to create the novel pandemic strain (181). The evolution of human PB1 has been 
estimated to be 0.87 x 10'  ^changes per nucleotide site per year, much lower than 
that of the human PA gene (181, 383).
The final component of the polymerase complex, PB2, is evolving at an 
approximate rate of 1.82 x 10'  ^ changes per nucleotide site per year in human 
influenza A viruses (114). This figure is similar to that of the evolution of the PA 
gene, but is much higher than the PB1 gene. The evolutionary patterns of PB2 
genes differ from those found for the PA and PB1 genes. PB2 has evolved into 
four main lineages; human, two distinct avian and equine lineages. The lineage 
containing the human strains also contains swine viruses that have a PB2 gene 
closely related to human strains (114).
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In general, the four units comprising the RNP complex (NP, PA, PB1 and PB2) 
have been found to follow different evolutionary pathways suggesting that 
selective pressures driving evolution affects the individual subunits and not the 
complex as a whole (114).
5.1.1.6 M1 and M2
There have been relatively few studies which have investigated the evolution of 
gene segment seven of influenza A viruses. Possibly the most important data were 
generated by Ito et al. (1991) who compared the evolution of the Ml and M2 
proteins from viruses of different lineages (175). It was found that the rates of 
evolution between the two proteins differed, with Ml changing at a much slower 
rate than M2 (Table 5.1). The rate of change of nucleotides for the human Ml and 
M2 genes were 0.83 x 10'  ^and 1.36 x 10'  ^per site per year respectively and 0.08 
X 10'^ and 1.38 x 10'  ^for amino acids respectively (175).
A more recent study by Park et al. (1997) investigated the evolution of Ml that 
originated from human influenza A viruses (273). The findings from this study 
indicated that nucleotide changes were occurring at a rate comparable to other 
studies but there were virtually no amino acid changes recorded over a period of 
approximately 60 years. From these results it was concluded that the human Ml 
had actually reached an evolutionary stasis and that any changes to the protein 
structure would be detrimental to the virus (273).
Analysis of the evolution of the Ml and M2 genes into different lineages show that 
in respect to amino acid differences. Ml is relatively conserved across human, 
avian and swine-specific lineages (175). However, M2 proteins have shown a 
much greater rate of change in lineages containing human and swine viruses but 
virtually none within avian viruses (175). The Ml and M2 proteins from equine 
viruses have also been shown to evolve at a much slower rate than human viruses 
(220). The overall reasons behind these observed differences in evolution in 
different lineages have been related to lower mutation rates of the polymerase 
complex during RNA replication and the origin of the influenza A viruses. The low
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rate of evolution in avian influenza strains confirms the accepted theory that 
influenza A viruses originated from an avian lineage. Therefore, it might be 
concluded that in their original hosts, the virus does not have to evolve to adapt as 
rapidly as viruses that have jumped the species barrier more recently.
In conclusion, it is apparent that each of the influenza A gene segments evolves at 
a different rate and in many cases follow different evolutionary lineages. 
Interestingly, a simple comparison of the silent changes observed within each 
gene reveals to some extent the degree of evolutionary pressure that a particular 
gene is under. For example, the human NP and M1 genes have 81 and 96 per 
cent silent changes respectively over a fifty year period (1933-83) indicating that 
the amino acid sequences are conserved and not undergoing any significant 
evolutionary change (383). It may be that these observed evolutionary constraints 
are due to vital functions associated with the proteins, or that a state of 
evolutionary stasis has been reached in that species for this gene. The latter point 
can be illustrated when the evolutionary rates of change for the majority of the 
influenza A genes are compared between human and avian influenza viruses. In 
all cases, the rate of change for influenza A genes in respect to amino acid 
changes per site per year in avian strains is significantly lower than in human 
strains; genes from avian viruses have often been reported to be undergoing no 
significant evolutionary change at all. These findings suggest that within these 
viruses, the viral genes are at an evolutionary optimum and are not forced to 
undergo change. This is likely to be because the avian reservoir is thought to be 
the ancestral origin of influenza A viruses, therefore all genes within these viruses 
are likely to be optimally adapted to the host.
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5.2 Aims
There are relatively little data describing the evolution of gene segment seven of 
influenza A viruses within the human host; there are no reported studies of the 
evolution of these genes specifically within a defined, geographically-contained 
population. Utilising the set of sequencing data generated from the work described 
in Chapters 3 and 4, including sequences of both amantadine-resistant and 
sensitive viruses, the evolution of gene segment seven over the past 30 years 
within the UK over a period of circulation of H3N2 and H1N1 viruses was 
estimated. The main aims of this work were:
To compare the evolution of M1 and M2; more specifically the evolution of 
these genes between amantadine-resistant and -sensitive strains and 
different subtypes to determine whether the phenotype or genotype affect 
the rate of change within the respective proteins.
To determine what lineages viruses have evolved into over the previous 30 
years in the UK using phylogenetic analysis. Also, to determine the 
positions of amantadine-resistant and -sensitive viruses within phylogenetic 
trees and relate these positions to drug genotype or phenotype.
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5.3 Results
5.3.1 Rate of Change of Ml and M2
In order to calculate the rate of change for the Ml and M2 genes of the influenza A 
viruses sampled during the study, nucleotide alignments for 84 influenza A strains 
'were prepared. Sequences were aligned to an ancestral strain, A/Aichi/2/68 and 
A/USSR/90/77 for H3N2 and MINI viruses respectively. The ancestral strains 
were chosen because they both represented original prototype H3N2 and MINI 
viruses. A/Aich i/2/68 represented one of the first characterised viruses that 
appeared when H3N2 viruses superseded the H2N2 subtype in 1968. Although 
MINI viruses circulated the globe from approximately 1918 to 1957, the majority 
of the MINI viruses used in this study were isolated post 1977, when the MINI 
subtype reappeared to cocirculate with H3N2 viruses. Therefore, it was thought 
that A/USSR/90/77 represented the prototype strain for MINI viruses that have 
been in circulation since 1977. Files containing both H3N2 and MINI sequences 
were aligned to the majority sequence calculated by the clustal algorithm in 
MegAlign. Synonymous and non-synonymous changes, and transitions and 
transversions were calculated from the nucleotide alignments. All substitutions 
'were compiled and plotted against the time value for each respective virus, i.e. the 
number of days from the date the ancestral virus was isolated. To calculate the 
rate of change, linear regressions were plotted on the charts to create y; values 
were quoted as changes per site per year (Figure 5.2 and Equation 5.1). Linear 
regressions were performed on the sets of data for Ml and M2, for nucleotide, 
amino acid, synonymous and non-synonymous changes, and for H3N2, MINI, 
and amantadine-resistant and -sensitive data (Figures 5.3 to 5.6; Appendix 1 to 
20). The y values obtained from the linear regressions were used to calculate the 
rate of change for all of the above data sets.
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FIGURE 5.2 Estimation of the rate of evolution using linear regression
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Red circles represent a hypothetical data set of changes within a protein or gene over a set 
period of time compared to an ancestral strain (time = 0; changes = 0). A linear regression 
performed on the data points results produces a “y” value that can then be used to 
calculate the rate of change using Equation 5.1.
EQUATION 5.1 Calculation of the rate of change of gene/protein per site per year
a X b _
------------  = Rate of Change per site per year
Where a = regression value “y”; b = number of days in year (365); c = number of sites in 
gene or protein.
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FIGURE 5.3 Rate of change of M1 in H3N2 viruses
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FIGURE 5.4 Rate of change of M1 in H1N1 viruses
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FIGURE 5.5 Rate of change of M2 in H3N2 viruses
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FIGURE 5.6 Rate of change of M2 in H1N1 viruses
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Initially, data were analysed for the M1 and M2 proteins in total. In order to make a 
comparison of the rate of evolutionary change of the M1 and M2 proteins, a mean 
value of the rate of change of both proteins was calculated (Table 5.2). It was 
apparent that the rate of change (nucleotides and amino acids) of the M2 protein 
was greater than the Ml protein, more significantly in respect to the rate of change 
of amino acids per site per year which evolved at approximately two-fold that of 
M1. Interestingly, the rate of synonymous changes was higher in M1, and the rate 
of non-synonymous changes higher in M2. The significance of these findings will 
.be discussed in section 5.4. The total rate of change for M1 and M2 was 
calculated for H3N2 and H1N1 subtypes using regression data from Figures 5.3 to
5.6 (Table 5.3). In general, it appeared that the evolution of M1 between H3N2 and 
H1N1 viruses was similar compared to M2 where H1N1 viruses displayed a 
greater rate of change than H3N2. To further explore this, the data sets were 
analysed separately for each protein.
TABLE 5.2 Comparison of the mean total rate of change of M1 and U2 of influenza A viruses
Total nt/site/yr Total aa/slte/yr Total syn/slte/yr Total n-syn/site/yr
M1 1.7x10' 1.4x10' 1.2x10' 0.5x10'
M2 2.1 xIO ' 3.3x10' 1.0x10' 1.1 X  10'
TABLE 5.3 Total rate of change of influenza A Ml and M2
Virus Ts:Tv
(number)
Ts:Tv
(ratio)
Total
nt/site/yr
Total
aa/site/yr
Total
syn/site/yr
Total n- 
syn/site/yr
H3N2 1129:404 3:1 1.6x10'^ 1.2x10'® 1.1 xIO® 0.5x10®
Ml _
MINI 208:62 3:1 1.6 xIO"" 1.3 xIO"" 1.2x10'-' 0.4x10"'
H3N2 552:34 16:1 1.6x10'® 1.5x10® 1.0x10® 0.5x10®
M2 _
MINI 129:36 4:1 2.6x10'^ 4.9x10"' 1.0x10"' 1.6x10"'
Ts -  transition; Tv -  transversion.
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The rate of change of the M1 protein was calculated for each subtype and drug 
genotype (Table 5.4). Between H3N2 and H1N1 viruses there was no apparent 
variation observed in the rate of change of the protein for both nucleotides and 
amino acids; similarly, the Ts:Tv ratio was almost identical for all viruses. When 
the amantadine-resistant and -sensitive viruses of both H3N2 and H1N1 subtypes 
were analysed no significant trends were observed. The H3N2 resistant viruses 
had lower values overall than H3N2 sensitive viruses, and the H1N1 resistant 
viruses had higher values than the H1N1 sensitive viruses. Therefore, it did not 
appear that there were any significant differences in the rate of change of the M1 
protein between either antigenic subtypes or drug phenotypes of the influenza A 
viruses tested.
TABLE 5.4 Total rate of change of influenza A M1
Virus N Ts:Tv
(number)
Ts:Tv
(ratio)
Totai
nt/site/yr
Totai
aa/site/yr
Totai
syn/site/yr
Totai n- 
syn/site/yr
H3N2R 37 678:239 3:1 1.7x10® 1.2x10® 1.2x10® 0.5x10®
H3N2S 27 451:465 3:1 2.0x10® 1.6x10® 1.3x10® 0.7x10®
H1N1 R 10 109:26 4:1 1.6x10® 1.6x10® 1.1 xIO® 0.5x10®
H1N1 8 11 99:36 3:1 1.5x10® 1.2x10® 1.2x10® 0.4x10®
N -  number of viruses; R -  amantadine-resistant; 8 -  amantadine-sensitive; Ts -  transition; 
Tv-transversion.
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The rate of change for the total M2 protein of the influenza A viruses tested in this 
study was analysed for H3N2, H1N1, amantadine-resistant, and amantadine- 
sensitive viruses (Table 5.5). Overall it was found that the H1N1 viruses had a 
higher rate of change for both nucleotide and amino acid when compared to H3N2 
viruses. This was most pronounced for amino acid changes where the rate was 
almost three-fold higher. It was also found that within the H3N2 group, the 
amantadine-resistant viruses had a higher rate of change than the viruses that 
were sensitive. When the total data were analysed for each functional domain of 
M2, it became apparent that there were several trends that could be identified. The 
rate of change within the extracellular domain (nucleotide residues 1-72) was 
extremely low for all viruses tested and, in some instances, there had been no 
change observed in nucleotides or amino acids between the viruses over the study 
period. The transmembrane domain (residues 73-129) demonstrated a greater 
rate of evolutionary change compared to the extracellular region. Overall, within 
this domain the MINI viruses appeared to have been evolving at a higher rate 
than the H3N2 viruses, and again the rate was generally higher for resistant 
viruses. The cytoplasmic domain (residues 130-291) was found to have the 
highest rate of change of all the functional domains of M2. MINI viruses again 
demonstrated higher rates of change but between amantadine-resistant and 
sensitive viruses of the same antigenic subtype, there appeared to be no 
differences in the rate of amino acid changes per year.
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TABLE 5.5 Rate of change of influenza A M2 proteins
Virus N TsiTv Ts:Tv Total Total Totai Total
Type (number) (ratio) nt/site/yr aa/site/yr syn/site/yr nsyn/site/yr
H3N2R 37 349:17 21:1 1.8x10® 1.9x10® 1.1 X 10® 0.6x10®
i H3N2S 27 203:17 12:1 1.5x10® 1.5x10® 1.0x10® 0.5x10®
g H1N1 R 10 59:15 4:1 2.5x10® 4.9x10® 1.0x10® 1.6x10®
H1N1 S 11 70:21 3:1 2.6x10® 4.9x10® 1.0x10® 1.6x10®
s
H3N2R 37 40:0 40:0 1.0x10® 0.2x10® 0.5x10® 0.05x10®
I H3N2S 27 20:0 29:0 0.5x10® 0.2x10® 0.5x10® 0.05 X 10 ®
i H1N1 R H1N1 S 1011 0:04:2 0:02:1 0.0x10®0.5x10® 0.0x10®0.8x10® 0.0x10®0.3x10® 0.0x10®0.3x10®
Ul
§
H3N2R 37 41:13 3:1 1.3x10® 1.2x10® 0.6x10® 0.4x10®
CD5 H3N2S 27 5:13 1:2 0.6x10® 0.2x10® 0.6x10® 0.05 X 10 ®
111
1H1N1 R 10 8:11 1:1 3.8x10® 5.8x10® 1.3x10® 1.9x10®H1N1 S 11 9:9 1:1 3.2x10® 5.8x10® 1.9x10® 1.9x10®
o
H3N2R 37 268:4 67:1 2.3x10® 2.7x10® 1.4x10® 0.9x10®
i H3N2S 27 169:4 42:1 2.0x10® 2.7x10® 1.1 xIO® 0.9x10®§H1N1 R 10 51:4 13:1 3.4x10® 6.1 xIO® 1.1 xIO® 2.0x10®
o
H1N1 S 11 57:10 6:1 3.4 X 10 ® 6.1 xIO® 1.1 xIO® 2.0x10®
The rate of change is shown for both nucleotide and amino acid expressed for total M2 and 
each respective functional domain (extraceliular, transmembrane and cytoplasmic) 
illustrated in the left-hand column of the table. N -  number of viruses; R -  amantadine- 
resistant; S -  amantadine-sensitive; Ts -  transition; Tv -  transversion.
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It was important to analyse the rates of synonymous and non-synonymous 
changes within the sequences of the viruses tested. For total M2, the rate of 
synonymous changes was similar between both H3N2 and H1N1, and 
amantadine-resistant and -sensitive viruses (Table 5.5). H1N1 viruses had a 
higher rate of non-synonymous changes per year, approximately three-fold 
greater. Within the extracellular domain, rates of synonymous and non- 
synonymous changes were extremely low. Within the transmembrane domain, 
H1N1 viruses had higher rates of synonymous and non-synonymous changes 
than H3N2 viruses. There was an interesting relationship within the 
transmembrane domain, where H3N2 resistant viruses had identical rates of 
synonymous changes to sensitive viruses, but had a higher rate of non- 
synonymous changes: conversely, H1N1 resistant viruses had an identical rate of 
non-synonymous changes to sensitive viruses but had a lower rate of synonymous 
changes. Within the cytoplasmic domain, H1N1 viruses had a higher rate of non- 
synonymous changes that H3N2 viruses but the synonymous changes were the 
same for all viruses with the exception of H3N2 resistant viruses that were higher.
The ratio of transitions to transversions (TsiTv) was calculated (Table 5.5). This 
figure was quoted as the actual number of Ts and Tv mutations found, and also as 
an adjusted ratio, to compensate for the different sizes of each domain, thereby 
allowing a direct comparison. For total M2, there was a much higher Ts:Tv ratio 
found within the H3N2 viruses compared to the H1N1 group (Table 5.5). 
Interestingly, within the transmembrane region the TsiTv ratio was much lower and 
Jn some cases there was a greater number of Tv than Ts mutations. The highest 
Ts:Tv ratio was found in the cytoplasmic region where again, the ratio was 
significantly higher in H3N2 viruses.
Therefore, from analysing the data it was apparent that there were domain-, 
subtype- and drug phenotype-specific differences in the rate of change of the M2 
protein in the influenza A viruses tested. However, the rate of change within M1 
was relatively constant for all variables analysed.
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5.3.2 Phylogenetic Analysis of M2 Originating from Resistant Strains
Alignments constructed for the estimation of the rate of evolution of the matrix 
genes were modified and used to construct phylogenetic trees. Trees were 
constructed from nucleotide sequences for each subtype and phenotype (Figures
5.7 to 5.13; Appendix 21 to 24). Initially, a sequence alignment of the entire matrix 
gene was prepared. The matrix gene spans 1027 nucleotide residues but several 
sequences in the alignment were slightly shorter than this due to poor quality 
reads at the extremities of the primers. In order to produce a phylogenetic tree all 
sequences had to be of identical length, therefore they were cropped to the length 
of the shortest sequence, which produced a shortened sequence of 972 residues 
To be used for phylogenetic analysis. Trees for M, Ml and M2 were initially 
constructed containing H3N2, MINI, resistant, and sensitive viruses (Figures 5.7 
to 5.9). Bootstrap values were calculated and values greater than 70 were 
superimposed onto the phylograms. Analysis of the resulting trees revealed two 
distinct lineages within each phylogram, containing the two antigenic subtypes. 
The trees were relatively similar in shape suggesting that there were no major 
differences between each gene in respect to their evolutionary pathways, although 
it did appear that the tree depicting M2 evolution was slightly “flatter” over the 
more recent isolates. Another interesting observation was the appearance of two 
distinct branches within the Ml H3N2 lineage (Figure 5.8). This was most 
pronounced within the Ml tree but was also evident within the M2 tree to a lesser 
extent (Figure 5.9).
'Further evidence for this phenomenon was obtained when the trees were 
separated into subtypes for each gene (Figures 5.10 to 5.13). The phylogeny of 
Ml and M2 originating from human H3N2 strains indicates two distinct groups of 
viruses that have evolved along separate branches. It was also apparent that the 
branch that separated from the main trunk in both the Ml and M2 H3N2 trees, 
contained a high proportion of amantadine-resistant viruses (Figures 5.10 and 
5.12).
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FIGURE 5.7 Phylogenetic analysis of matrix protein of influenza A viruses 1968-1999
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Trees were constructed using all H3N2 and MINI viruses used in the present study.
Branches containing H3N2 and H1N1 subtypes have been labelled. Trees were bootstrapped
and values greater than 70 displayed on relevant branches.
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FIGURE 5.8 Phylogenetic analysis of M1 nucleotide sequence of influenza A viruses 1968-1999
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FIGURE 5.9 Phylogenetic analysis of M2 nucleotide sequence of infiuenza A viruses 1968-1999
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Trees were constructed using all H3N2 and H1N1 viruses used in the present study.
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and values greater than 70 displayed on relevant branches.
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FIGURE 5.10 Phylogenetic analysis of M1 nucleotide sequence from H3N2 viruses
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Trees were bootstrapped and values greater that 70 displayed on relevant branches. Viruses 
phenotypically resistant to amantadine are highlighted in red; those shown to carry 
mutation within the M2 transmembrane region are marked with a red asterisk. Two groups 
of viruses isolated from outbreak cases (Clusters 1 and 2) have been highlighted.
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FIGURE 5.11 Phylogenetic analysis of M1 nucleotide sequence from H1N1 viruses
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FIGURE 5.12 Phylogenetic analysis of M2 nucleotide sequence from H3N2 viruses
AENG62986' 
1 AENG55086' 
AENG63286' 
AENG54986*
Cluster 1
AENG40086
AENG55786
AENG26886"
AENG5086
AENG58986
AENG20786
AENG17986
AENG39586
ASCOT4986
AENG27786
AENG63886
AENG58886
AENG31086
Cluster 2
AENG32790
AENG31188
AENG25983’
AENG11684'
AENG784
AENG62783’
AENG94782
AENG12989
ASGOT1888”
AENG82998
AENG79898
AENG24795
AENG33393
AENG23992
AENG28093
AENG62389
AENG28990
AENG27391
AENG69298
AENG35796’
AENG3992'
AENG13298
AENG49199
AENG21289
AENG12889"
ASGOT8792
AENG36896
AENG96878 
1 AENG93778 
.  AENG55182
AENG90783"
AENG64082’
AENG44882
AENG183
AENG36480
ASGOT1683
AENG38087
AENG255476
AENG51476
AENG45975
AENG4272
AENG87869
AAichi268
0.01
Trees were bootstrapped and values greater than 70 displayed on relevant branches. 
Viruses phenotypically resistant to amantadine are highlighted in red; those shown to carry 
mutation within the M2 transmembrane region are marked with a red asterisk. Two groups 
of viruses isolated from outbreak cases (Clusters 1 and 2) have been highlighted.
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FIGURE 5.13 Phylogenetic analysis of M2 nucleotide sequence from H1N1 viruses
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5.4 Discussion
5.4.1 Rate of Evolution of M1 and M2
Analysis of the results demonstrated that overall, M2 evolved at a faster rate than 
M1 at both the nucleotide (2.1 x 10'  ^ and 1.7 x 10'  ^ changes per site per year 
respectively) and the amino acid level (3.3 x 10'^ and 1.4 x 10'^ changes per site 
per year respectively). These figures appear to be higher than values from 
comparable studies (175) but demonstrate the same difference In evolutionary rate 
between the two proteins.
The results from this work demonstrate that within the M2 protein, the three 
functional domains appear to evolve at different rates. The least evolutionary 
change was observed within the extracellular domain; this supports data 
presented In Chapter 4 Illustrating the extremely conserved nature of this region at 
both the nucleotide and amino acid level (Figures 4.9 to 4.13; pages 119, 124, 
125, 129 and 130). It Is possible therefore, that a functional constraint on the 
extracellular domain has resulted In the same sequence being conserved over the 
study period. The function of the extracellular domain remains unclear but It Is 
thought to Interact with other membrane proteins and facilitate their Incorporation 
Into progeny virions during the replication cycle (272). It would appear that the 
extracellular domain Is not able to carry a significant number of mutations, most 
probably because they are deleterious to the function of the protein, preventing the 
formation of Infectious particles.
The rate of change within the M2 protein transmembrane domain was shown to be 
higher In amantadine-resistant strains for both H3N2 and MINI viruses. It seemed 
that the most likely reason for this result was the occurrence of mutations within 
The transmembrane domain of the viruses causing resistance. It was also 
Interesting to note that the ratio of Ts:Tv mutations was very low within the 
transmembrane domain. The reason for this observation was unclear but It Is 
possible that the M2 transmembrane domain has greater “plasticity” than other 
regions of the protein and Is therefore able to accommodate mutations that are not 
readily selected when occurring In other domains. The M2 Ion channel can 
accommodate mutations that confer amantadlne-reslstance and alter the structure 
of the pore region. The resulting virus can remain Infectious, however, which
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demonstrates how the domain can retain its function whilst accommodating 
structure-altering changes. It is possible that the Tv changes are more likely to 
alter the structure or chemical composition of a protein due to the nature of the 
mutation. Therefore this again demonstrates that the transmembrane domain can 
withstand the effects of Tv mutations. It is likely that the benefit of the plasticity of 
the transmembrane domain is that the virus can gain resistance to amantadine 
through these mutations thereby providing the virus with evolutionary selection 
advantage under certain conditions. Such structure-changing mutations in the 
other domains may not provide such selective advantages and are therefore not 
fixed.
The cytoplasmic domain was found to be evolving at a rate higher than the other 
two functional domains of M2. The rate of amino acid change was the same for 
both amantadine-resistant and -sensitive viruses of H3N2 and H1N1 subtype. The 
rate of nucleotide change was the same for H1N1 viruses. However, the H3N2 
resistant viruses rate of change was higher than H3N2 sensitive viruses. In the 
case of the H1N1 viruses, this provided evidence that there were no mutations 
occurring within the cytoplasmic domain that may have conferred resistance to the 
virus. Therefore, it could be concluded that the cytoplasmic domain did not have 
any direct control over the amantadine susceptibility of the H1N1 viruses. Although 
the nucleotide change rate of the H3N2 resistant viruses was higher than the 
sensitive H3N2 viruses, it appeared that the cause of this was a higher rate of 
synonymous changes i.e. silent mutations. These changes would not have 
affected the amino acid sequence of the protein and therefore it was concluded 
that within the H3N2 subtype viruses, the cytoplasmic domain did not have any 
role in determining the susceptibility of the viruses to amantadine.
To explain the differences observed between M1 and M2 in respect to evolutionary 
change, it is postulated that the structure/function relationships associated with 
each protein were involved. M2 is classified as a surface antigen; at least 18 
residues of the extracellular domain are present at the cell/membrane surface 
(206). Although only a minor component of the influenza A virion (411), M2 is 
expressed abundantly at the membrane surface of virus-infected cells and 
therefore represents a target for the immune response (206). The presence of 
anti-M2 antibodies suggests that during infection, humoral immunity to the M2 
protein could provide a role in the protection against infiuenza A (29, 362, 411).
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The immunogenic property of M2 has led to research that has investigated the 
vaccination potential by using purified M2 preparations to produce heterotypic 
immunity against influenza A (100, 331). It could be hypothesised that the 
production of anti-M2 antibodies would increase the selective pressure on M2, 
forcing changes within its amino acid sequence in order for it to evade detection.
A reason why the three domains appeared to evolve at different rates may have 
been due to the host immune response. The M2 protein is positioned with the 
extracellular domain presenting at both the virion and infected cell surface. This 
would suggest that the primary immunological epitopes on the protein would be 
situated within this domain. Studies with an anti-M2 monoclonal antibody 1402 
demonstrated that the 1402 antibody-binding site was located within the 
extracellular terminus of M2; the epitope was further defined to involve residues 11 
and 14 (411). Although the antibody-binding site of 1402 lies within the 
extracellular domain, the residues surrounding the epitope are highly conserved 
(Chapter 4; (175, 412). If the virus was to select variants carrying mutations, which 
would enable it to escape detection by antibody, then it could be hypothesised that 
the extracellular domain should be more variable; the results from this study and 
others demonstrate that this is not true. Characterisation of 1402 resistant variants 
revealed that mutations within the cytoplasmic domain conferred resistance to M2 
antibody inhibition (410). Although the effect of the antibody on M2 is not clear, it is 
likely that the binding of the antibody to the extracellular domain causes a 
conformational change in the cytoplasmic tail region. Antibody-resistant variants 
containing mutations within the tail may prevent this change occurring. This theory 
can therefore be linked with the above results; it was postulated that immune 
pressure has caused the formation of viruses with mutations within the 
cytoplasmic domain rendering them resistant to antibody. Results from Chapter 4 
confirm this; mutations at amino acid position 78 were found (Figures 4.11 and 
4.13; pages 125 and 130) which have been correlated to antibody resistance 
(410). Therefore, the increased rate of evolution within the cytoplasmic tail may be 
a direct consequence of the pressure exerted on the extracellular domain of the 
protein. Another study conducted with anti-M2 mouse sera demonstrated its 
reactivity to different synthetic peptides produced representing the entire M2 
sequence (331). This study demonstrated that the highest serum antibody titre 
was raised against a peptide representing amino acid residues 79-97. The second 
highest titre was achieved with a peptide representing residues 2-18. This was
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evidence that although epitopes for the laboratory-produced monoclonal antibody 
(14C2) were found within the extracellular domain, the primary epitopes for this 
naturally-occurring antibody were located within the cytoplasmic region. This 
supported the results found in this study and was an additional explanation for the 
'increased rate of change found within the cytoplasmic region of M2. An antibody 
binding to this region would force the selection of mutants allowing the virus to 
escape the activity of the antibody. The study by Slepushkin et al. (1995) also 
provided evidence that relatively high antibody titres were produced against 
synthetic peptides representing the N-terminal region of the M2 protein supporting 
the 14C2 work by Zebedee and Lamb (1989) (331,410).
The location of M2 at the infected cell/viral membrane surface would suggest that 
the evolution of this gene would be in excess of reported estimates and more like 
those reported for the other influenza A surface glycoproteins (Table 5.1). 
Conversely it has been suggested that constraints placed upon M2 might restrict 
the rate of change within the gene. This might be as a result of the bicistronic 
nature of the M gene; Ml and M2 are transcribed from gene segment seven and 
they share a sequence of nine amino acids at the NHs-terminal end (204). It has 
been proposed that Ml has several important functions within the replication cycle 
of the virus, and mutations causing amino acid changes within the protein may be 
detrimental to the survival of the virus. Therefore, the relatively low rate of 
evolution of Ml might exert an evolutionary constraint on the rate of change of M2 
in order to retain Ml as a functional protein. The results demonstrated that the rate 
of Ml was lower than that of M2 (1.4 x 10'  ^and 3.3 x 10'  ^amino acid changes per 
site per year, respectively). Ml is an internal virus protein located between the 
lipoprotein and the RNP (413). Due to the location of the protein within the virion, 
there is far less potential for immune pressure to be exerted compared to M2, a 
possible explanation for observed results. However, there has been evidence to 
show that Ml is recognised by human cytotoxic T iymphocytes and therefore may 
be subjected to some degree of immune pressure (116, 176, 296). This might 
correlate to the low levels of evolutionary change observed within Ml over the 
study period.
Results demonstrated that overall, M2 isolated from MINI viruses evolved at 
higher rates than H3N2 viruses. This was an interesting observation; comparisons 
of the rate of change of other influenza A genes between the H3N2 and MINI
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subtypes are limited to the HA1 gene where it is reported that compared to H1N1, 
H3N2 viruses evolved at elevated rates (59). The observed difference could be 
attributed to the smaller sample size of the set of H1N1 viruses simply causing a 
bias in the results. There were approximately three H3N2 viruses tested for every 
H1N1 virus, however this ratio represented the circulation of the viruses within the 
community over the study period. Alternatively, it could be that M1 and M2 of 
H1N1 viruses may have been more closely related to another species lineage 
other than human. If the matrix genes were more avian in character than human, 
when in the human host, the viruses would demonstrate an increased rate of 
change in an attempt to adapt to the host. To investigate this idea, a sample of 
human H1N1 and H3N2 and avian viruses were analysed phylogenetically (data 
not shown). The results were inconclusive; the H1N1 lineage did not appear to be 
closer to avian species than the human H3N2 viruses within the phylogenetic tree. 
The H1N1 viruses were not significantly more avian in character and therefore the 
increased rate of change observed is likely to be caused by another factor.
The genetic characterisation of both amantadine-resistant and -sensitive strains 
revealed a trend among H1N1 viruses (Chapter 4, Figures 4.11 and 4.13, pages 
125 and 130). The majority (95%) of the MINI viruses sequenced contained a Glu 
residue at position 78 within the cytoplasmic tail. As previously discussed, this 
mutation had been associated with conferring resistance to the M2 antibody 1402. 
Therefore, the assumption could be made that a large proportion of the H1N1 
viruses in this study would be resistant to the activity of anti-M2 antibody. The 
1402 antibody has been shown to reduce the growth of certain influenza virus 
strains (411). Viruses resistant to the antibody would have the potential to grow 
and therefore replicate at an increased rate. It might be hypothesised that without 
the selective pressure from the immune system, and increased viral growth rates, 
the matrix genes from these antibody-resistant viruses would evolve at a higher 
rate than antibody-sensitive strains. This hypothesis correlated with the data 
presented in this study; all MINI viruses, irrespective of drug phenotype or 
genotype had a greater rate of change over the study period than H3N2 viruses. 
An amino acid alignment of human and avian viruses was created to see whether 
the Glu residue at position 78 was also found in avian viruses (Figure 5.14). A 
selection of MINI and H3N2 viruses from this study, and four avian viruses of 
different subtype were used. Sequences were aligned to A/WSN/33, this 
represented the earliest prototype strain for the viruses. As previously shown, the
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H1N1 viruses all carried a Glu at position 78 except A/WSN/33, which in common 
with the H3N2 viruses had a Lys residue (Figure 5.14). Interestingly, M2 from 
avian strains contained a Lys78Gln mutation. This suggested that these avian 
strains had a mutation rendering them resistant to the effects of the 14C2 
antibody, similar to postulations made about the HI N1 viruses in this study.
FIGURE 5.14 Amino acid alignment of M2 protein of human and avian influenza A strains
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"AENG49199 .............................V. .S. .G.................... L. .H...............................A. .S. . .S---
AENG28990  V. .S.. G....L. .H.................. A. .S. . .S.
AENG45975  V. .S.. G.......F.EH.......................... S. . .A. .S. . .S.
AENG12989  V .G ............ L. .H.................. A. .S. . .S.
AENG62986  V .G ............ L. .H.................. A..S...S.
AENG54986  V .G ............ L. .H.................. A. .S. . .S.
AENG16886  IV. .S.. G.... L. .H. .T............... A. .N. . .S.
'AHK15697H5  LT. .G S ...... V..S..G............................................... Q .................
ATEALHK97H6  LT. .G.E.K.S...... V. .S...G............................................... Q ................
AFPVD0BS0NH7  T. .G.E. . .S.......... S.. G..............V ...... L ............. L ........ Q .................
AHK107399H9  LT. .G.E.K.R...... V. .S...G............................................... Q ................
Amino acid alignments of human and avian influenza A M2. Sequences were aligned to the 
prototype strain A/WSN/33. Arrows 1 and 2 indicate the residues thought to be involved in 
the binding of anti-M2 antibodies. The asterisk highlights residue 78 within the cytoplasmic 
domain, thought to confer resistance to MAb 1402 activity (410).
Another observation made was that within the extracellular domain of the avian 
strains, there were several differences in sequence compared to the human 
viruses. In particular, there were differences between residues 11 and 14, the 
avian strains carried lle llTh r and Glu14Gly mutations (Figure 5.14). These 
residues have previously been demonstrated to comprise the epitope for the 14C2 
antibody (410). Therefore, these avian strains appeared to have mutations at both 
sites for antibody binding and at positions within the cytoplasmic region that have 
been shown to confer resistance to the antibody. The implications of these findings 
are interesting. Although only four avian viruses were selected for this analysis, 
two represented subtypes (H5N1 and H9N2) that have been the cause of recent
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avian to human transmission of influenza (48, 129). The hypothesis can be made 
that the anti-M2 antibody 1402 has less antiviral activity against these avian 
strains. This could be construed as an additional explanation for the increased 
pathogenicity and virulence demonstrated by these viruses when they cross the 
species barrier into humans. The M2 protein is highly conserved amongst 
influenza A viruses and therefore may offer cross-protection to the host from novel 
Viruses (175, 410). If these avian strains carried mutations allowing them to evade 
this form of immunity then it could result in an increased potential for severe 
disease.
In critique of the work performed here, it was recognised that there were some 
weaknesses associated with the estimation of the rates of evolution for particular 
genes. This was especially apparent when the transmembrane region of M2 was 
analysed. This region is relatively conserved and the occurrence of mutations is 
predominantly associated with viruses acquiring amantadine-resistance (118, 142, 
175, 412). Due to the lack of evidence for transmission of resistant viruses in the 
community presented in this study (Chapter 3), it might be hypothesised that under 
normal conditions, without the selective pressure of drug, the genotype of the virus 
will revert to sensitive. This aspect of the virus presents problems for calculating 
the rate of change. If over a period of time, the only mutations occurring within the 
M2 transmembrane region were as a result of amantadine-resistance and 
therefore not fixed, then there would be no overall accumulation of mutations. This 
makes the calculation of the rate of change difficult to interpret because the 
resulting figure does not give an accurate picture of what is actually happening. 
The evolution of other influenza genes also seems to involve the appearance and 
disappearance of mutations, but there is also a proportion of mutations that 
become fixed within the virus population that results in the overall accumulation of 
mutations over time.
Another critical aspect of the work was the small sample size within some data 
sets. For example, when analysing the resistant MINI viruses, there were only ten 
data points to plot (Appendix 9, page 290). When performing a linear regression 
on this small data set it was apparent that certain data points, that in a larger set of 
data would not have been so influential, might have biased the best line of fit. 
However, the methods used to calculate the rates of change were similar to those
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used in other studies and therefore it was thought that those methods should be 
employed here to enable the comparison of results.
5.4.2 Phylogenetic Analysis
Phylogenetic analysis of the M, M1 and M2 nucleotide sequence revealed that 
there were two subtype-specific lineages of the matrix genes, H3N2 and H1N1. 
Further analysis of the H3N2 lineage revealed genetic divergence of M1 into two 
distinct branches. The branch that had separated from the main trunk of the tree 
contained viruses isolated between 1982 and 1990 although the majority (80%) 
were isolated during the 1985/86 influenza season; the main trunk of the tree has 
continued to evolve until present day. Interestingly, the branch that separated from 
the main trunk was almost entirely composed (88%) of amantadine-resistant 
(phenotypic or genotypic) strains. It was hypothesised that from the emergence of 
the H3N2 subtype in 1968, one lineage of Ml had evolved until approximately 
1982 when the genetic divergence occurred and the second branch separated. 
This could have been as the result of the appearance of a variant that circulated in 
the population. This variant could have had a lower susceptibility to amantadine, or 
had the potential to be replicated and transmitted when carrying a resistant 
genotype. This would have resulted in the appearance and circulation of 
,amantadine-resistant viruses over the period that the variant was present in the 
population. Evidence from the phylogeny suggests that the first amantadine- 
resistant strains appeared during the 1982/83 season at which point the variant 
emerged and circulated.
Analysis of the phylogeny of the M2 H3N2 tree showed that similar to M l, there 
was a divergence of the gene into two distinct branches. However, it was found 
that there were differences between the separated branches of Ml and M2. Each 
branch contained a similar number of viruses but they were not identical.
The presence of the branch containing mainly amantadine-resistant strains 
supported conclusions that were drawn in Chapters 3 and 4. It was found 
previously that a large proportion of the viruses that were resistant by phenotypic 
\assays did not carry any mutations within the M2 transmembrane domain. It could 
be that the presence of quasispecies within each virus isolate tested may have 
resulted in the amplification of a genome from a sensitive genotype. In a highly 
resistant strain this would not be as common because the balance of resistant
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genotypes would outweigh the sensitive genotypes. However, in a virus of low 
resistance a higher proportion of sensitive genomes may have been present, 
increasing the chance that the M2 sequence produced would not contain any 
mutations within the transmembrane domain. Analysis of the population dynamics 
of the viruses that were phenotypically resistant but lacked mutations within the 
M2 transmembrane region would support this theory. Two approaches could be 
made; initially, viruses of interest could be titrated in a plaque reduction assay in 
the presence and absence of amantadine. Plaques formed in the presence of drug 
could be picked, biologically cloned and sequenced to determine the genotype of 
the virus particles contained within the plaque. Alternatively, using a different 
cloning method, gene segment seven of the virus could be amplified and 
transformed into a suitable bacterial host. Selection of a number of colonies, and 
amplification and sequencing of the gene segment seven contained within each 
colony would give an estimate of the heterogeneity of the gene sequence within 
the virus sampled.
The phylogeny of the viruses tested demonstrated that viruses resistant by 
phenotype and genotype were grouped together in the second main branch. This 
indicated that these viruses were very similar in respect of M1 and M2. Therefore it 
was concluded that this was further evidence of the presence of quasispecies 
'within individual virus isolates that had biased the results. It was interesting to note 
that within the cluster of amantadine-resistant strains there were also several 
sensitive viruses interspersed. This suggested that these viruses were very similar 
to the resistant strains. It would be interesting to repeat the testing of these viruses 
to see whether the original phenotypic and genotypic testing had not detected their 
resistance. If this reveals that they were actually resistant this would demonstrate 
how phylogenetic analysis could indicate the drug susceptibility of viruses.
Suspected outbreaks of amantadine-resistant viruses as indicated in Chapter 3 
were identified within the trees. There were two small groups of viruses identified 
within the M1 and M2 trees that could be correlated with viruses suspected of 
originating from outbreaks (Figures 5.10 and 5.12). The first group (A/ENG/629/86, 
A/ENG/550/86, A/ENG/632/86 and A/ENG/549/86) all carried a Ser31Asp 
'mutation within the M2 transmembrane domain and epidemiological data indicated 
that they were originally isolated from Guildford. Therefore, the clustering of these 
viruses within the trees was further evidence that the viruses were isolated from an
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outbreak of an amantadine-resistant strain. The other small group of viruses 
(A/ENG/637/86, A/ENG/586/86 and A/ENG/168/86) all similarly contained a 
Ser31Asp mutation within the M2 transmembrane domain. Again, phylogenetic 
analysis provided evidence of the emergence and possible transmission of 
amantadine-resistant viruses.
Overall, the appearance of the phylogenetic trees suggested that the main trunk of 
the phylograms, containing a majority of amantadine-sensitive viruses was 
evolving at a relatively steady rate. This was especially true of the matrix and M l. 
The branch containing resistant viruses appeared to be more stationary, i.e. there 
was no evolution occurring in these viruses. This may have been because the 
majority of the viruses contained within the branch were isolated in the 1985/6 
influenza season and therefore, over such a short period of time it would be 
difficult to ascertain the evolution of the genes. Alternatively, the resistant 
phenotype and genotype might have put an evolutionary constraint on the viruses. 
This might have been evidence that these viruses, carrying mutations within M2, 
were at a selective disadvantage to the sensitive wild-type viruses and therefore, 
once emerged, could not survive within the population for any significant period of 
time.
5.4.3 Concluding Remarks
In summary, the work from this Chapter estimated the relative rates of evolution of 
the gene segment seven from influenza A viruses illustrating that the different 
proteins transcribed from gene segment seven were undergoing different 
evolutionary rates of change. It was hypothesised that these observations were as 
a consequence of the different levels of selective pressure exerted on each 
respective protein. Phylogenetic analysis of the Ml and M2 separated viruses into 
subtype-specific lineages with some clustering of amantadine-resistant strains into 
separate branches.
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6.1 Introduction
Natural infections of human influenza are generally self-limiting in healthy adults. 
Following the introduction of virus into the host, a series of events stimulate the 
immune response, which eventually prevails in eliminating the invading pathogen. 
In certain situations, where the immune system of the host has been depleted or 
suppressed, the virus has an opportunity to prolong replication and therefore the 
period of infection, often resulting in increased severity of disease or persistence 
of infection. It has been commonly reported that one of the groups most at risk 
from complications arising from influenza infection are the immunocompromised 
where the immune system has been suppressed either through drug therapy (e.g. 
cancer or organ transplants) or disease (e.g. human immunodeficiency virus; HIV).
The consequences of a deficient immune system in the immunocompromised host 
can have numerous effects on the response to infection. Some forms of 
chemotherapy have been reported to reduce mucosal integrity and possibly IgA 
antibody levels within the upper respiratory tract; these two factors represent one 
of the first lines of natural defence against infection. Several forms of immune 
deficiency result in reduced serum immunoglobulin levels, T cell function and 
neutrophil numbers. The overall severity of immune deficiency has been shown to 
have a direct consequence on the frequency and severity of infections acquired 
(223, 311). Both severe and mild immune deficiency in immunocompromised 
patients account for a higher frequency of infection and greater risk of death when 
compared to immunocompetent hosts.
Influenza infections in immunocompromised children have been poorly 
documented. Feldman et al. (1977) studied twenty children and young adults with 
cancer; each patient was receiving immunosuppressive therapy (95). Although the 
symptoms presented by the patients were not unusual, the clinical course of 
disease lasted twice as long (two weeks) as in the general population. This study 
also found that the rate of complications arising in the patients was low, and were 
in fact related to secondary bacterial infections rather than as a direct result of the 
influenza. A similar study that followed a group of immunocompromised children 
with cancer determined the risk of influenza infection and severity of disease in 
these patients compared to a control group (183). Although there was no 
significant difference in duration of symptoms between the two groups, eleven per
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cent of the immunocompromised children were hospitalised during their influenza 
illness; none of the control children were admitted (183).
Reports documenting the severity of influenza in immunocompromised patients of 
all age groups can be conflicting. The majority of the data suggest the influenza 
infections are a frequent cause of serious respiratory disease in hospitalised 
immunocompromised patients. This has been reported for transplant recipients (9, 
239, 311) and patients with leukaemia (408), neoplastic disease (387) and cancer 
(95). Infections of patients in these groups can be fatal (9, 183, 274, 408). 
Complications arising from influenza infections in immunocompromised patients 
are mainly primary viral pneumonia or secondary bacterial or fungal pneumonias; 
the development of these complications can lead to relatively high mortality rates 
(388). Although the majority of data indicate that influenza is the cause of serious 
respiratory disease in immunocompromised patients, there are reports that 
suggest the contrary. A study by Ljungman et al. (1993) identified 
immunocompromised patients during the progression of two influenza seasons. 
They reported incidences of infection and disease to be mild and self-limiting in 
most immunocompromised patients but occasionally they caused severe 
complications (223).
General respiratory pathogens that circulate within the community are an 
important cause of respiratory disease in immunocompromised patients (91, 216, 
385, 388). In a study of bone marrow transplant recipients during two influenza 
seasons, respiratory pathogens circulating within the community were diagnosed 
in 31 percent of recipients (388). Using a range of isolation techniques, it was 
determined that the infections were caused by respiratory syncytial virus (49%), 
influenza viruses (18%), picornaviruses (18%), parainfluenza viruses (9%) and 
adenoviruses (6%). The appearance and disappearance of the viruses within the 
patients mirrored the circulation of the viruses within the community at that time 
(388).
The susceptibility of immunocompromised patients to infection with community- 
acquired respiratory viruses means that stringent infection controls and treatments 
must be used to prevent or limit the severity of disease. Basic precautions to limit 
nosocomial transmission and spread of disease i.e. handwashing, gloving and 
'masking, where implemented, have been shown to significantly reduce the
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incidence of infection (291). Infections with RSV or PIV have the potential to cause 
severe lower respiratory tract disease associated with high mortality. Trials have 
been performed in an attempt to treat these severe infections with the nucleoside 
analog ribavirin. This drug has been shown to have a broad antiviral spectrum 
against influenza A and B viruses and some paramyxoviruses (131,151,167, 240, 
255, 267). Against PIV infection in immunocompromised patients, intravenous 
ribavirin has been shown to temporarily arrest viral replication and improve clinical 
presentation of symptoms (151). Studies that have investigated the effect of 
ribavirin on immunocompromised patients infected with RSV have shown that 
despite treatment with the drug, mortality rates remain high (91, 215).
In addition to basic infection control procedures, two strategies exist for the 
prevention and treatment of influenza in immunocompromised patients; 
immunisation and the use of antiviral drugs. Prevention of influenza infection by 
vaccination is highly recommended for all at risk groups (7). Not surprisingly, the 
immunological response to the inactivated vaccine has been shown to be impaired 
during suppressive chemotherapy treatments in cancer and transplant patients 
(123, 269) and therefore the individual responses to vaccination are considered to 
be unpredictable.
The use of amantadine and rimantadine in preventing influenza A infections in 
immunocompetent adults has been well documented (37, 74,149, 165). However, 
data for the chemoprophylactic use of these antiviral compounds in 
immunocompromised patients is poorly defined. A common policy for prevention of 
influenza infections is seasonal amantadine prophylaxis, which has been shown to 
be 71% effective in preventing influenza (251). Combinations of seasonal 
vaccination and amantadine prophylaxis during periods of influenza activity within 
the community can provide optimal protection against influenza for 
immunocompromised patients.
The use of amantadine and rimantadine for treating influenza infections in 
immunocompromised patients is also poorly defined. The limited data suggests 
that transplant patients receiving amantadine treatment recovered from infection 
but non-treated patients also have a high rate of rate of recovery (145). The known 
disadvantages of using the drugs for treatment of influenza infections, i.e. 
emergence of resistance and side-effects, present problems in the
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immunocompromised host. The shedding of resistant viruses in 
immunocompromised patients has been documented (193) and shedding of virus 
for prolonged periods presents additional problems. Several publications have 
reported the shedding of influenza A and B from patients with deficient immune 
systems. The length of time that virus can be isolated in samples can range from 
days, to several months (151,193, 304).
Immunocompromised patients diagnosed with influenza are commonly prescribed 
antiviral drug treatment to prevent or control disease. The net result of the 
treatment is the common emergence of resistant mutants. In several cases, 
.viruses isolated from persistent infections have been characterised and mutations 
within the M2 transmembrane domain conferring resistance identified (90, 193). 
However, in the majority of cases where influenza has been isolated during or 
after treatment with amantadine or rimantadine, and genetic characterisation has 
not been possible, there is a high possibility that the viruses will show reduced 
susceptibility to the drugs (93).
With the recent high profile launch of influenza neuraminidase inhibitor (Nl) drugs 
e.g. zanamivir, new hope was revived for the efficient control of influenza within 
the immunocompromised host. Evidence from early work and clinical trials 
demonstrated that unlike amantadine and rimantadine, the emergence of resistant 
mutants was rare both in vitro and in vivo (124, 127, 128, 242, 243). A major 
criticism of the Nl drugs prior to launch was the lack of substantial data provided 
Tor the use of the drugs in, and the benefit provided to immunocompromised 
patients. Interestingly, evidence for the emergence of an influenza B mutant 
resistant to zanamivir was reported during the treatment of an 
immunocompromised patient (127). This was further evidence of the problems 
raised when treating influenza infections in the immunocompromised host. It would 
appear that the virus is able to replicate unchallenged which may give it added 
opportunity to develop resistance to antiviral drug therapy.
There have been numerous reports of persistent viral infections involving a range 
of pathogens both in vitro and in vivo (12, 13, 80, 246, 292). Persistent influenza 
infections have been documented in vitro involving different influenza types (49, 
103, 115, 225). The available data show that persistent infections in vitro involve 
the maintenance of a balance between virus replication and host cell survival.
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Persistent infections have been shown to involve the production of mutant virus 
particles or unusual patterns of protein synthesis (208, 225, 234). In particular, 
during a persistent infection of influenza 0 it was shown that viruses isolated 
contained single nucleotide changes and variation within separate proteins that 
could be functionally linked to the persistent virus phenotype (208, 234). 
Therefore, it seems that molecular changes within virus proteins can alter the 
replication of the virus in such a way that persistence within the environment 
becomes possible. It has also been shown that influenza viruses with the ability to 
initiate persistent infections are able to outcompete wild-type strains that have a 
“normal” replication cycle indicating that the persistent viruses are at a selective 
advantage (234).
Persistent influenza infections of varying lengths within the human host have been 
described (90, 93, 127, 134, 193, 244, 304). Prolonged infections lasting more 
than a few weeks are extremely rare. The two longest recorded episodes of 
persistence were an influenza A H3N2 and an H1N1 infection, both of 
approximately ten months duration (134, 244, 304). One clinical feature associated 
with these cases of persistence is the infection of an immunodeficient host. This 
indicates that the suppressed immune response within these hosts enables the 
virus to replicate in the absence of any immune selective pressures and therefore 
prolong the period of infection.
In persistent infections of influenza, there has been evidence to demonstrate the 
presence of heterogeneous populations of viruses (quasispecies). With respect to 
drug-resistance, it has been shown that over the course of a persistent infection, 
viruses isolated at different stages can carry different mutations within the M2 
protein conferring resistance to amantadine and rimantadine (90, 193). This 
suggests that within the viral quasispecies there are mixtures of variants of 
different drug genotype, which due to unknown pressures or variables can be 
selected and become the predominant species. This would account for the 
appearance of certain resistance mutations that can then be superseded by 
different genotypes. This pattern has also been documented by characterising 
other proteins of influenza recovered from persistently infected patients (304).
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6.2 Case Study
The case studied here involved a female patient aged 13 years old (at the time of 
study). The patient is subsequently referred to as GS. The patient was HIV 
positive with a low CD4 count (18 x 10^ /1; 3%); the history of the clinical 
manifestations and treatments of GS are summarised in Figure 6.1. During June 
1995, the diagnosis of a chest infection subsequently led to the detection of 
influenza A H3N2 from a nasopharengeal aspirate (NPA) by immunofluoresence; 
the virus was designated A/ENG/292/95 and typed by haemagglutination inhibition 
as AyThess/1/95-like. A course of amantadine treatment was initiated which lasted 
ten days. During the amantadine treatment, several more clinical samples were 
, collected and tested for influenza all of which were positive for influenza A (Table 
6.1). Following the cessation of amantadine treatment, influenza A H3N2 
continued to be isolated for a period of approximately eighteen months. Viruses 
isolated were propagated in MDCK cultures and stored for further analysis.
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TABLE 6.1 Summary of GS viruses
Isolate Date of Specimen No. Days from GS1 Specimen type
GS1 21/06/95 0 NPA
GS1A 30/06/95 9 Nose swab
GS1B 30/06/95 9 Gargle
GS2 03/07/95 12 Nose swab
GS3 10/07/95 19 Nose swab
GS4 24/07/95 33 Gargle
GS5 24/07/95 33 Nose swab
GS6 09/08/95 49 Gargle
GS7 14/12/95 156 Gargle
' GS8 14/12/95 156 Gargle
GS9 25/06/96 378 Gargle
GS10 04/12/96 531 Saliva/Oral fluid
Table Illustrates each sequential Isolate, the date of isolation and the type of specimen from 
which the viruses was isolated.
196
_______Chapter 6 - Persistent Influenza Infection in an Immunocompromised Host
6.3 Aims
The current study, where influenza A was isolated over a period of eighteen 
months represents the longest reported persistent infection to date and provides 
an invaluable opportunity to study different aspects of viral persistence in the 
immunocompromised host. The aims of this study were designed to investigate 
differences between sequential viruses isolated in respect to drug-resistance and 
antigenic properties. There were several objectives to the work:
• Drug susceptibility testing of each virus including phenotypic and genotypic 
characterisation.
• The evaluation of antigenic properties to identify sequence changes within 
the sequential viruses that may provide evidence for adaptation or evolution 
within the host.
• The determination of immune response by GS to the initial influenza 
infection.
• Estimate the evolution of M1, M2 and HA1 of the GS viruses and field 
strains that circulated over the period of study.
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6.4 Results
6.4.1 Phenotypic Analysis of GS Virus Isolates
To determine the phenotypic characteristics of each sequential virus isolated from 
GS, the amantadine susceptibility EIA and plaque reduction assay described in 
Chapter 3 were used (Figure 6.2). Each virus was grown in tissue culture prior to 
testing, although attempts to culture GS6 were unsuccessful meaning that this 
virus could not be included in any of the phenotypic testing. The initial results 
demonstrated that the viruses isolated after the patient’s treatment with 
amantadine generally had reduced susceptibility to the drug compared to those 
isolated prior to treatment. The first two isolates, GS1 and GS1A were both 
considered to be amantadine-sensitive, the inhibition by EIA was greater than 60% 
and the reduction in PFU/ml by plaque assay was approximately 40%. Viruses 
isolated after this point had reduced sensitivity to the drug and were considered 
amantadine-resistant (Figure 6.2). The isolates GS1A and GS1B were both 
isolated on the same day but were different specimens originating from 
independent sites, a nose swab and gargle respectively. Therefore, it was 
interesting to note that the apparent drug susceptibility of each virus appeared to 
be significantly different, one sensitive and one resistant both by EIA and plaque 
reduction assay (Figure 6.2). Similarly, GS7 and GS8 were isolated at the same 
time but from different sites, and again the phenotypic characteristics of each virus 
differed. Although this was only apparent from the plaque reduction assay data, it 
appeared that GS7 had a higher sensitivity to drug than GS8, although GS8 
seemed to have increased growth in the presence of amantadine. Interestingly, 
several other viruses (GS3, GS5, and GS9) had negative values for reduction in 
PFU/ml indicating that these viruses had actually increased replication rates in the 
presence of drug. In general, there was a good correlation between the 
susceptibility in EIA and plaque reduction assay; both identified resistant and 
sensitive viruses. The only exception was GS7, where the plaque reduction assay 
indicated that the virus was sensitive but results from the EIA contradicted this 
(Figure 6.2). Overall, the pattern of susceptibility over the range of viruses was 
high for the first two isolates, medium for the next two and then low for the 
remainder.
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FIGURE 6.2 Comparison of sensitivities of GS isolates to amantadine using plaque assay and EIA
Amantadine
I
GS1 GS1A GS1B GS2 GS3 GS1 GS5 GS7 GS8 GS9 GS10
Virus Sanrple
■%  Reduction PFU/ml ■ %  Inhibition (EIA) ■  Amantadine Treatment
The morphology of the plaques was recorded and analysed (Table 6.2). There 
was a correlation between the percentage reduction in plaque size in the presence 
of drug and the inhibition of the viruses by EIA and plaque assay. GS1 and GS1A 
had plaques that showed a 62 and 46 percent reduction in size respectively when 
grown in the presence of amantadine. These figures were relatively large when 
compared to the reduction of plaques grown from other viruses isolated after 
amantadine treatment, these viruses generally showed a reduction in the range of 
-2  to 38 percent, a mean of approximately 18 percent. Therefore, it appeared that 
the viruses isolated prior to drug treatment had plaques that were greatly reduced 
in size in the presence of amantadine compared to those post treatment, which did 
not display such evident reductions (Figure 6.3). These results indicated some 
viruses had increased replication and growth rates in the presence of drug; this 
was a characteristic that was observed for some amantadine-resistant isolates in 
Chapter 3.
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TABLE 6.2 Plaque morphology of sequential GS virus isolates
Virus
Isolate
Isolation
Date
% Red" Plaque size (diameter, mm)
PFU/ml - Drug + Drug % Reduction
GS1 21/06/95 38 2.74 1.04 62
GS1A 30/06/95 36 2 1.08 46
GS1B 30/06/95 0 2.65 2.14 20
GS2 03/07/95 27 3.08 2.2 29
GS3 10/07/95 -3 1.94 1.45 25
GS4 24/07/95 3 2.74 2 27
GS5 24/07/95 -9 2.5 2.56 -2
GS6 09/08/95 NVG* NVG NVG NVG
GS7 14/12/95 31 2.7 2.29 15
GS8 14/12/95 -36 2.14 2.18 -2
GS9 ! 25/06/96 -4 1.82 1.64 10
GS10 04/12/96 5 1.86 1.14 38
*NVG - No virus grown.
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FIGURE 6.3 Characterisation of drug-sensitive and -resistant viruses from GS
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MDCK cells were infected with GS1 (A+B) and GS10 (C+D) stained at 72 hours post 
infection. Amantadine at 1.0 pg/ml was incorporated into overlay B+D.
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6.4.2 Genotypic Characterisation of GS Virus Isolates
PCR amplification and sequencing of the GS virus isolates was performed by 
J.Ellis and C.Sadler of the Respiratory Virus Unit, CPHL Amplification and 
sequencing of the M2 gene from the twelve sequential isolates revealed the drug 
genotype of each virus (Table 6.3). Sequence analysis of the transmembrane 
region of M2 revealed that viruses sampled prior to amantadine treatment had a 
sequence homogeneous to a wild-type sensitive virus. From the results it was 
apparent that the viruses isolated post drug treatment contained mutations within 
the transmembrane domain of M2. The mutations discovered all correlated to 
previous studies demonstrating the molecular basis for amantadine-resistance 
(118, 142). Another observation from resistant viruses GS1B to GS10 was that 
sequences from each virus were heterogeneous, i.e. there were viruses carrying 
different M2 mutations within the viral quasispecies (Table 6.3). The most common 
mutation discovered was Ser31Asn occurring in 7/12 viruses; other mutations 
found were Val27Ala and Ala30Thr. Three viruses were found to contain mixed 
populations of genotypes. The viruses GS2, GS3 and GS6 all contained mutations 
at sites known to confer amantadine-resistance but sequences of the sensitive 
wild-type viruses were also found. Interestingly, sequencing of GS3 revealed that 
there was a mixture of two resistant genotypes, Ala30Thr and Ser31Asn in 
addition to the sensitive wild-type genotype (Table 6.3).
Viruses that had been isolated on the same day were analysed for sequence 
homology. GS1A and GS1B were isolated from a nose swab and gargle washings 
respectively; both samples were collected on 30/06/95. The M2 transmembrane 
sequence revealed that the two viruses differed; GS1A carried a series of amino 
acids resembling the sensitive wild-type sequence and GS1B had a Ser31Asn 
mutation known to confer amantadine-resistance. GS4 and GS5 were isolated 
from gargle washings and a nose swab respectively and also had heterogeneous 
sequences. Both viruses had resistance mutations but each was different. The 
transmembrane sequence of GS4 had a Val27Ala mutation and GS5 a Ser31 Asn 
mutation. The final two samples taken simultaneously were GS7 and GS8; both 
were gargle washings. The two viruses isolated from the samples shared complete 
sequence homology of the M2 transmembrane domain.
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TABLE 6.3 Sequence variations in the M2 gene of isolates GS1 to GS10
Virus Date Amino acid position and substitution^ Drug
26 27 30 31 34 Genotype^
Sensitive Leu Val Ala Ser Gly S
GS1 21/06/95 Leu Val Ala Ser Gly S
GS1A
GS1B
30/06/95 Leu 
30/06/95 Leu
Val Ala 
Val Ala
Ser Gly S
w l m m A A i # , 1 #
Asn Gly R
GS2 03/07/95 Leu Val Ala Ser/Asn Gly M
GS3 10/07/95 Leu Val Ala/Thr Ser/Asn Gly M
GS4 24/07/95 Leu Ala Ala Ser Gly R
GS5 24/07/95 Leu Val Ala Asn Gly R
GS6 09/08/95 Leu Val Ala Ser/Asn Gly M
GS7 14/12/95 Leu Ala Ala Ser Gly R
GSB 14/12/95 Leu Ala Ala Ser Gly R
GS9 25/06/96 Leu Val Ala Asn Gly R
GS10 04/12/96 Leu Val Ala Asn Gly R
 ^ Only those amino acids within the M2 transmembrane of influenza A viruses previously 
reported to confer amantadine-resistance are shown.  ^S - sensitive genotype; R - resistant 
genotype; M - mixed genotype comprising of either sensitive and resistant genotypes, or 
different resistant genotypes. Sequencing multiple samples of the same virus and 
comparing the accumulated sequences achieved data for viruses demonstrating mixed 
genotypes.
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6.4.3 Analysis of Antigenic Properties of GS Virus Isolates
In order to determine the overall antigenicity of the GS viruses, a 
haemagglutination inhibition (HAI) assay was performed. A panel of polyclonal 
ferret antisera was prepared to include reference virus types representing the 
period prior to, and during, the time when the GS isolates were collected. To 
complete the panel, antisera were generated for the first and last GS isolates. The 
antisera were then reacted with the constituent viruses and the ability of the virus- 
serum complex to agglutinate turkey erythrocytes was assessed (Table 6.4). All of 
the GS viruses were included in the test but only selected strains are displayed in 
the results. Analysis of the results demonstrated that within the control panel of 
reference viruses there was good correlation between the reaction of homologous 
virus and antiserum, and reduced reactivity between viruses of different 
antigenicity i.e. antigenic drift variants. The GS viruses were isolated in the 
1995/96 winter season and were antigenically related to prototype viruses isolated 
at the same time e.g. A/JHB/34/94 and A/Thess/1/95. The results from the HAI 
assay confirmed this (Table 6.4). GS10 did not react as well as GS1 with the 
prototypes with an observed difference in titre of up to sixteen-fold. When the 
results for GS1, GSB, GS9 and GS10 were analysed for reactivity to the 
A/JHB/34/94 and A/Thess/1/95 antisera, it appeared that the titres fell from the first 
virus to last. This type of pattern was evidence for antigenic drift; the gradual 
changes occurring in a virus over a period of type result in the virus becoming less 
homologous to its respective antisera resulting in the drop in reactivity titre. This 
suggests that over the period of persistent carriage, there was genetic drift in the 
viruses that resulted in antigenic variation. However, GS10 still reacted more 
closely to the 1995/96 prototype viruses (A/JHB/34/94 and A/Thess/1/95) than to 
A/Wuhan/359/95, indicating that reinfection with a different virus had not occurred.
A selection of the GS viruses was tested with the GS1 and GS10 ferret antisera 
(Table 6.4). The GS1 virus and homologous antiserum produced a strong end 
point titre (1280), however the GS10 virus combined with GS10 antiserum had a 
much lower titre (Table 6.4). When the selection of GS viruses was reacted with 
the GS1 antiserum, there was further evidence of drift occurring within these 
viruses. There was an eight-fold reduction in titre between the GS1 and GS10 
isolates. When the GS viruses were reacted with the GS10 antiserum, the 
resulting titres were poor and there was no evidence of drift.
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In order to relate the antigenic changes to the sequence of the HA, the HA1 region 
was sequenced from each individual GS isolate. It was thought that sequencing 
this particular region would give the best “picture” of changes in the virus that were 
occurring due to selection pressures. Amino acid alignments were constructed 
from the 347 residue HA1 sequence using the GS viruses and a selection of field 
isolates that had circulated prior to and after the study period. Two prototype virus 
strains were also included in the alignment, A/Thess/1/95 and A/Wuhan/359/95. At 
the time of the GS infection, viruses circulating the community had been 
A/Thess/1/95-like; towards the end of the GS infection the circulating strains had 
drifted to an A/Wuhan/359/95-like virus. The HA1 sequence of A/Thess/1/95 was 
used as the consensus to which all sequences were compared (Figure 6.4). 
Overall, the MAI region was relatively conserved between all viruses. There were 
three positions where mutations had occurred that appeared to have some 
significance. At position 158, the majority of the GS viruses carried a mutation that 
was not observed in any of the field strains sequenced. GS1, GS1B and GS4 all 
shared residues with the A/Thess/1/95 prototype but the remaining nine GS 
viruses all carried either Glu158Gly (1/9) or Glu158Lys (8/9) mutations. It 
appeared that the appearance of the Glu158Lys mutation in GS3 was then fixed in 
The virus population over the remaining sequential isolates.
In GS7, a Val196Ala mutation was identified that was then found in the next three 
sequential isolates. The position of the mutation within MAI was interesting 
because it was located within antigenic site B (Figure 6.4). The fixation of this 
mutation through the next three sequential isolates representing a period of 
approximately twelve months suggested that the viruses carrying the mutation had 
acquired a selective advantage resulting in the predominance of this genotype 
within the viral quasispecies. The sequence alignment also revealed that GS10 
had also acquired a change within another area of antigenic importance. The virus 
contained a His75Asn mutation within antigenic site E (Figure 6.4).
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Viruses that had been isolated on the same day were analysed for sequence 
homology. GS1A and GS1B were isolated from a nose swab and gargle washings 
respectively. The sequence of HA1 revealed that the two viruses differed; GS1B 
was homologous to GS1 in sequence but GS1A carried a Glu158Gly mutation. 
Similarly, GS4 and GS5 were isolated from gargle washings and a nose swab; 
these two viruses had heterogeneous sequences. Two amino acid changes were 
identified between the two viruses; GS4 carried a Ser45lle mutation and GS5 had 
a Glu158Lys mutation. The final two samples taken simultaneously were GS7 and 
GS8; both were gargle washings. The two viruses isolated from the samples 
shared complete sequence homology of HA1.
When the results from the HA1 sequencing and the HAI assay were compared, a 
correlation was observed between the two sets of data. The appearance of the 
Val196Ala mutation in GS7, GS8, GS9 and G10 correlated with a drop in reactivity 
demonstrated in the HAI assay. It was therefore hypothesised that this was 
evidence that the mutation has affected the virus in its capacity to either bind with 
antibody or to the receptors on the erythrocytes used in the experiment. In an 
attempt to prove this idea a further set of experiments were performed to assess 
the receptor binding properties of the GS viruses carrying the Val196Ala mutation.
6.4.4 Analysis of the Receptor Binding Properties of GS Viruses
The occurrence of the Val196Ala mutation had been demonstrated by sequencing 
the HA1 region of the GS viruses (Figure 6.4). The possible consequence of this 
mutation on the antigenic or receptor binding properties of the viruses had been 
illustrated from the HAI data. Therefore, in order to ascertain whether the mutation 
did affect the potential affinity to bind to sialic acid receptors on erythrocytes, a 
simple receptor binding experiment was performed. This involved titrating GS1 
(lacking Val196Ala mutation) and GS7, GS8, GS9 and GS10 to a known dose and 
then mixing with a range of erythrocytes originating from different species. The 
binding affinity of the GS viruses to turkey, guinea pig, chick and human 
erythrocytes were all analysed; the chick erythrocytes produced the most 
interesting result (Table 6.5). It appeared that GS1 bound with a relatively high 
affinity compared to the last four viruses. GS7 demonstrated some evidence of
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binding however GS8, GS9 and GS10 all completely lacked the ability to 
agglutinate the chick erythrocytes. The experiment was performed at different 
temperatures to ensure that such variables were not influencing the final outcome 
of the test; the results were almost identical at each reaction temperature. This 
was evidence for the potential effect of Val196Ala in HA1 on virus function.
TABLE 6.5 Affinity of GS haemagglutinin binding to chick erythrocytes
Virus Incubation Temperature
4°C RT* 37°C
A/Beij/359/89 8 8 8 8 4-8 8
A/Eng/301/95 2 2 2 2 2 2
A/Wuh/359/95 8 8 8 8 8 8
A/Syd/5/97 4 4 4 4 4 4
A/Eng/729/97 8 8 4 4 8 8
GS1 4 4 4 4 2 2
GS7 +/- +/- +/- +/- +/- 2
GS8 <2 <2 <2 <2 <2 <2
GS9 <2 <2 <2 <2 <2 <2
GS10 <2 <2 <2 <2 <2 <2
-VE Control <2 <2 <2 <2 <2 <2
* RT -  room temperature. Numbers represent the haemaggiutination titre of virus. +/- 
represents welis where the HA titre could not be distinguished between an undetectable
value (<2) and a HA titre of 2.
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6.4.5 Determination of the Immune Status of GS Serum Samples
A series of serum samples had been taken from GS (GSa to GSh) prior to, and 
during the persistent influenza infection (Figure 6.1). In order to determine the 
extent of the humoral immune response raised to the infection, a series of assays 
were used to measure levels of specific antibody within the samples. Initially, a 
HAI assay was used. The GS serum samples were titrated against a panel of 
.reference viruses selected as those strains representing the viruses thought to be 
circulating at the time of, or prior to the GS infection. Results demonstrated an 
inability of the serum samples to inhibit the agglutination properties of the HA 
within the assay. This provided evidence that there were very low levels of specific 
anti-HA antibody present within GS (Table 6.6). The virus strain most antigenically 
similar to the GS viruses, A/Thess/1/95, should have been the virus most likely to 
demonstrate some inhibition of agglutination, however the serum samples 
contained no apparent antibody titre to this virus even after eighteen months of 
infection.
Another method of detecting anti-influenza antibody activity within the samples 
was to assess the neutralising capacity of the GS sera. This technique, performed 
as a microneutralisation test was designed to detect the presence of neutralising 
.antibody within the GS serum samples (262, 308). It was possible that although 
the HAI assay had not detected any specific anti-HA antibody, there could be 
some neutralising activity present. The samples were titrated against a panel of 
reference viruses and the resulting serum-virus complex was tested for its ability to 
infect cell monolayers, which was subsequently quantified by a modified EIA 
(Table 6.7). The results from the test showed that each serum sample had failed to 
raise any significant response to any of the viruses in the reference panel. The 
titres produced from the assay were all low enough to provide evidence that 
neutralising antibody within the GS sera failed to inhibit the infection of virus 
particles in the EIA. GSg showed some evidence of neutralising activity against 
A/Thess/1/95 and A/Shan/9/93 suggesting that at the time of sampling, the 
neutralising antibody level within GS had been raised (Table 6.7).
210
0)
c
§ .
o
c
(0
Q-
m
t
c
(0
m
T
i
8
co
Q.
E
S
E
2
(DCO
CO
O
ce
c
4-"3O)
I
gX
.<o
(O
3
g
m
(0e
(O
00
c
i
(5
û
o
CO
c/)
o
i n m i o m i O L o m i o c o L n
V V V V V V V V C M V
l o i o i n m i n m i o m c o m
V V V V V V V V C M V
l o m i n i n i n i n i n i n S L O  vvvvvvvvgj v
l o m i o i n m i o i o i ovvvvvvvv
o
S
T n i n i O L O L O i n L O L O C O m
v V V V V V V V C M V
T f i n i n m m i n c o c o
0 ) 0 ) 0 ) 0 ) 0 ) 0 5 0 ) 0 )
LO CM O O
CO
h- CO CO O)
o  o  o  go
^  CO o  
CM o  T -
O
O)o
o
CM
CM CO 
T— CM
o o o o o o o o + <
0)
(0
i
t
V
co
%c
o
Q .
■Ô
C
0)
<D
1
Q .
2
I
E
3
i
o.
1
E
2 
$ 
CO 
0
‘5
§
1
1
0)
co
5
lü
;
s
c
(0
£
C/)
E
3
O
( /)
( / )
O
1010101010101010 = 
v v v vv vv v "CO
o o o o o o
CM CM CM CM
O
CO
O'If lO o o o o o oV CM CM CM CM CO f
■ç
o o o o o
' f  CO CO CO ' f
o
CO
' f ' f CM' f CMCMCO^
' f  LO lOm ^  ^
LO CM M  O p  ^
CO N  CO 
T - O  CM
LO LO LO^  ^  5 )
CO CO O)Q ^  ^  
CO O  O  
O  1-  CM
CO CO
N  O) 
P  O  
CM CO 
T - CM
CO .0 ü
to CO CO 
0 0 0
TJ 
CO
0 0 0
oo CO 10 
' f  10 V  
CM
O
CM
10
A
O
CM
10
A
L O O O O O O O l O C O  
V  CM - f  00 - f  CM CO V I O
CM
O O O O O O O O C M  10
10
V
( ^ 5  ^  w 
0 0 '+
>
1
ïI
I
g
I
g
C
CO
Eo
s
I
g
1
I
£
Chapter 6 -  Persistent Influenza Infection in an Immunocompromised Host
6.4.6 Cloning of GS1 and GS10 to Determine the Quasispecies
To investigate the population dynamics of the GS viruses, a series of cloning 
experiments were performed. The HA1 of GS1 and GS10 was amplified and 
cloned. Clones were produced for both GS1 and GS10 and then the HA1 gene 
contained within each clone was amplified and sequenced. Nucleotide and amino 
acid alignments were constructed and analysed for the presence of residue 
changes. In total, seventeen clones were analysed, eight GS1 and nine GS10 
clones. The data demonstrated that there was greater heterogeneity within the 
HA1 sequence of the GS1 clones compared to GS10 (Table 6.8; Appendix 25 and 
26). Mutations were broken down into different categories; transition, transversion, 
synonymous and non-synonymous. The occurrence of mutations within 
antigenically important regions i.e. antigenic sites was also noted. In general, 
mutations of all categories occurred more frequently within the GS1 clones that 
GS10. Within the antigenic regions, there was a predominance of non- 
synonymous (coding) changes over synonymous. When amino acid changes were 
calculated as a percentage of the total site available for change (279 non-antigenic 
and 68 antigenic residues) this was confirmed. Within the GS1 and GS10 clones, 
non-synonymous mutations occurred in 11.8% and 4.4% respectively of the 
residues available compared to 9% and 2.9% of non-antigenic residues for GS1 
and GS10 respectively.
From the sequence alignments produced for each set of clones, it was possible to 
confirm the presence of mutations initially found during the original sequencing of 
the GS viruses. The mutations of interest were His75Asn (GS10) and Val196Ala 
(GS7, GS8, GS9 and GS10), both mutations were located within antigenic sites of 
the HAI molecule. Sequence analysis of the GS1 clones revealed that none of the 
clones contained either mutation. All the GS10 clones were found to contain both 
mutations (Figure 6.5; Appendix 25 and 26). This suggested that the Val196Ala 
mutation was fixed within the viral population. In a series of additional experiments 
performed by J. Ellis (Respiratory Virus Unit, CPHL), a limiting dilution of GS10 
was made and PCR amplification and sequencing performed on the resulting 
material. Results demonstrated that at the end point of PGR detection, the viral 
species found contained the Val196Ala mutation illustrating the dominance of this 
sequence.
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TABLE 6.8 Sequence diversity of HA1 within GS1 and GS10 clones
Number of Changes
Clone N Total Ts Tv Syn N-Syn
Ant Non-Ant Ant Non-Ant
GSl 8 49 32 17 2 13 8 26
GS10 9 13 12 1 0 2 3 8
Total 17 62 44 18 2 15 11 34
Sequence changes within each set of clones were compared to the sequence of the original 
virus isolate of GS1 and GS10. N -  number of clones; Ts -  transistion; Tv -  transversion; 
Syn -  synonymous; N-Syn -  non-synonymous; Ant -  antigenic region; Non-Ant -  non- 
antigenic region.
FIGURE 6.5 Amino acid sequence of the HA1 region of (A) GS1 and (B) GS10 clones
A
GSl
GSl CLONE 1 HAI SEQ 
GSl CLONE 2 HAI SEQ 
GSl CLONE 3 HAI SEQ 
GSl CLONE 4 HAI SEQ 
GSl CLONE 5 HAI SEQ 
GSl CLONE 6 HAI SEQ 
GSl CLONE 7 HAI SEQ 
GSl CLONE 8 HAI SEQ 
GSl CLONE 10 HAI SEQ
S T D S D Q T S L Y V 3 A S G R V T V S
1
190
1
1
200
S T D S D Q T S L Y V Q A S G R V T V S
B
GS 10
GSIO CLONE 1 SEQ HAI
GSIO CLONE 2 SEQ HAI
GSIO CLONE 3 SEQ HAI
GSIO CLONE 5 SEQ HAI
GSIO CLONE 6 SEQ HAL
GSIO CLONE 7 SEQ HAL
GSIO CLONE 8 SEQ HAI
GSIO CLONE 9 SEQ HAI
GSIO CLONEIO SEQ HAI
S T D S D Q T S L Y
S T D S D Q T S L Y  
. . E ...........
3 A S G R V T V S T
200 
 I___
3 A S G R V T V S T
Clones were aligned to the sequence of the original GS1 or GS10 virus isolate. Only 
residues 186-206 of the HAI region are displayed. Amino acid residue 196 is boxed to 
demonstrate the heterogeneity between, and the homology within, the two sets of clones at 
this position. See Appendix 25 and 26 for complete HAI alignments.
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6,4.7 Evolution of the M1, M2 and HA1 Originating from the GS Viruses
The rate of nucleotide and amino acid changes for the GS viruses and field strains 
isolated over the study period was calculated for the M1, M2 and HA1 proteins 
Tables 6.9 to 6.11). The rate of change of Ml was calculated for the GS and field 
strains using the methods described in Chapter 5 (page 161). The results showed 
that the field strains had undergone much greater evolutionary change in respect 
to both nucleotide and amino acid over the study period compared to the GS 
viruses. It seemed that there was an unusually high rate of change within both the 
GS and field viruses (Table 6.9). The number of GS viruses available for this 
analysis was restricted to five isolates. The relatively small number of samples 
'within both data sets may have influenced the overall values for rate of change 
calculated for M l.
TABLE 6.9 Rate of change of Ml (amino acid and nucieotide) for GS and fieid isolates
Virus N Total nt/site/year Total aa/slte/year
GSl -  GS9* 5 8.8x10® 3.9x10®
Field Isolates** 11 21.6x10® 14.1 xIO®
* The GS viruses used for M1 analysis were GSl, GS1B, GS3, GS5 and GS9. ** Fieid isolates 
were A/Thess/1/95-iike in antigenicity. N -  number of viruses.
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The rate of change of M2 from the GS and field strains was calculated (Table 
6.10). Values were much lower than those calculated for M l.
TABLE 6.10 Rate of change of M2 (amino acid and nucleotide) for GS and fieid isolates
Virus N Total nt/site/year Total aa/slte/year
GSl -  GSIO 12 0.09x10^ 0.2x10'^
Field Isolates* 12 0.1 x IO^ 0.08x10-3
Field isolates were A/Thess/1/95-iike in antigenicity. N - number of viruses.
The rate of change of the HAI region of the GS and field strains was calculated 
(Table 6.11). A selection of data from previous studies was included to enable 
further comparisons (59, 96). The rate of change of the field strains from all three 
studies was comparable. When the values for the GS viruses were analysed it was 
apparent that there were elevated levels of change compared to the field strains. 
This was especially noticeable for the amino acids, which were evolving at a rate 
of 13.15 X 10’  ^ residues per site per year (Table 6.11). This represented an 
increase in excess of two-fold between the rate of amino acid change within the 
GS viruses and the field strains from the present study.
TABLE 6.11 Rate of change of HA1 (amino acid and nucleotide) for GS and field isolates
Sample Period of 
Circulation
N Total
nt/slte
Total
aa/slte
Reference
H3N2 1968-1994 183 3.65x10-3 5.83x10-3 (59)
H3N2 1984-1996 254 5.7x10-3 9.7x10-3 (96)
Field Isolates* 1995-1996 20 4.45x10-3 4.42x10-3 Present study
GSl -  GSIO 1995-1997 12 6.56x10-3 13.15x10-3 Present study
Field isolates were A/Thess/1/95-iike in antigenicity. N - number of viruses.
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6.5 Discussion
The above case study presented an ideal opportunity to study the progression of a 
persistent influenza infection. As previously stated, to our knowledge this 
represented the longest documented period of persistence, twelve influenza A 
viruses were isolated and characterised over an eighteen-month period.
6.5.1 Phenotypic Analysis of GS Viruses
The phenotypic characterisation of the GS viruses by susceptibility EIA and plaque 
reduction assay revealed that the viruses isolated seemed to be composed of 
different drug susceptibilities (Figure 6.2 and Table 6.2). The first two isolates, 
GSl and GSl A were amantadine-sensitive by both methods. However, the period 
of amantadine treatment coincided with a reduction in susceptibility to the drug. 
Amantadine treatment was initiated prior to the time that GSl A and GS1B were 
isolated but phenotypic analysis seemed to suggest that although isolated on the 
same day, these two viruses differed in their susceptibility to amantadine being 
sensitive and resistant, respectively. The available data showed that the presence 
of drug treatment had resulted in an overall reduction in amantadine susceptibility. 
The generation of amantadine-resistant populations as a direct result of 
amantadine treatment has been previously documented. The rate at which 
resistant viruses were isolated in the present study was extremely quick. Clinical 
details showed that amantadine had been administered on 29/06/95 lasting for ten 
days. GSl A and GS1B had been isolated from samples taken from the patient on 
30/06/95. Therefore, it had only taken approximately one day of amantadine 
treatment to reduce the overall susceptibility of the virus population to the drug, 
apparently rendering the viruses resistant. This finding illustrated the major 
problem in using amantadine or rimantadine in the clinical treatment of influenza A 
infections. The generation of a resistant virus population was almost immediate 
and it was maintained for a prolonged period even without the selective pressure 
of drug.
There were several GS isolates (GS3, GS5 and GS8) that had negative values for 
reduction in PFU/ml (Table 6.2). These results suggested that virus yield had 
increased in the presence 1.0 pg/ml amantadine. The most striking result was that
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of GS8, which demonstrated a relative increase in PFU/ml of over thirty percent in 
the presence of amantadine. The reasons behind this phenomenon were not clear; 
there have been no similar reports to the findings made here. However, results 
from the amantadine susceptibility screening of UK influenza A isolates 
demonstrated similar findings (Table 3.7, page 75). From these findings it was 
hypothesised that the dissociation of the M1/RNP complex could occur at higher 
pH to compensate for the biochemical effects of amantadine. This could also have 
explained the results found in the GS viruses. It seemed that in chronological 
order, the three viruses (GS3, GS5 and GS8) displayed increasing negative values 
(Table 6.2). This may have indicated that over the study period, variants carrying 
M1 species with the ability to compensate for the antiviral effect of amantadine 
accumulated producing the above results. The implications of some of these 
findings were that the amantadine-resistant GS viruses had heterogeneous growth 
properties. The mean plaque sizes of each virus grown in the presence and 
absence of drug were measured (Table 6.2). This highlighted an apparent 
reduction in the size of plaques from highly sensitive viruses suggesting that the 
growth potential of the virus in addition to the PFU/ml was reduced in the presence 
of amantadine. Plaques isolated from viruses with negative PFU/ml values, grown 
in the presence of amantadine, seemed to be similar in size to those plaques 
grown without drug. This suggested that these resistant variants were able to 
maintain viral growth in the presence of drug possibly demonstrating adaptation to 
the conditions.
6.5.2 Genetic Characterisation of M2
Sequence analysis of the M2 protein originating from the GS virus isolates 
demonstrated the emergence of an amantadine-resistant genotype. When these 
data were analysed in parallel with clinical details, there was a correlation between 
the course of amantadine treatment administered after the initial diagnosis of 
influenza and the appearance of a population of resistant viruses. Therefore, it 
was apparent that the treatment with amantadine had been sufficient to provide 
the pressure required to select resistant variants within the host. The emergence 
of the resistant virus population was rapid; GS1B, genetically characterised as 
resistant, was isolated within a few days of the initiation of drug treatment. These 
findings supported results from other studies that have reported the rapid
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Vemergence of drug-resistance in patients undergoing amantadine and rimantadine 
treatment (147,193).
The nature of the mutations occurring within the M2 transmembrane domain was 
consistent with previous reports defining the changes required to confer 
amantadine-resistance to the virus (118, 142). The most frequent mutation was 
Ser31Asn (7/12), which provided further evidence for the common nature of this 
mutation within amantadine-resistant human influenza A viruses and supported 
results from Chapter 4 and previous studies (90, 144, 147, 166, 417). However, 
sequencing M2 of the remaining sequential GS isolates illustrated the 
heterogeneity of the virus population in respect to amantadine-resistance. The 
Ser31Asn mutation in GS1B, the first resistant virus isolated, was not fixed 
throughout the remaining viruses. Other mutations included Val27Ala (3/12) and 
\Ala30Thr (1/12), similarly these mutations had been previously described in 
human viruses resistant to amantadine (147,166,193, 238). In addition, there was 
no temporary fixation of mutations, i.e. specific mutations emerged, were 
superseded by another mutation and then were seen to re-emerge as the 
dominant genotype at a later stage of the infection; there seemed to be random 
selection of the resistance genotypes.
Following the emergence of a resistant viral population within GS, it was 
interesting to note that this genotype was maintained in the absence of any 
selective pressure from the drug. Eighteen months after drug treatment, GS was 
still shedding resistant virus. The implication of this finding was that once the 
resistant genotypes had become dominant within the viral quasispecies, they were 
able to survive and possibly outcompete the wild-type sensitive viruses. It has 
been previously documented in certain animal models that amantadine-resistant 
viruses are unaltered in virulence and growth characteristics compared to sensitive 
viruses (22, 350); the results from this study support these findings. Once 
established, the resistant variants remained dominant demonstrating that in the 
absence of the selective pressure they remained at a selective advantage over the 
sensitive genotypes.
In some isolates, mixtures of sensitive and resistant genotypes were discovered 
e.g. GS2, GS3 and GS6 (Table 6.3). It was hypothesised that because GS2 and 
GS3 were isolated during and immediately after the amantadine treatment
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respectively, they would contain a higher proportion of sensitive genotypes. When 
the correlating plaque reduction assay and drug susceptibility-EIA data were 
analysed (Figure 6.2), it appeared that GS2 demonstrated an increased 
susceptibility to amantadine compared to other resistant viruses subsequently 
isolated. This finding supported the sequencing data, it appeared that in the short 
period between initiation of drug treatment and isolation of GS2, there had been 
insufficient time for the resistant population to become completely dominant and 
sensitive genotypes could still be readily detected. GS3 also contained a mixed 
population of resistant and sensitive genotypes but the overall drug susceptibility 
of the virus by plaque reduction assay and the susceptibility-EIA was low. 
Although mixed genotypes were found in GS3, overall there might have been a 
higher proportion of resistant variants that would have reduced the susceptibility 
as detected by plaque reduction and EIA. The mixed populations of genotypes 
found in this study are supported by previous work that determined that once drug- 
resistant virus has emerged from a subject, the genotype of subsequent isolates 
remains resistant or comprises a mix of resistant and sensitive viruses even in the 
absence of drug treatment (22).
In order to determine the population dynamics of heterogeneous populations of 
sensitive and resistant variants, it would be interesting to perform a competition 
study. After co-infecting cell monolayers with known amantadine-resistant and 
sensitive viruses the progression of infection could be monitored. At time periods 
throughout the infection, samples could be taken to estimate the proportion of 
genotypes present within the culture. This type of experiment would provide data 
concerning the competition between resistant and sensitive genotypes under 
“normal” growing conditions. To simulate the present case study, amantadine 
could be introduced to the cell system and the effect of the selective pressure on 
the population dynamics monitored. The data would provide an indication of the 
delicate balance between resistant and sensitive genotypes in a mixed population 
of virus. The addition of amantadine would also reveal how that balance would 
change with the selective pressure introduced, whether the resistant genotype 
would dominate or mixed populations could still be readily detected.
The heterogeneity of the M2 transmembrane domain from the GS isolates was 
evidence for the presence of quasispecies within the host. This supported previous 
studies that had reported similar findings (193, 304). The genetic variability
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observed was probably a reflection of the fluctuations within the viral quasispecies, 
i.e. there was continuous competition between variants. The results also 
demonstrated the heterogeneity within the resistant strains. Even though the 
pressure from amantadine treatment had selected a resistant population, there 
was still significant heterogeneity of variants carrying different resistance traits. 
This was especially evident within GS3 where a mixture of resistant variants was 
found carrying Ala30Thr and Ser31Asn mutations. This demonstrated that at any 
one time there were mixed populations of resistant variants within the viral 
quasispecies.
An interesting observation was made concerning viruses that were isolated from 
different anatomical sites at the same time. On three separate occasions viruses 
were isolated on the same day. GS1 A and GS1B were isolated from a nose swab 
and gargle and were characterised as amantadine-sensitive and -resistant, 
respectively. GS4 and GS5 were isolated from a gargle and nose swab and were 
found to carry different mutations within the M2 transmembrane domain, Val27Ala 
and Ser31 Asn respectively. The final pair of viruses, GS7 and GS8  were isolated 
from separate gargle samples taken on the same day but these two viruses 
shared complete sequence homology of the M2 transmembrane domain. It 
appeared that viruses isolated from different sample sites were genotypically 
different in respect to M2. It was difficult to explain these findings, but it was 
hypothesised that the most logical reason was the presence of quasispecies within 
the host. Sampling and PCR amplification had simply detected different variants. 
Alternatively, it was postulated that variants with different drug genotypes might 
have been restricted to different sample sites. It has been previously reported that 
amantadine-resistant viruses with different mutations within the M2 
transmembrane domain potentially have different growth rates (118). It is possible 
That resistant viruses carrying different mutations may also demonstrate some 
form of cell tropism as a result of varying growth and replication rates. Although 
there has been no reported evidence for this theory, the idea of 
compartmentalisation of HIV-1 virus has been documented (1, 15, 293, 367). It 
has been shown that resistance to zidovudene (ZDV) exhibited by HIV-1 can be 
heterogeneous between different organ or tissue systems due to the increased 
replication rate of the virus that allows the generation of a greater number of 
variants (15). Similarly, it has been reported that the distribution of HIV-1 variants 
carrying different point mutations within certain organs or tissue types can vary
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(15). It would be interesting to perform an experiment to assess the potential 
compartmentalisation of different amantadine-resistant genotypes. Theoretically, 
This could be achieved by using an animal model. The animal would be infected 
with a known population of mixed sensitive and resistant genotypes and after a 
given period, tissue samples from various sites could be isolated and virus 
extracted to assess the genotype of the variants. This type of experiment could 
provide evidence for this phenomenon occurring in influenza. Alternatively, if 
disproved, then it would appear that the presence of quasispecies and random 
amplification and sequencing of different variants would explain the above results.
6.5.3 Evolution of GS and Field Strain Ml and M2
The rate of change of Ml and M2 isolated from the GS viruses, and a selection of 
field strains that had been circulating over the study period was calculated. Values 
gained for Ml appeared to be high for both the GS and field strains compared to 
previous findings from the present study (Chapter 5, page 165) and other 
published results (175). This might have been the result of a smaller number of 
viruses analysed. The rate of change of Ml in the GS viruses was lower when 
compared to the rate in the field isolates. It was possible that this was supporting 
evidence for the severely suppressed immune system in GS. Ml has been shown 
to be the target of cytotoxic T lymphocytes in the immune response, therefore if 
the immune system in GS was compromised, the immune pressure on Ml would 
not be as significant as Ml from the field isolates (116, 176, 296). The rate of 
change of M2  from both GS and field isolates was similar but lower than previous 
results from this study and others (175). It was unclear to why these values were 
lower but it was possible again that the small number of viruses analysed might 
have biased the results.
6.5.4 Antigenic Characterisation of GS Viruses
The antigenic profile of each GS virus was assessed. Results obtained strongly 
suggested that antigenic drift had occurred from GSl to GS10. Under normal 
conditions, the pressure from the host immune system exerted upon the surface 
glycoproteins of the influenza virus drives changes in the form of nucleic acid and
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amino acid mutations (59). This gradual process results in the drift of the virus that 
can be detected by cross-reacting with antisera raised against specific antigenic 
types of virus (performed by HAI). Typically, a fall in titre of approximately four-fold 
indicates antigenic drift has occurred. HAI studies on the GS viruses had 
demonstrated the GS10 had an eight-fold reduction in end-point titre with 
A/Thess/1/95 when compared to GSl (Table 6.4). Therefore, it appeared that over 
the eighteen-month study period, GSIO had significantly changed in its antigenicity 
when compared to the first virus isolated (GSl). Analysis of the GS serum 
samples had provided evidence that there had been very little humoral immune 
response to the influenza infection. Specific and neutralising antibody could only 
be detected at very low levels in certain samples and was below the threshold for 
detection in others. Analysis of the clinical details of GS revealed that throughout 
the study period, several courses of immunoglobulin (IgG) had been administered 
to GS, presumably in an attempt to boost the immune system. It was hypothesised 
that this could have resulted in certain serum samples having slightly elevated 
antibody titres. For example, analysis of the neutralising potential of the GS serum 
samples revealed that GSg had elevated antibody titres compared to the other 
samples (Table 6 .6 ). When the following serum sample (GSh) was tested, the titre 
of antibody had fallen to a level that was barely detectable with the 
microneutralisation assay. It was possible that the GSg sample had been taken 
immediately after an IgG booster, which might have influenced the results. It was 
concluded that the data from the neutralisation and HAI testing of serum provided 
evidence that within GS there was minimal selective pressure from the humoral 
immune system.
Therefore, the immunological evidence had shown that antigenic drift had 
occurred from the isolation of GSl to GSIO, a period of eighteen months. There 
was strong evidence that the immune system of GS was severely depleted i.e. 
,CD4 undetectable, and that a minimal response had been raised against the 
influenza H3N2 infection. Antigenic drift had been observed in a system that 
lacked the driving force of immune pressure. This was an extremely interesting 
observation. The only other reported case similar to this involved persistent 
infection of a H3N2 virus in an immunocompromised host (244). Similarly, the 
virus was observed to drift, in this case from an A/Wuhan/395/95-like to 
A/Syd/5/97-like strain over the period of infection (twelve months). It was 
postulated that the drift was driven by humoral immunity. However, it cannot be
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excluded in this case that the patient was reinfected with a virus of differing 
antigenicity. The pattern of viral drift mirrored changes that had occurred within the 
community during the period of infection. In addition, there was a transition phase 
where an accurate antigenic profile of the virus had not been possible. Therefore, 
an alternative explanation for these findings could be that the host had acquired a 
nosocomial influenza infection from the community when the antigenicity of the 
circulating virus had drifted to the novel form. This would have resulted in the 
observed results, implying that the virus had drifted within the host.
This was a serious consideration for the GS viruses, that the persistent infection 
might have actually been composed of several separate infections. To prove that 
the drift within GS was not caused by the acquisition of a novel infection, a chart 
illustrating the antigenic subtypes of community-acquired influenza during the 
1995-1999 influenza seasons was constructed (Figure 6 .6 ). The HAI of the GS 
viruses had shown that they were A/Thess/1/95-like in profile. Although there was 
evidence to show that GSIO had drifted, it had remained more A/Thess/1/95-like 
Than A/Wuhan/359/97-like (Table 6.4). When this data was compared with Figure 
6 .1 2 , it could be seen that GSIO had been isolated at a time when the virus 
circulating the community was A/Wuhan/359/97-like. However, it had been shown 
that GSIO was more antigenically related to A/Thess/1/95, evidence that GSIO 
was not the result of reinfection, but was the end result of a strain that had drifted 
from GSl. This was further ruled out by the presence of the drug-resistant 
phenotype and genotype in GSIO. This characteristic is very rare in natural 
isolates and was supported by the drug susceptibility screening of the 1995/96 
influenza season, there were no naturally occurring amantadine-resistant viruses 
detected within the UK (Chapter 3, page 72).
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Sequencing the HA1 region of the GS viruses and other field and prototype strains 
had revealed amino acid changes at certain positions between the A/Thess/1/95- 
like and A/Wuhan/359/95-like strains. Previous reports have defined antigenic drift 
variants to differ by at least four amino acid changes within two antigenic regions 
(59). The A/Wuhan/359/95-like viruses contained two to three amino acid changes 
located in antigenic sites when compared to A/Thess/1/95. Therefore, although the 
sequence changes between these two prototype viruses did not fit with the 
definition of drift variants, it had demonstrated that over the time that the two 
viruses had been isolated, changes had occurred resulting in the formation of the 
drift variant (A/Wuhan/359/95). Compared to the sequence of A/Thess/1/95, GSIO 
contained two amino acid mutations within antigenic regions demonstrating the 
apparent drift that had occurred within the GS viruses culminating with this final 
isolate. Therefore, the molecular data appeared to confirm the findings from the 
HAI testing of the GS viruses.
Within the GS viruses, HAI sequencing had revealed a mutation (His75Asn) in the 
last virus isolated (Figure 6.4). His75Asn was located within antigenic site E but it 
was difficult to postulate the significance of this mutation because there was no 
evidence that it had been fixed within the virus population. To investigate this 
further, viruses isolated after GSIO would have provided the evidence required to 
assess the importance of the mutation. The two amino acids differed in their 
structures quite considerably. His is positively charged and Asn is uncharged 
(314). The size of His and Asn was similar, 155 and 132 Daltons respectively but 
the side groups attached to each residue differed. His is associated with a basic 
side group and Asn with an amide (314). It was postulated that this His75Asn 
mutation, occurring within an antigenic domain of HAI would have the potential to 
cause change within the protein. There were no viruses isolated after GSIO and 
therefore it could not be determined whether the mutation had been fixed. If there 
had been evidence to show fixation of the mutation within the virus population, it 
may be concluded that the difference between the two amino acid residues might 
have been sufficient to cause changes within the receptor-binding site to affect 
virus function.
The HAI sequencing had revealed the presence of another mutation that occurred 
in a region of antigenic importance (Figure 6.4). Sequencing the HAI region of the 
GS viruses revealed a fixed mutation (Vail 96Ala) in the last four viruses isolated.
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This mutation was known to be located within the site of a series of conserved 
residues that constituted an antigenic domain (393). Due to the location of this 
mutation it was hypothesised that some function of the virus, e.g. affinity for host 
cell receptors or antibodies, might have been affected. Both Val and Ala are non­
polar, hydrophobic molecules with aliphatic side chains and of 117 and 89 Daltons 
in size respectively (314). Therefore, the two residues are very similar in character 
and it was concluded that the Val196Ala mutation would not have caused major 
structural changes to the HAI region.
The receptor binding properties of the viruses with and without Val196Ala were 
assessed. It seemed that the viruses carrying the mutation had reduced affinity to 
bind to chick erythrocytes. It was postulated that this provided evidence that the 
mutation had affected the function of the virus in respect to its binding properties. 
Although it had been concluded that the similar natures of the two amino acids 
involved would not cause significant structural changes within H AI, it appeared 
that the mutation had been sufficient to affect the protein function. The fixation of 
Val196Ala from GS7 to GslO implied that the presence of the mutation had 
conferred a selective advantage. It was postulated that if the mutation had been 
detrimental, Val196Ala variants would have been lost in the viral quasispecies 
because they represented an evolutionary “dead-end”. If this had happened, the 
mutation may have been evident within GS7 but would not have been detected in 
the next three sequential viruses. To determine whether the mutation was actually 
fixed, and not an artefact of the amplification process randomly selected and 
sequenced, data from the HAI cloning was analysed. Each clone of GSl was 
found to have the wild type Val residue at position 196 and all GSIO clones carried 
the mutation (Figure 6.5). The receptor binding study had also shown that GS7 
differed slightly from the other three viruses carrying the Val196Ala mutation in its 
ability to agglutinate chick erythrocytes. It was postulated that GS7 might have 
represented a transition state where there was a mixture of wild-type and mutant 
variants within the viral quasispecies. If the mutants were at a selective advantage 
over the wild-type then the proportion of variants carrying the Val196Ala mutation 
would have increased until GS8  where the majority would have carried the 
mutation. This would have accounted for GS7 retaining the ability to agglutinate 
despite carrying the mutation.
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The selective advantage that the Val196Ala mutation conferred to GS7, GS8 , GS9 
and GS10 is difficult to explain. It had been demonstrated that the potential for 
receptor binding had been reduced but it was not clear how this change in function 
could carry a selective advantage to the virus. The alteration in receptor binding 
capacity of the last four GS viruses might have been related to the adaptation of 
the viruses to the localised environment within GS. The mutations may have 
increased the specificity of the HA molecule to host cell receptors, allowing the 
virus to increase the rate at which attachment and penetration into host cells 
occurred. This mutation may also have enabled the virus to persistently infect the 
patient. In certain influenza viruses it has been postulated that mutations or 
variation within certain genes allow the virus to maintain a persistent infection 
(208, 234). Therefore, it was possible that this mutation within the HA1 region of 
the later GS viruses, had in some way permitted the virus to maintain the infection.
Alternatively, it is possible that a change within this region of antigenic importance 
could have affected some aspect of antibody binding to the protein. Although it 
had been shown that antibody levels were very low and clinical details had 
revealed a very low CD4 count within GS, quantitative analysis of other 
components of the immune system, e.g. T cells, killer cells, neutrophils etc. was 
not possible. It was postulated that a mutation within antigenic site D might have 
enabled the virus to escape detection from one of the above immune components. 
In support of this theory is evidence that demonstrates the presence of possible 
epitopes for T lymphocytes within the HA1 region. Several distinct overlapping 
epitopes have been mapped to HAI residues 56-76, 71-91, 81-97, 177-199, 186- 
205 and 206-227 (18, 42). Within the 177-199 region, changes of single amino 
acid residues at positions 198 and 199 have been shown to cause differences in T 
cell recognition (19). Therefore, these data provide a possible explanation for the 
fixation of Val196Ala. It was possible that the mutation enabled the virus to escape 
recognition by T lymphocytes. Within GS, T cells may have provided the only form 
of immune response. Therefore, the acquisition of this mutation would have 
provided a distinct selective advantage over other variants within the virus 
population. This might have explained why this particular mutation was fixed in 
subsequent viruses over a period of at least twelve months. Interestingly, the 
His75Asn mutation described in GSIO was also located within a T lymphocyte 
epitope (residues 56-76). Although it had been postulated that this mutation was 
relatively severe in respect to differences between the His and Asn residues and
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therefore may have affected virus function, if it enabled escape from T lymphocyte 
detection it would have been advantageous to the virus. This might have resulted 
in the fixation of this mutation in the virus population and would have been 
detected in subsequent isolates after GS10 if they had been available for analysis.
The cloning of the first and last GS viruses confirmed the absence and presence 
of Van 96Ala in antigenic site D of GS and GS10 respectively. Further analysis of 
the cloning work enabled conclusions to be drawn concerning other areas of the 
work. It was hypothesised that over the period of the persistent infection, changes 
within the overall viral quasispecies would occur. It had been demonstrated that 
there was minimal immune response to the virus and therefore there was low 
selective pressure slowing the progression of infection. Without this restriction, the 
GS viruses had the opportunity to replicate at elevated levels, speeding up the 
overall rate of change of each virus over the persistent infection. Evidence for this 
was generated when the rate of change of HA1 for the GS viruses and field strains 
representing A/Thess/1/95-like viruses circulating the community at the time of 
infection was calculated (Table 6.11). It was apparent that the rate of change of 
nucleotides and amino acids was much higher within the GS viruses compared to 
field strains and other published rates (59, 96). It was concluded that this was 
evidence to suggest that the elevated rates of change in the GS viruses were as a 
consequence of the depleted immune system of the host. From this, it was logical 
to postulate that increased replication rates would have given rise to the 
generation of greater numbers of variants within the viral quasispecies, especially 
in the later GS viruses. However, the cloning work demonstrated that GSl 
contained more sequence variation than GSIO in respect to HAI homology 
between clones (Table 6 .8 ). There were several possibilities to explain the results 
presented here.
The unrestricted progress of the persistent infection might have led to a situation 
where competitive selection occurred between variants. This had previously been 
observed within other virus populations (290). The high rates of replication and 
competition within the viral quasispecies might have led to the emergence of a 
variant with increased fitness and demonstrating optimal adaptation to the 
environment. When sampled, this virus population would appear to be less 
heterogeneous in nature due to the selection of highly adapted variants. 
Therefore, it seemed that GSIO might have represented a virus population with
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increased fitness when compared to GS1. There was strong evidence to show that 
GS10 had a modified antigenic profile compared to GS1. HAI data demonstrated 
that the GS10 virus had an end point titre eight-fold lower than GS1 when reacted 
with the GSl antiserum. Additionally, when the GS1 0  antiserum was cross-reacted 
with the GS viruses, poor titres were observed, supporting the idea that GS1 0  was 
significantly different to the other GS viruses. Further evidence to support this 
Theory came indirectly from HAI testing of the GS viruses. To create the ferret 
antisera required for the test, two preparations of virus (GS1 and GS10) were 
prepared and inoculated intranasally into separate ferrets. Both viruses had been 
prepared to ensure that the inoculums contained approximately the same dose of 
infectious particles. Upon harvesting the sera it was found that the GS1 virus had 
invoked a good response in the ferret. When the GS10 antiserum was tested there 
was no antibody detected by HAI. A modified preparation of virus, containing 
approximately sixty times the dose of GS10 was inoculated into another ferret and 
the resulting serum harvested was shown to have higher levels of antibody than 
the first GS1 0  serum produced, but compared to GS1 the response to the virus 
had been poor. It was postulated that this could have been evidence of the 
adaptation of GS1 and GS10 to the environment within GS. It appeared that GS1 
was able to replicate efficiently within the ferret producing a good immune 
response as shown by the antibody titre within the respective antiserum. The 
evidence suggested that GS10 was highly adapted to the selective environment 
within GS to such an extent that when presented with novel conditions, the virus 
failed to thrive and could not raise a strong immune response within the ferret. 
This form of extreme fitness differences between hosts has been reported for 
other viruses but there are no available data for influenza to compare the above 
findings with (263).
A series of future experiments were designed to study the relative fitness of GS1 
and GS10. It was proposed that simple growth curves of the virus in cell culture 
could be obtained initially to demonstrate any differences in growth rate between 
the viruses. Conditions for replication, e.g. temperature and cell line could be 
altered to see if the either virus was more efficient at replicating under certain 
growth conditions. In another experiment, it was proposed that GS1 and GS10 
would be reinoculated into ferrets. The condition of each animal would be closely 
monitored and regular samples taken for analysis would provide evidence of the 
relative replication rates of each virus within the ferret. It was hypothesised the
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results would show that GS1 had the potential to Initiate a strong Infection and 
GS10 would struggle as demonstrated by the symptoms presented by, and the 
overall condition, of each respective animals. However, the result might be 
misinterpreted as a direct effect of the mutations conferring amantadlne-reslstance 
within GS10. The failure of GS1 0  to cause disease within the ferret might be 
construed as a result of the reduced virulence caused by amantadlne-reslstance 
rather that the hypothesis that GS10 was highly adapted to Its host, GS. 
Therefore, It would be Interesting to Infect an additional ferret with GS1B. This 
virus had been Isolated early In the GS Infection but had the same resistance 
mutation as GS10 (Table 6.3). Previous evidence has documented the ability of 
amantadine-resistant viruses to Infect ferrets and cause typical Influenza (350). 
Therefore, If GS1 B caused Infection and disease similar to GS1, this would 
provide strong evidence that the lack of virulence shown by GS10 was as a result 
of the extreme fitness difference between GS1 and GS1 0 .
In order to Isolate the effect of the amino acid mutations present within the HA1 
region of GS10 (Hls75Asn and Val196Ala), a simple reverse genetics procedure 
could be employed to create a chimeric virus. The entire HA gene of GS10 could 
be transfected with the remaining gene segments of GS1 Into a mammalian cell 
line according to methods already published (105, 358). The resulting virus 
rescued from culture could then be either Inoculated Into ferrets or tissue culture to 
compare the relative fitness to the original GS1 and GS1 0  virus. These 
experiments would provide evidence for the HA1 mutations conferring a fitness 
advantage to GS7, GS8 , GS9 and GS1 0 .
One major factor that had to be considered In the molecular population analysis of 
GS1 and GS10 was the effect of Taq polymerase (Taq) on the results. It has been 
shown that Taq can cause substitution errors due to the lack of proof-reading 
mechanisms within the molecule (338). It has been estimated that the error rate for 
Taq can range from 0.2 to 2.0 x 10 "^ errors per base pair per cycle (227, 312). In a 
cloning study of vesicular stomatitis virus (VSV), Bracho et al. (1998) 
demonstrated that during the molecular cloning of a PCR product and sequencing 
of recombinant plasmids, the Taq enzyme used In the PCR amplification 
Introduced errors at a rate of 0.27 x 10'"^  mislncorporatlons per base pair per cycle 
In addition to mutations present In the natural virus population (36). Therefore, It 
can be concluded that If the nucleotide substitution rate of a virus was similar or
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lower than the misincorporation rate of the DMA polymerase used in PCR 
reactions, the genetic analysis of the population variables could be affected by 
such errors. In addition to errors originating from the polymerase molecule, errors 
produced during the reverse transcription of the virus can occur at a frequency of 
approximately 1 x 10'"^  (333). Combined with Taq errors, it has been estimated that 
during a 30 cycle PCR of a 300 base pair product, approximately 0 . 2  to 2 
spontaneous artefactual substitutions will occur (333).
A potential approach to reducing the rate of artefactual substitutions during 
molecular population studies is to use an alternative polymerase molecule with a 
lower error rate that Taq. One such thermostable enzyme, Pyrococcus furiosus 
polymerase (Pfu) has been reported to reduce the error rate by up to 90 percent, 
significantly reducing the variability of clones and the number of mutations 
Including both synonymous and non-synonymous changes (227). To enable a 
direct comparison of the fidelity between Taq and Pfu, the error rate of Pfu has 
been estimated to be between 1.3 x 10 ® and 1.6 x 10'® errors per base pair per 
cycle (50, 227). Although artefactual substitutions occurring during PCR are 
reduced using a high fidelity polymerase enzyme, errors arising during the reverse 
transcription stage still continue to occur at a frequency of approximately 1 x 1 0 '"^  
(333). Therefore, by using a polymerase molecule with higher fidelity such as Pfu, 
The number of mutations that could be attributed to polymerase errors would 
theoretically be reduced.
Unfortunately, a polymerase molecule with a higher fidelity than Taq was not used 
In the present cloning study. However, Taq has been commonly used In molecular 
biology, and many published studies have utilised this enzyme (337). Although the 
effect of Taq on the results must be considered, there was evidence that It did not 
have a significant effect. For example, GS7 and GS8  had been Isolated on the 
same day from the same sample site and therefore It was likely that they would be 
very similar In sequence. In fact, the sequencing of GS7 and GS8  showed that 
there was complete sequence homology between these two viruses In the HA1 
region and the M2 transmembrane domain (Figure 6.4 and Table 6.3). Therefore, 
this demonstrated that the effects of Taq had not cause the appearance of 
'mutations In viruses that were expected to be very similar In sequence. 
Additionally, the cloning of GS1 and GS10 had shown that the GS1 0  clones had 
little variation within the HA1 region (Appendix 25 and 26). This provided further
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evidence that the effects of Taq within this study had not been detrimental to the 
results.
6.5.5 General Conclusions
In summary, the rapid development of drug-resistant following a short course of 
amantadine treatment Illustrated the limitations of amantadine, especially In the 
Immunocompromised host. It was Interesting to note the apparent selective 
advantage that the resistant population maintained over the sensitive for a long 
period of time In the absence of drug selective pressure. The study revealed the 
presence of complex viral populations undergoing constant fluctuations, possibly 
as a direct result of selective pressures of “Intra-populatlon” competition. This was 
Illustrated by the changing drug genotype found throughout the study period and 
the presence of mixed variants within the virus population. It was hypothesised 
that over the study period, the relative fitness of the viral population. In respect to 
adaptation to the host, had Increased as Indicated by evidence from Inoculation of 
the first and last viruses Into ferrets. This was also supported by antigenic profiles 
of the viruses that Illustrated the gradual changes and accumulation of mutations 
over the study period, antigenic drift.
This work Illustrated the Importance of studying virus population dynamics In 
Individuals, and how the Immunocompromised host represents an Invaluable 
source of data concerning the progression of persistent Influenza Infections.
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7.1 Amantadine-Resistance in Natural Isolates and an Immunocompromised 
Host
This project investigated the emergence and evoiution of amantadine-resistant 
viruses in the UK population and an individuai immunocompromised host. The 
characterisation of each set of resistant viruses revealed some interesting 
features. Resistance within the population appeared to occur sporadically and 
often in clusters. There was evidence from phenotypic, genotypic and phylogenetic 
analyses to suggest that some of these clusters were actually small outbreaks that 
had occurred as a direct consequence of amantadine use. The available data 
suggested that there was no persistence of resistant strains in the population. 
Seasons containing resistant viruses were often foilowed by a season(s) where no 
resistance could be detected. This might have been due to the iack of drug 
selective pressure acting on the resistant viruses, not enabiing them to compete 
with wild-type sensitive strains. However, in the immunocompromised host (GS), 
resistant viruses were maintained in a relatively long persistent infection in the 
absence of any selective drug pressure.
When comparing the evoiution of influenza through changes occurring in antigenic 
regions in the normal and immunocompromised host, it is important to remember 
the selective pressures targeting the viral surface antigens involved in each 
system. In the immunocompetent host, the immune system, consisting of both 
humorai and cell-mediated responses, manages to clear infectious virus from the 
host within 7-10 days after initial infection. Therefore, the time that the virus has in 
the immunocompetent host is relatively limited, it is possibie that the antigenic 
changes required to evade the immune system of susceptible hosts are acquired 
over a number of infectious episodes i.e. mutations are accumulated over time. 
Therefore, it would appear that the evolution within susceptible groups does not 
occur exclusively through individual hosts. Instead, a virus infecting a series of 
susceptibie hosts is exposed to a certain level of immune pressure during each 
infection. This continual pressure selects variants with changes in antigenic 
regions that graduaily alters the overall antigenicity of the virus. This process 
enables the virus to eventually evade immune detection by changing the profile of 
its' antigenic “cloak”.
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In contrast, the immune system present in GS was severely compromised and 
therefore there was no significant clearance of virus from the host, which resuited 
in the persistent infection. Evidence has been gathered to suggest that the 
invading virus was not under any detectable selective pressure, yet evidence for 
apparent antigenic drift within this set of viruses was observed. Unlike the viruses 
circuiating the general population where immune pressure was driving change, in 
GS it was possibie that other forces were causing the observed changes. One 
possible reason for this was the selection of variants that dispiayed more 
adaptation to the host. This couid have selected for variants containing changes in 
receptor-binding sites, altering the affinity for different host-cell receptors, giving 
those variants a selective advantage. This gradual selection of variants could have 
been responsible for the overall changes observed in antigenicity. Therefore, it 
was possible that the hypothesised drive to adapt to the host induced the selection 
of variants that had antigenic changes and gave the appearance of drift, in the 
absence of immune pressure it was thought that the virus would have been able to 
replicate unhindered, as suggested by the rate of evolution determined in the HA1 
region of the viruses. It was thought that this coupled with a continual drive to 
seiect variants most adapted to the host, probably resulted in the observed results. 
It was possible that the overall consequence of this selection procedure would 
have been that the final virus (GS10) wouid have been highly adapted to the host 
when compared to the first isoiate (GS1) that initiated the infection. Evidence to 
support this was seen when the above viruses were inoculated into ferrets; the first 
virus repiicated extremely efficiently but the last virus appeared to struggle, i.e. it 
was highly adapted to GS, but when introduced into a different environment it lost 
the relative fitness gains accumulated over the persistent infection. Therefore, a 
comparison of the two sets of data demonstrated continual and combined host- 
driven immune pressure in the normal population, and interspecies-driven 
competition to adapt to the conditions in the immunocompromised host.
In relation to amantadine-resistance, similar comparisons between the population 
and individual host could be made. In immunocompetent hosts there was little 
evidence for transmission, and thus persistence of amantadine-resistance 
suggesting that resistant variants were at a selective disadvantage. In GS, the 
continued selection of resistance for a long period of time in the absence of drug 
selective pressure suggested that in this situation the resistant variants were not at 
a seiective disadvantage, it was possible that in GS, the proposed higher
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replication rate of the viruses might have enabled the resistant population to 
maintain higher numbers and therefore remain dominant over time. In a host 
where an active immune system suppressed replication, it was possible that this 
selective pressure might have favoured the wild-type sensitive variants resulting in 
a swing back to a sensitive phenotype. In this scenario, it would be interesting to 
perform an experiment to simulate the conditions observed in this study. An 
immunocompetent and immunosuppressed animal model could be infected with 
an amantadine-sensitive influenza virus. A short course of amantadine treatment 
would possibly select a resistant population that could be detected by sampling 
and determining the drug susceptibility of the viruses. The amantadine treatment 
could then be stopped and the progress of infection monitored to see if the 
resistant population reverted back to the sensitive wild-type in either set of 
animals. This type of experiment could also be repeated using two groups of 
susceptible animals, again competent and suppressed to see if transmission of 
resistant strains in the absence of drug results in the virus reverting back to the 
sensitive wild-type. The data that this proposed experiment wouid produce could 
increase the understanding of how immune pressure might affect the selection of 
amantadine-resistant and -sensitive variants.
7.2 Influenza and HIV Antiviral Drug-Resistance
The development of antiviral drugs has revolutionised patient management and 
the treatment of viral diseases including those caused by influenza, HIV, herpes 
and hepatitis viruses. In contrast to the development of a relatively small number 
of influenza antiviral compounds over the past thirty years, there is a broad range 
of drugs availabie for targeting various stages of the HIV replication cycle. 
However, resistance to anti-retroviral drugs of all classes has been documented, 
especially with the nucieoside analogue reverse transcriptase inhibitors and 
protease inhibitors (155). The frequency of amantadine-resistance has been 
estimated to be approximately 1-2% in natural influenza A isolates (85, 417), and 
30-60% in patients undergoing amantadine treatment (147, 238). Although the 
frequency of HIV infection varies considerably world wide, in Europe and the US 
the frequency of HIV drug-resistance it is thought to be in the range of 10-25% (32, 
2 2 1 , 405). This figure is more comparable with influenza A resistance in 
immunocompromised patients. A common factor in these relatively high figures
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might be that patients associated with these levels of resistance generaily have 
depleted immune systems.
There are several similarities between the emergence of drug-resistance in 
influenza and HIV. Both are RNA viruses, undergo rapid genetic change and exist 
as heterogeneous populations (quasispecies). Therefore, both viruses have the 
potentiai to rapidly select drug-resistant mutants and establish resistant 
populations within the host. Studies have provided evidence for the transmission 
of amantadine-resistant influenza variants between hosts (2 2 , 147). Comparative 
studies of amantadine-sensitive and -resistant influenza A viruses have shown that 
in certain modeis, resistant variants potentialiy have equal levels of virulence as 
the sensitive strains (350). The documented transmission of drug-resistant HIV-1 
viruses also suggests that they may also possess equal levels of virulence when 
compared to sensitive populations (155, 172, 370, 405). Multi-drug resistant HiV-1 
strains have also been shown to transmit between hosts (155). It would appear 
however that certain HIV-1 -resistant mutations might reduce the replication rate 
and fitness of the virus (17). Drug-resistant viruses carrying mutations within the 
reverse transcriptase (RT) gene were shown to have reduced RT enzyme activity 
That resulted in the virus having a lower rate of replication. It would appear that this 
form of mutation might reduce the efficiency of transmission and decrease the 
potential for this resistant mutant to spread to other susceptible hosts (17). 
Therefore, transmission of resistant viruses, both influenza and HIV probably 
involves resistant mutants with the highest levels of fitness in respect to replicative 
potential.
The overall implication of transmissible drug-resistant mutants is extremeiy 
worrying from a pubiic health perspective. This could potentially result in 
treatment-naiVe patients acquiring an infection for which there is no effective drug 
therapy avaiiable. Presently, for influenza this only has serious consequences for 
at-risk groups where influenza related mortality is highest. However, if an epidemic 
or pandemic strain possessing the same virulence as seen in the 1918 pandemic 
'was to emerge, drug prophylaxis or therapy would probably represent the only 
method to combat the spread of disease. To imagine that widespread drug 
treatment could result in the appearance of resistant, transmissible strains, 
rendering uninfected hosts susceptible and untreatable, illustrates the seriousness 
of this situation.
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7.3 Virus Ion Channels
The influenza A M2 ion channel represents the most intensively studied of all viral 
ion channeis. From previous work, there is now a good understanding of the 
processes involved in the antiviral activities of amantadine and rimantadine and 
the overali importance of the ion channel in the replication cycle of the virus (142). 
Other viral ion channels studied include the influenza B and C channels, NB and 
CM2 respectively (205, 276). Also, two HIV-1 proteins have been implicated in 
having channel activity, Vpu and Vpr (94, 205, 280).
The presence of an ion channel may highlight the presence of a possible target for 
antiviral compounds, as shown with influenza A and amantadine. However, 
amantadine can oniy inhibit influenza B at millimolar concentrations when the drug 
actually acts as a lysosomaltrophic agent, raising the lumenal pH of intracelluiar 
compartments. Eiectrophysiological studies of Vpu expressed in different cell 
systems have shown that after applying Vpu to bilayers, permeability to selected 
cations was recorded (205). This represents good evidence for the presence of ion 
channel activity associated with the Vpu protein. The function of this protein is to 
regulate the release of virus particles from HIV-1 infected celis (357). Therefore, 
this protein would seem to represent a good target to formulate a compound that 
would inhibit channel activity and therefore limit the reiease of progeny virus 
particles.
7.4 Future Work
Although proposed future work has been outlined in each respective chapter, there 
are some important areas that required completion to finalise parts of the project. 
The finding that some phenotypicaily resistant viruses lacked M2 transmembrane 
mutations requires further analysis. It was proposed that the observed results 
might have been due to the presence of quasispecies within the virus isolates. 
This might have resulted in the RT-PCR amplification of sensitive ampiicons 
instead of resistant. However, it has been previously shown that resistant viruses 
can have a wild-type sensitive M2 protein, compensated by mutations within the 
HA2 molecuie (340). Therefore, it wouid be interesting to sequence the HA2 
region of this set of resistant viruses to see if they possessed this mutation. If it
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were found that some of the resistant viruses did have HA2 mutations, this would 
have important implications. The previous studies were performed using avian 
viruses, where the HA and M2 proteins have a close relationship in the replication 
cycle (346). The viruses sequenced in this study were exclusively human in origin, 
therefore if mutations in the HA2 molecule were conferring amantadine-resistance, 
this might imply that the HA within these viruses had been altered its overall 
.structure or function to behave more avian-like.
It has been previously suggested that the growth potential and virulence of 
amantadine-resistant strains can be dependent on the M2 transmembrane 
mutation conferring the resistance (118, 350). It was proposed that a simple 
reverse genetics system be designed and implemented to clone gene segment 
seven of a resistant virus into a sensitive wild-type virus. The resulting virus could 
be rescued and analysed by growth curve assays in vitro to assess the importance 
of Ml and M2 from resistant viruses in controlling growth. The results from these 
experiments could provide further data to possibly explain why certain M2 
mutations occur commonly in human resistant strains e.g. Ser31Asn, while some 
are extremely rare or cannot be detected e.g. Gly34Glu. This technique could also 
be used to assess the effects of novel mutations found in the present study. These 
mutations have not previously been reported in human influenza A viruses 
therefore data regarding their effect on viral replication and function of gene 
segment would be vital.
Previous studies have demonstrated that different shapes of the influenza virion
i.e. spherical or filamentous can influence the viral yields and plaque sizes of the 
viruses in question (302). in this present study, it was hypothesised that the GS 
viruses isolated from an immunosuppressed child displayed continual adaptation 
to the host resulting in the final virus isolate (GS10) to be the most highly adapted 
isolate. Therefore, it was proposed that several GS viruses couid be investigated 
for particle shape. This would reveal any correlation between particie shape and 
the relative level of fitness that viruses had acquired to GS. In addition, it is 
proposed that a selection of amantadine-resistant viruses with different drug 
genotypes are analysed for particle shape. The Ml and M2 proteins have been 
impiicated in controlling particle shape, therefore it would be interesting to 
investigate whether amantadine-resistant mutations within M2 alter the 
morphology of the virion. Resuits from this work might possibly provide a further
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explanation for the apparent dominance of certain human amantadine-resistance 
mutations, i.e. if resistance confers particle shape that increases virus yield, this 
might increase the fitness of the resistant genotype and therefore its’ prevalence.
Although the majority of work in this study has concentrated on the functionai 
properties of M2, the data accumulated regarding M1 also has great importance 
for future work. M1 has previously been implicated in controlling rapid virus growth 
Jn certain influenza strains (402, 404). Results from Chapter 3 demonstrated the 
variation in infectivity titres (PFU/ml) of viruses tested. The sequencing of the M1 
gene from a large number influenza A viruses in this study provides an ideal 
opportunity to relate observed molecular differences with the reiative growth rates 
of the viruses. This type of data might reveal M1 mutations that are responsible for 
altering the growth properties of viruses. The relevance of this proposed work is 
associated with deveioping annuai human influenza vaccines. Current research is 
developing methods to change the production of infiuenza vaccines from eggs to 
tissue culture (270, 373). Growing vaccine strains in eggs has many probiems and 
also prevents individuals with specific albumen allergies from receiving the vaccine 
(248). Growth of vaccine strains in tissue culture also presents problems, generally 
viruses grow at much iower titres in tissue culture than eggs. Therefore, 
investigating the potential influence of M1 on viral growth has important 
implications for future vaccine work. If M1 or M2 containing the relevant motifs 
required for high growth could be packaged into a parental virus backbone 
presenting the required surface glycoproteins, then the recombinant virus could be 
grown to high titres in tissue cuiture and used to create vaccine preparations.
The current work has demonstrated the methods that are used to determine the 
susceptibility of influenza A viruses to amantadine. Viruses were tested by 
phenotypic methods and those viruses that were determined resistant were then 
characterised geneticaily to identify resistance markers. With the predicted future 
increased use of NI drugs, it is important to set up similar protocols for the testing 
of virus susceptibility to these new drugs. Although similar methodologies can be 
used, there are severai difficuities when testing the susceptibility of infiuenza 
viruses to NI drugs. In previous studies using traditionai in vitro susceptibility 
assays, there has been considerable variation observed in the susceptibility of 
viruses in the plaque reduction assay (PRA) (20, 126). Additionally, viruses that 
appeared to have reduced sensitivity to NI drugs in vitro (PRA) were highly
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sensitive to drug in the ferret model (20). Therefore, it appears that susceptibility 
testing for NI drugs requires a modified approach. The widely accepted method for 
predicting the sensitivity of viruses to NI drugs in vivo is the NA assay. This 
measures enzymatic activity of the moiecule and is usually confirmed with HA 
sequencing (43,126).
Therefore, future work should involve the implementation of protocois and 
screening for both amantadine and NI drug susceptibility in the routine laboratory 
setting. It will be interesting to observe the frequency of resistance to NI drugs 
occurring in the general population especially during an infiuenza season within 
high levels of activity. The development of resistance has not been predicted, 
however the genetic variabiiity of the influenza virus almost makes it a forgone 
conclusion that it will occur. If both drugs were used in combined therapy as 
previousiy described (2 1 1 ), it would be interesting to screen viruses for dual 
resistance markers. Influenza strains resistant to both ciasses of drug would 
represent a serious problem as has been observed with other multi-drug resistant 
organisms e.g. Staphyiococcus aureus and HIV (117, 155, 356). Therefore, work 
should be performed to assess the predicted virulence, transmissibility, fitness etc. 
of these theoretical strains to ensure that maximal protection can be afforded to 
patients at risk from infection.
7.5 Concluding Remarks
The surveillance of antiviral susceptibility is a fundamental requirement for 
understanding the mechanisms responsible for emerging resistant virus strains. 
The genetic makeup of influenza A viruses is continually changing, a feature that 
enabies the virus to generate resistant mutants with relative ease. This study was 
designed to assess the impact of antiviral drug use in the UK by testing the 
susceptibility of influenza A virus strains to amantadine. This demonstrated low 
levels of resistance to amantadine and provided evidence to suggest that these 
viruses were not readily transmitted within the population. Sporadic clusters of 
resistant viruses within certain influenza seasons could be linked with evidence 
suggesting that they had originated in the institutional setting, e.g. boarding 
schools.
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With the recent advent of novel NI drugs, the future clinical usefulness of 
amantadine and rimantadine in the treatment of influenza has been put in doubt. 
However, at present the relative number of ciinical studies demonstrating the use 
of these NI inhibitors is iimited and the ciinical effectiveness and safety has not 
been substantiated in some at-risk groups. There have been numerous controlled 
studies using amantadine and rimantadine on all patient groups demonstrating 
their abiiity to prevent and treat iliness (37, 74, 149, 165), and therefore these 
drugs stili appear to be preferential when treating certain patients. Cost is aiso a 
, major consideration when prescribing influenza inhibitors. A course of amantadine 
treatment is approximately one fifth the cost of an equivalent course of zanamivir, 
making the former drug much more economicaliy viable. Another consideration is 
the relative shelf life of each inhibitor compound. Amantadine and rimantadine 
have been shown to retain their antiviral potency for up to thirty years (319). 
Similar data for NI drugs has not been possible due to their relative novelty. The 
relevance of this point is illustrated when planning for future pandemic situations. 
A stable drug with a iong shelf life can easily be stockpiled for future use in 
combating wide scale disease.
The above discussion demonstrates some of the advantages that amantadine and 
rimantadine have over NI inhibitors. There are of course many disadvantages as 
previously mentioned in this thesis with anti-M2 protein drugs, including the 
.generation of resistant mutants. However, it might be suggested that combined 
treatment and prophylaxis using both ciasses of drug under certain situations 
might actually represent the most efficient method of controiiing the spread of 
influenza where vaccination has not been implemented or has failed (2 1 2 ).
Although the advent of NI drugs has provided a new approach to the provision of 
protection against infiuenza infections, the nature of the influenza virus requires 
that continuing research into future drugs should continue. Presently, new NI 
drugs continue to be developed, each containing novel structural alterations 
improving their antivirai potency e.g. RWJ-270201 and ABT-675 (178, 407). 
However, focusing research on this single protein might increase the selective 
pressure exerted and thus increase the probability of resistant mutants emerging 
through drug prophylaxis and treatment. Mutations within the NA molecule may 
indeed eventuaily provide compiete cross-resistance to ali NI drugs, mutations 
have aiready been identified in vitro that reduce sensitivity of influenza to two NI
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inhibitors (352). Therefore, it is vital to maintain continued surveillance of drug 
susceptibility on a national and global scale and within certain at-risk groups, e.g. 
the immunocompromised, where the emergence of unique virai infections can be 
studied.
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APPENDIX 5 Rate of change of M2 transmembrane domain from resistant viruses (H3N2)
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APPENDIX 7 Rate of change of M2 cytoplasmic domain from resistant viruses (H3N2)
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APPENDIX 9 Rate of change of M2 from resistant viruses (HI N1)
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APPENDIX 13 Rate of change of M2 transmembrane domain from resistant viruses (MINI)
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APPENDIX 15 Rate of change of M2 cytoplasmic domain from resistant viruses (MINI)
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